Synbiotic aerated dessert: diet product development and evaluation of the intake effects in individuals with metabolic syndrome

Douglas Xavier dos Santos

Corrected version of the thesis according to the resolution CoPGr 6018

Thesis presented for the Degree of Doctor in Sciences, Graduate Program in Biochemical and Pharmaceutical Technology, Concentration area of Food Technology and Doctor in Philosophy, Graduate Program in Chemical Engineering and Processing of the University of Genova (Double Degree Program)

Supervisors:
Prof. Dr. Susana Marta Isay Saad (USP)
Prof. Dr. Patrizia Perego (UNIGE)

São Paulo
2017
Cataloguing data
Elaborated by the Library and Documentation Division of
the USP Chemical Group

Xavier dos Santos, Douglas
Synbiotic aerated dessert: diet product
development and evaluation of the intake effects in
individuals with metabolic syndrome / Douglas
Xavier dos Santos. - São Paulo, 2017.
177 p.

Tese (doutorado) - Faculdade de Ciências
Farmacêuticas da Universidade de São Paulo.
Departamento de Tecnologia Bioquímico-Farmacêutica.
Orientador: Igay Saad, Susana Marta
Orientador: Perego, Patrizia

1. Food Technology. 2. Experimental Nutrition.
3. Functional Food. I. T. II. Isay Saad, Susana
Marta, orientador. III. Perego, Patrizia,
orientador.
Douglas Xavier dos Santos

Synbiotic aerated dessert: diet product development and evaluation of the intake effects in individuals with metabolic syndrome

Commission
of
Thesis for the degree of Doctor in Sciences and Philosophy

Professor Susana Marta Isay Saad
Supervisor/President

Professor____________________________Signature________________________

1º. Examiner

Professor____________________________Signature________________________

2º. Examiner

Professor____________________________Signature________________________

3º. Examiner

Professor____________________________Signature________________________

4º. Examiner

São Paulo, ___de_______de 2017.
This thesis is dedicated to everyone who believed in my ideals and, in special, to my mother Nádia, aunt Gecilene, and aunt Marilange (in memoriam).
ACKNOWLEDGEMENTS

To God for granting me the opportunity to live with health, peace, freedom, and with the path always illuminated, protected with his eternal goodness even during the critical moments.

To my mother Nádia for the love, support, understanding, giving me peace of mind in the moments I needed more patience for the conclusion of the experimental part of this thesis. Thank you very much for believing in my ideals and always encouraging me to overcome the most difficult times.

To my family from São Paulo and aunt Gecilene for the moments of fun and attention.

To Professor Susana Marta Isay Saad for the support, guidance, dedication and the opportunity given me to get a double PhD degree.

To Professor Dr. Patrizia Perego and Professor Dr. Attilio Converti for their attention, support and the opportunity to do the second part of my double PhD degree in Genoa. In this beautiful Italian city I lived one year with the best moments of my life.

To my friend Dr. Raquel Bedani for the suggestions that helped me a lot in the development of this research, attention, support, education, guidance, and for always helping me in all the moments that I needed assistance during my PhD.

I would also like to thank all my friends who are so special and who have always been on my side at all times: Raquel Bedani, Marcela Albuquerque, Laís Moro, Elizandra Hertel (Iza), Biljana Kukić, Maki Asai, Giusi Genova, Marina Padilha, Xiong Miner, Enrique Coronado, Glenda Franca, Hokuto Kotaki, Fabio Lastrico, Pier Francesco (Piffa), Margherita Bartowski, Elena Zattera, Raquel Rios, Évellin do Espírito Santo, Thamires Simões, Bianca Lisman, Anna Carolina Meireles, Priscilla Alves, Russany Costa, Dani Honorato, Angélica Ishikawa, Mariana Ishikawa, Angélica Penha, Marcelo Tiago (Marcelão), Luciane Texeira, and Carolina Battistini. You are the best people anyone could ever know in life!

To the staff and professors of my post-graduate program in particular to Professor Dr Juliana Ract, Professor Dr Marina Ishii, Alexandre Mariane, Professor Dr Adalberto Pessoa Júnior, Nilton Bloisi, Tânia Nogueira, Miriam Lopes, Rose Dedivitis, Professor Dr Cristina Bogsan, Professor Dr Carlota Rangel, Professor Dr Suzana Lannes, Professor Dr Luiz Antonio Gioielli, Dona Dé, and Elsa Goes.
To the staff and professors of Bl14 and 13B, Professor Dr Silvia Cozzolino, Alexandre Pimentel, Professor Dr Julio Orlando Tirapegui Toledo, Ivanir Pires, Fabiana Lima, Dona Lúcia, and Katia Leani.

To the employees of the Division of Clinical Medicine of the University Hospital (HU) of the University of São Paulo (USP), in particular to Dr. Egidio Dorea Lima, for the support that was fundamental in order to carry out this work.

To the employees, Luiz and Dúlce of the Specialized Hygiene Service at HU and Regina of the Institute of Geosciences. I thank you very much for the cooperation, open-mindedness and attention.

To Professor Dr Andréa Name Colado Simão of the University of Londrina (UEL) for the statistical support and collaboration that were essential in the development of this work.

To my laboratory colleagues at USP: Clara Simone, Antonio Diogo, Graziela Leal, Natália Matias, Mayra Garcia, Bruna Cabral, Vanessa Cabral, Juanita Solano, Fernanda Perlis, Marina Gomes, Débora Yamacita, Felipe Daum, Luiz Garutti, Igor Ucella, Gabriela Ooki, and Isabel Bossi.

To my laboratory colleagues at University of Genoa (UNIGE), Alessandro Alberto Casazza, Bahar Aliakbarian, Mattia Comotto, Pier Francesco (Piffa), Margherità Bartowski, Livio, Laura Bisio, Laura Morando, Giulia Fossa, Francesca Mazzocco, Elena Zattera, Francesca Lovaglio, Vittorio Bassano, Lidia Piccinno, Chiara Muccetti, Taís Gabbay, Filippo Dellanno, David Moncalvo, Renato Enrico, Valentina Spezza, Giulia Moda, Milena Fernandes, and Irene Briasco. I would also like to thank the PhD student Fabio Magrassi and Roberto Pace for the attention and friendship.

To my friends of the School of Pharmaceutical Sciences: Rafael Martinez, Graziela Biude, Gabriel Moretti, Juliana Cajado, Poliana Fernandes, Bruna Fernandes, Marcos Knirsch, Jessica Veridiana, Richard Saldaña, Natasha Lorenzo, Maria Eduarda Lousada, Margarete de Sá Soares, Verônica da Silva Bandeira, Sibylle Sophie Hacker, and Natália Marchesan.

To the employees of the Bl 13A, Irineu Ruel, Sueli Duarte, Cláudia, Jorge de Lima, Cilene Zago, and Elaine Ychico, thank you very much for the cooperation, open-mindedness and attention.

To the professors and friends of the Faculty of Technology of the State of São Paulo/campus of Marília (FATEC/Marília), where I graduated, for whom I have a lot of affection and
respect. I would like to say a very special thank you to Professor Dr. Alice Tanaka and Professor Dr. Alda Ortoloni for the attention and encouragement during the undergraduation course.

To the teachers of the Antonio Reginato State School where I did my high school with great pride, especially to the Professor Lúcia Jerep and the Professor Rosana Amorim, for whom I have a lot of affection.

I also cannot forget my friends from the football team of the Chácara Paraíso do Vale (Marília-SP), where I met the best players of the history of world football!

To FAPESP (Process #2013/04422-7, doctorate fellowship, 2013/50506-8 and 2013/07914-8 – Food Research Center, financial support) and CAPES (BEX 6602/15-0, doctorate sandwich fellowship), for the collaboration of this work in terms of financial support and fellowships.

A special thank to all the volunteers who participated and helped to develop this thesis!

I hope I did not forget anyone, if that happened, forgive me.

My sincere thanks to all who participated in the project.
AGRADECIMENTOS

A Deus por me conceder a oportunidade de viver com saúde, paz, liberdade e com o caminho sempre iluminado, protegido com a sua eterna bondade mesmo durante os momentos críticos.

À minha mãe Nádia pelo amor, apoio, compreensão, passando tranquilidade nos momentos que mais necessitava de paciência para a conclusão da fase experimental. Agradeço muito por investir em meus ideais e sempre acreditando em minha superação nos momentos mais difíceis como sempre.

À minha família de São Paulo e a Tia Gecilene pelos momentos de descontração e atenção.

À Professora Drª Susana Marta Isay Saad pela oportunidade, apoio, orientação e dedicação em meu duplo doutorado.

À Professora Patrizia Perego e o Professor Attilio Converti por tanta atenção, apoio e a oportunidade de realizar o meu duplo doutorado em Gênova. Nesta belíssima cidade italiana, eu vivi um dos melhores momentos de minha vida.

À minha amiga Drª. Raquel Bedani pelas dicas que me ajudaram muito no desenvolvimento desta pesquisa, atenção, apoio, orientação e por sempre me ajudar em todos os momentos que mais precisei ao longo do meu doutorado.

Gostaria também de agradecer a todos os meus amigos que são especiais demais e que sempre estiveram ao lado em todos os momentos: Raquel Bedani, Marcela Albuquerque, Laís Moro, Elizandra Hertel (Iza), Biljana Kukić, Maki Asai, Giusi Genova, Marina Padilha, Xiong Miner, Enrique Coronado, Glenda Franca, Hokuto Kotaki, Fabio Lastrico, Pier Francesco (Piffa), Margherita Bartowski, Elena Zattera, Raquel Rios, Évellin do Espírito Santo, Thamires Simões, Bianca Lisman, Anna Carolina Meireles, Priscilla Alves, Russany Costa, Dani Honorato, Angélica Ishikawa, Mariana Ishikawa, Angélica Penha, Marcelo Tiago (Marcelão), Luciane Texeira e Carolina Battistini. Vocês são as melhores pessoas que alguém poderia conhecer em vida!

Aos funcionários e docentes do meu programa de pós-graduação em especial à Professora Drª Juliana Ract, Professora Drª Marina Ishii, Alexandre Mariane, Professor Dr Adalberto Pessoa Júnior, Nilton Bloisi, Tânia Nogueira, Miriam Lopes, Rose Dedivitis, Professora Drª Cristina Bogsan, Professora Drª Carlota Rangel, Professora Drª Suzana Lannes, Professor Dr Luiz Antonio Gioielli, Dona Dé e Elsa Goes.
Aos funcionários e docentes do Bloco 14 e 13B, Professora Drª Silvia Cozzolino, Alexandre Pimentel, Professor Dr Julio Orlando Tirapegui Toledo, Ivanir Pires, Fabiana Lima, Dona Lúcia e Katia Leani.

Aos funcionários da Divisão de Clínica Médica do Hospital Universitário (HU) da Universidade de São Paulo (USP), em especial ao Dr. Egidio Dorea Lima, pelo apoio que foram fundamentais para realização deste trabalho.

Aos funcionários, Luiz e Dúlce do Serviço de Higiene Especializada do HU e Regina do Instituto de Geociências. Agradeço-lhes muito a cooperação, ajuda e a atenção.

A Professora Drª Andréa Name Colado Simão da Universidade Estadual de Londrina (UEL) pelo suporte estatístico e colaboração que foram essenciais no desenvolvimento deste trabalho.

Aos meus companheiros de laboratório na USP, Clara Simone, Antonio Diogo, Graziela Leal, Natália Matias, Mayra Garcia, Bruna Cabral, Vanessa Cabral, Juanita Solano, Fernanda Perls, Marina Gomes, Débora Yamacita, Felipe Daum, Luiz Garutti, Igor Ucella, Gabriela Ooki e Isabel Bossi.

Aos meus companheiros de laboratório na Università degli Studi di Genova (UNIGE), Alessandro Alberto Casazza, Bahar, Bahar Aliakbarian, Mattia Comotto, Pier Francesco (Piffa), Margherita Bartowski, Livio, Laura Bisio, Laura Morando, Giulia Fossa, Francesca Mazzocco, Elena Zattera, Francesca Lovaglio, Vittorio Bassano, Lidia Piccinno, Chiara Muccetti, Taís Gabbay, Filippo Dellanno, David Moncalvo, Renato Enrico, Valentina Spezza, Giulia Moda, Milena Fernandes e Irene Briasco. Também gostaria de agradecer ao doutorando Fabio Magrassi e ao Roberto Pace pela atenção e amizade.

Aos meus amigos da Faculdade de Ciências Farmacêuticas, Rafael Martinez, Graziela Biude, Gabriel Moretti, Juliana Cajado, Poliana Fernandes, Bruna Fernandes, Jessica Veridiana, Marcos Knirsch, Richard Saldaña, Natasha Lorenzo, Maria Eduarda Lousada, Margarete de Sá Soares, Verônica da Silva Bandeira, Sibylle Sophie Hacker e Natália Marchesan.

Aos funcionários do Bloco 13 A, Irineu Ruel, Sueli Duarte, Cláudia, Jorge de Lima, Cilene Zago e Elaine Ychico, agradeço muito pela cooperação, receptividade e atenção.

Aos professores e amigos da Faculdade de Tecnologia do Estado de São Paulo/campus de Marília (FATEC/ Marília), onde me formei, pelo quais tenho muito carinho e respeito.
Gostaria de dizer um “obrigado” muito especial a Professora Drª Alice Tanaka e Professora Drª Alda Or托boni pela atenção e incentivo durante a graduação.

Aos professores da Escola Estadual Antonio Reginato onde estudei o meu ensino médio com muito orgulho, em especial a Professora Lúcia Jerep e Professora Rosana Amorim, pelo quais tenho muito carinho.

Eu também não posso me esquecer dos meus amigos do futebol da Chácara Paraíso do Vale (Marília-SP), onde se reúnem os maiores jogadores de final de semana da história do futebol mundial!

À Fundação de Amparo à Pesquisa do Estado de São Paulo (FAPESP) (Processo #2013/04422-7, bolsa de doutorado, 2013/50506-8 e 2013/07914-8 – Food Research Center, apoio financeiro) e a Coordenação de Aperfeiçoamento de Pessoal de Nível Superior (CAPES) (BEX 6602/15-0, bolsa de doutorado sanduíche), pela colaboração deste trabalho (apoio financeiro e bolsas de estudo).

Espero não me esquecer de ninguém, caso isso tenha ocorrido, me perdoem...

A todos que participaram desta trajetória meus sinceros agradecimentos.
“Anyhow, I've learned one thing now: you only really get to know people when you've had a jolly good row with them. Then and then only can you judge their true characters!”

“De qualquer forma, eu aprendi uma coisa: só se conhece realmente uma pessoa depois de uma discussão. Então e então se pode avaliar o seu verdadeiro carater!”

“Because paper has more patience than people.”

“O papel tem mais paciência do que as pessoas.”

Anne Frank
ABSTRACT

XAVIER-SANTOS, D. Synbiotic aerated dessert: diet product development and evaluation of the intake effects in individuals with metabolic syndrome. 2017. 177p. Thesis (PhD). Faculty of Pharmaceutical Sciences, University of São Paulo, São Paulo, 2017.

The objective of this work was to adapt a synbiotic aerated diet dessert, produced with the addition of a probiotic culture of *Lactobacillus acidophilus* La-5 and prebiotic ingredients (fructooligosaccharides and inulin), from the previously developed sucrose-containing formulation, and to evaluate the effects of its ingestion on adult volunteers with metabolic syndrome (MetS) during a period of 8 weeks of intervention. In addition, to improve the resistance of the probiotic to simulated gastrointestinal conditions, a microencapsulation process was optimized. For the development of the product, the formulations were produced in triplicates, in which probiotic culture survival, instrumental texture and sensory acceptability were evaluated up to 112 days of storage under freezing (-18 °C). Subsequently, a randomized, double-blind, placebo-controlled trial was carried out in which the product developed was administered to forty-five volunteers with MetS assigned into two groups, each receiving 40 g/day of: synbiotic diet mousse (SDM) (n=23) and placebo diet mousse (PDM) without pro- and prebiotics (n=22). Fasting blood samples were collected at the beginning and after 8 weeks of daily consumption of both mousses to determine the anthropometric, biochemical, haematological, inflammatory, and immunological parameters. Afterward, with the goal of improving the survival of *L. acidophilus* La-5 to *in vitro* simulated gastrointestinal conditions, the microencapsulation process conditions of the probiotic strain via spray drying were optimized using inulin as the encapsulating agent. The viability of *L. acidophilus* La-5 incorporated into SDM was above 7.8 log CFU/g and remained stable throughout storage. PDM showed lower acceptability (5.77-6.50) after storage than SDM (6.67-7.03). The texture was the most appreciated attribute and hardness of the SDM increased during storage, but remained stable for PDM. The clinical trial revealed significant reductions of total cholesterol and HDL-cholesterol, as well as of immunoglobulins (A and M), and interleukin-1β in both groups during the intervention period. However, regarding intergroup changes, there were not any significant differences for all parameters evaluated (p>0.05). After the optimization of the microencapsulation process of the probiotic culture (80 mL/min, 82% and 10%, respectively for feed flow, aspiration rate, and inulin concentration), the microencapsulated probiotic strain incorporated in the SD mousse showed the highest *in vitro* gastrointestinal survival (p<0.05) in the different stages of the assay, as follows: after the gastric phase: 5.68 log CFU/g (83.3%), the enteral phase I: 5.61 log CFU/g (82.3%), the enteral phase II: 5.56 log CFU/g (81.4%). Therefore, these results suggest that the presence of probiotic and prebiotics in SDM did not provide an additional effect on the health of volunteers with MetS. Additionally, the results confirm the appropriateness of the spray drying process to microencapsulate *L. acidophilus* La-5 using inulin as coating agent, providing increased resistance to the microencapsulated probiotic strain under *in vitro* gastrointestinal stress.

Key-words: Probiotic; *Lactobacillus acidophilus*; Inulin; Fructooligosaccharides; Dairy dessert; Clinical trial; Microencapsulation; *In vitro* gastrointestinal resistance.
RESUMO

XAVIER-SANTOS, D. Sobremesa aerada simbiótica: desenvolvimento do produto diet e avaliação dos efeitos da ingestão sobre indivíduos com síndrome metabólica. 2017. 177p. Tese (Doutorado). Faculdade de Ciências Farmacêuticas, Universidade de São Paulo, São Paulo, 2017.

O objetivo deste trabalho foi adaptar uma sobremesa aerada simbiótica diet do tipo musse, processada com a adição de uma cultura probiótica de *Lactobacillus acidophilus* La-5 e de ingredientes prebióticos (fruto-oligossacarídeos e inulina), a partir da formulação contendo sacarose desenvolvida anteriormente, e avaliar os efeitos de sua ingestão em voluntários adultos com síndrome metabólica (MetS) durante um período de 8 semanas de intervenção. Adicionalmente, para melhorar a resistência do probiótico frente às condições gastrintestinais simuladas, otimizou-se um processo de microencapsulação da cepa probiótica. Para o desenvolvimento do produto, as formulações foram produzidas em triplicata, em que se avaliou a sobrevivência da cultura probiótica, a textura instrumental e a aceitabilidade sensorial até 112 dias de armazenamento sob congelamento (-18 °C). Em seguida, foi realizado um estudo randomizado, duplo-cego e controlado por placebo, no qual o produto desenvolvido foi administrado a quarenta e cinco indivíduos com MetS divididos em dois grupos, cada um recebendo 40 g/dia de: mousse simbiótica diet (SDM) (n=23) e musse placebo diet (PDM) sem componentes pro- e prebióticos (n=22). As amostras sanguíneas foram coletadas em jejum no início e após 8 semanas de consumo diário de ambas as musses para a determinação dos parâmetros antropométricos, bioquímicos, hematológicos, inflamatórios e imunológicos. Posteriormente, com o intuito de melhorar a sobrevivência do *L. acidophilus* La-5 em condições gastrintestinais simuladas in vitro, as condições de processo de microencapsulação da cepa probiótica via spray drying foram otimizadas, utilizando inulina como agente encapsulante. A viabilidade de *L. acidophilus* La-5 incorporados na SDM foi superior a 7,8 log UFC/g e se manteve estável ao longo do armazenamento. A PDM mostrou menor aceitabilidade (5.77-6.50) após o armazenamento do que a SDM (6.67-7.03). A textura foi o atributo mais apreciado, sendo que a dureza da SDM apresentou elevação, enquanto a da PDM manteve-se estável. O ensaio clínico revelou reduções significativas de colesterol total, colesterol-HDL, imunoglobulinas (A e M) e interleucina1β em ambos os grupos durante o período de intervenção. Entretanto, no que se refere às mudanças intergrupos, não se observou diferenças significativas para todos os parâmetros avaliados (p>0,05). Após a otimização do processo de microencapsulação da cultura probiótica (80 mL/min, 82% e 10%, respectivamente para o fluxo de alimentação, taxa de aspiração e concentração de inulina), a cepa probiótica microencapsulada incorporada a amostra SDM apresentou a maior sobrevivência gastrointestinal in vitro (p<0,05) nas diferentes etapas do ensaio, a saber: após a fase gástrica: 5,68 log UFC/g (83,3%); fase entérica I: 5,61 log UFC/g (82,3%); fase entérica II: 5,56 log UFC/g (81,4%). Portanto, esses resultados sugerem que a presença de probiótico e prebiótico na SDM não apresentou efeitos adicionais na saúde dos voluntários com MetS. Adicionalmente, os resultados confirmaram a adequação do processo de spray drying para a microencapsulação de *L. acidophilus* La-5 utilizando inulina como agente de revestimento, proporcionando uma maior resistência da cepa probiótica microencapsulada às condições gastrintestinais simuladas in vitro.

Palavras-chave: Probiótico; *Lactobacillus acidophilus*; Inulina; Fruto-oligossacarídeos; Sobremesa láctea; Ensaio clínico; Microencapsulação; Resistência gastrointestinal in vitro.
RIASSUNTO

XAVIER-SANTOS, D. Dessert aerato simbiotico: sviluppo del prodotto dietetico e valutazione degli effetti dell’ingestione su individui con sindrome metabolica. 2017. 177p.
Tesi (Dottorato). Facoltà di Scienza Farmaceutiche, Università di San Paolo, San Paolo, 2017.

L’obiettivo di questo lavoro è stato formulare un dessert aerato simbiotico dietetico tipo mousse, ottenuto con l’addizione di probiotici (Lactobacillus acidophilus La-5) e di prebiotici (frutto-oligosaccaridi e inulina), partendo da una formulazione contenente saccarosio sviluppata precedentemente. Inoltre è stato valutato l’effetto dell’assunzione di tale mousse da parte di volontari adulti con sindrome metabolica (MetS) per un periodo di 8 settimane. Inoltre, per migliorare la resistenza del probiotico alle condizioni gastrointestinali, è stato eseguito e ottimizzato un processo di microincapsulazione del ceppo probiotico. Per lo sviluppo del prodotto, le formulazioni sono state eseguite in triplicato, su queste sono state valutate: la sopravvivenza della cultura probiotica; la struttura e l’accettabilità sensoriale fino a 112 giorni di conservazione (-18 °C). In seguito, è stato realizzato uno studio randomizzato, in doppio cieco con controllo placebo, somministrando a quarantacinque soggetti con MetS il prodotto sviluppato. I pazienti sono stati divisi in due gruppi, somministrando a ciascun gruppo 40 g/giorno sia la mousse simbiotica dietetica (SDM) (n=23) che la mousse placebo dietetica (PDM) senza pro- e prebiotici (n=22). Campioni di sangue sono stati raccolti a digiuno all’inizio e dopo 8 settimane di alimentazione con entrambe le mousse. Su questi sono stati determinati parametri antropometrici, biochimici, ematologici, immunologici e infiammatori. In seguito, con l’intento di migliorare la sopravvivenza di L. acidophilus La-5 alle condizioni gastrointestinali simulate in vitro, le condizioni di processo di microincapsulazione del ceppo probiotico via spray drying sono stati ottimizzate utilizzando inulina come agente incapsulante. La vitalità di L. acidophilus La-5 incorporato nell’SDM è stata di 7,8 log UFC/g e si è mantenuta stabile durante tutto il periodo di stoccaggio. Il PDM ha mostrato minore resistenza (5,77-6,50) alla conservazione che il SDM (6,67-7,03). La struttura è stata il parametro più apprezzato, essendo aumentata la consistenza dell’SDM, mentre quella del PDM è rimasta stabile. Lo studio clinico ha rilevato riduzioni significative del colesterolo totale, del colesterolo-HDL, delle immunoglobuline (A e M) e dell’interleuchina-1β in entrambi i gruppi durante tutto il periodo di studio. Tuttavia, per quanto riguarda i cambiamenti intergruppi, non sono state osservate differenze significative per tutti i parametri (p>0,05) studiati. Dopo l’ottimizzazione del processo di microincapsulazione (parametri spray dryer: flusso di alimentazione 80 mL/min, aspirazione 82% e concentrazione di inulina 10%), il ceppo probiotico microincapsulato e incorporato nell’SDM ha presentato una maggiore sopravvivenza gastrointestinale in vitro (p<0,05) nelle differenti fasi studiate come segue: dopo nel fase gastrica: 5,68 log UFC/g (83,3%); fase enterica I: 5,61 log UFC/g (82,3%); fase enterica II: 5,56 log UFC/g (81,4%). Pertanto, questi risultati suggeriscono che la presenza di probiotico e prebiotici nell’SDM non ha portato ad effetti addizionali nella salute dei volontari con MetS. Inoltre, i risultati hanno confermato la fattibilità del processo di spray drying per la microincapsulazione di L. acidophilus La-5 usando inulina come agente di rivestimento, portando ad una maggiore resistenza del ceppo probiotico alle condizioni gastrointestinali simulate in vitro.

Parole-chiavi: Probiotico; Lactobacillus acidophilus; Inulina; Frutto-oligosaccaridi; Dessert a base di latte; Studio clinico; Microincapsulazione; Resistenza gastrointestinale in vitro.
ABREVIATIONS

AOAC - Association of Analytical Communities
ATP III - Adult Treatment Panel III
BC - Before Christ
BMI - Body mass index
CAAE - Certificate of Presentation for Ethical Consideration
CD 40 - cluster of differentiation 40
CFU - Colony Forming Units
CVD - Cardiovascular disease
DBP - Diastolic blood pressure
DP - Degree of polymerization
DVS type - Direct vat set
DWpart - Initial weight of microparticles (dry basis)
DWsup - Dry weight of the supernatant
FOS - Fructooligosaccharides
GALT - Gut-associated lymphoid tissue
GIT - Gastrointestinal tract
Group P - Group placebo
Group S - Group synbiotic
Hb - Hemoglobin
HCl - Chlorine acid
HDL-C - High-density lipoprotein cholesterol
Hg - Mercury
HOMA-IR - Homoeostasis model of assessment of insulin resistance
IgA - Immunoglobulin A
IgE - Immunoglobulin E
IgG - Immunoglobulin G
IgM - Immunoglobulin M

IL-10 - Interleukin 10

IL-12 - Interleukin 12

IL-1β - Interleukin 1β

IL-6 - Interleukin 6

IL-8 - Interleukin 8

LDL-C - Low-density lipoprotein cholesterol

LDL-C/HDL-C - LDL-cholesterol to HDL-cholesterol ratio

LPS - Lipopolysaccharide

M1 - Macrophage 1

M2 - Macrophage 1

MCP-1 - Monocyte chemoattractant protein-1

MetS - Metabolic syndrome

mRNA - messenger RNA

NCEP - National Cholesterol Education Program

NF-κB - Nuclear factor kappa B

NGF - Nerve growth factor

PDM - Non-synbiotic diet mousse

pH – Hydrogen-ionic potential

PW - Weight of pellet after centrifugation.

rpm - Revolutions per minute

SBP - Systolic blood pressure

SC - Swelling capacity

SCFA - Short chain fatty acids

SDM - Synbiotic diet mousse

T0 - Baseline

T8 - Week 8
TC/HDL-C - Total cholesterol to HDL-cholesterol ratio
TEV - Total energy value
TG - Triglycerides
TLR-5 - Toll-like Receptor-5
TNF-α - tumor necrosis factor alpha
TPA - Texture profile analysis
Tregs - regulatory T
UHT – Ultra Heat Temperature
VLDL-C - Very low density lipoprotein cholesterol
WAI - Water absorption index
WC - Waist circumference
WHO - World Health Organization
WPI - Whey protein isolate
WSI - Water solubility index
LIST OF FIGURES

Chapter 2

Figure 1. The main steps of synbiotic diet mousse production. ........................................67

Figure 2. Instrumental texture profiles of mousse formulations: (■) non-synbiotic diet mousse; (□) synbiotic diet mousse. Different uppercase letters indicate statistically significant difference ($p<0.05$) between the two diet mousse formulations for the same storage time. Different lowercase letters indicate statistically significant differences ($p<0.05$) among different storage times for the same mousse formulation. *Absolute values of adhesiveness in module............................................................76

Figure 3. Relative frequencies of scores assigned to mousses in all storage times. 1, dislike extremely; 2, dislike very much; 3, dislike moderately; 4, dislike slightly; 5, neither like or dislike; 6, like slightly; 7, like moderately; 8, like very much; 9, like extremely. (□) Non-synbiotic diet mousse; (■) Synbiotic diet mousse; (■) Control synbiotic mousse.............81

Chapter 4

Figure 1. The main steps of synbiotic diet mousse production. ........................................133

Figure 2. Response surface plot for survival rate after spray drying as a function of aspirated rate and feed flow at inulin concentration of 10% (a), 15% (b), and 20% (c).....................141

Figure 3. Survival of *Lactobacillus acidophilus* La-5 during exposition to simulated gastrointestinal conditions. (▲) Mousse with microencapsulated cells, (■) Mousse with free cells, (Δ) Microencapsulated cells, and (□) Free cells. Different uppercase letters indicate statistically significant differences ($p<0.05$) among the four samples for the same time. Different lowercase letters indicate statistically significant differences ($p<0.05$) among different times for the same parameters........................................144
LIST OF TABLES

Chapter 1

Table 1. Main effects described for the supplementation of probiotics and/or prebiotics on the human health. ................................................................. 37

Chapter 2

Table 1. Ingredients employed in the production of synbiotic diet mousse (SDM), and non-synbiotic diet mousse (PDM), and control synbiotic mousse (CSM) ......................... 65

Table 2. Mean pH values (standard deviation) of non-synbiotic diet mousse (PDM) and synbiotic diet mousse (SDM) stored at -18±2 °C for up to 112 days ....................... 73

Table 3. Chemical composition, energy contribution of macronutrients, and total energy values (TEV) of synbiotic diet mousse (SDM) and non-synbiotic diet mousse (PDM) referred to 100 g of mousses (dry weight) ...................................................... 74

Table 4. Mean scores of sensory acceptability (standard deviation) attributed by consumers to non-synbiotic diet mousse (PDM), synbiotic diet mousse (SDM), and control synbiotic mousse (CSM) stored at -18±2 °C for up to 112 days ................................................................. 79

Chapter 3

Table 1. Amounts of ingredients employed in the production of synbiotic diet mousse (SDM) and placebo diet mousse (PDM) ................................................................. 100

Table 2. Chemical composition, energy contribution of macronutrients, and total energy values (TEV) of synbiotic diet mousse (SDM) and placebo diet mousse (PDM) in 100 g of whole mousses (dry weight) ................................................................. 101

Table 3. General characteristics of the participants of the placebo and synbiotic groups at the beginning of the study ................................................................. 105

Table 4. Clinical and biochemical parameters at baseline (T0) and after 8 weeks (T8) of mousse consumption ................................................................. 107

Table 5. Haematological parameters at baseline (T0) and after 8 weeks (T8) of mousse consumption ................................................................. 108
Table 6. Inflammatory parameters and antibodies at baseline (T0) and after 8 weeks (T8) of mousse consumption.

Chapter 4

Table 1. Box–Behnken experimental design matrix employed.

Table 2. Proportions of the ingredients used in the production of the synbiotic diet mousse.

Table 3. Box–Behnken experimental design matrix and responses.

Table 4. Results of variance analysis.

Table 5. Criteria for optimization of process conditions along with responses.
3.3. Chemical composition and total energy value........................................................................ 73
3.4. Texture profile analysis .................................................................................................... 75
3.5. Sensory analysis .............................................................................................................. 78

4. CONCLUSIONS .................................................................................................................. 83

5. REFERENCES .................................................................................................................... 84

CHAPTER 3 .............................................................................................................................. 95

Effect of the consumption of a synbiotic diet mousse containing *Lactobacillus acidophilus* La-5 by individuals with metabolic syndrome: a randomized controlled trial............ 96

ABSTRACT .............................................................................................................................. 96

1. INTRODUCTION .................................................................................................................. 97

2. SUBJECTS AND METHODS ............................................................................................... 100
   2.1. Production of synbiotic and placebo diet mousses ....................................................... 100
   2.2. Participants .................................................................................................................. 102
   2.3. Study design ................................................................................................................ 103
   2.4. Anthropometric, heart rate, and laboratory blood analysis ....................................... 103
   2.5. Statistical analysis ..................................................................................................... 104

3. RESULTS AND DISCUSSION .............................................................................................. 105

4. CONCLUSION ..................................................................................................................... 115

5. REFERENCES ..................................................................................................................... 116

CHAPTER 4 .............................................................................................................................. 124

Microencapsulation of *Lactobacillus acidophilus* La-5 using inulin as coating agent by spray drying and its survival under in vitro simulated gastrointestinal conditions ..... 125

ABSTRACT .............................................................................................................................. 125

1. INTRODUCTION .................................................................................................................. 126

2. MATERIAL AND METHODS ............................................................................................... 127
   2.1. Microencapsulation of *Lactobacillus acidophilus* La-5 through spray drying .... 127
2.1.1. Preparation of the encapsulating solution ........................................ 127
2.1.2. The spray drying process ................................................................. 128
2.2. Optimization of spray drying process parameters through Box-Behnken experimental design ................................................................. 128
2.3. Microcapsules powder analysis ............................................................. 129
  2.3.1. Count of microencapsulated and free cells of *Lactobacillus acidophilus* La-5 129
  2.3.2. Survival of encapsulated probiotic strain in acid conditions ............... 130
  2.3.3. Moisture content ............................................................................. 130
  2.3.4. Microencapsulation yield ................................................................ 130
  2.3.5. Water solubility index, water absorption index and swelling capacity ...... 131
2.4. Production of the Synbiotic Diet Mousse (SDM) ...................................... 131
2.5. Survival of microencapsulated *Lactobacillus acidophilus* La-5 to *in vitro* simulated gastrointestinal after storage ...................................................... 133
2.6. Statistical analysis ................................................................................ 134

3. RESULTS AND DISCUSSION ..................................................................... 135
  3.1. Box–Behnken experimental design of the spray drying conditions ........... 135
  3.2. Optimization of the spray drying conditions ........................................... 142
  3.3. *In vitro* simulated gastrointestinal conditions ...................................... 144

4. CONCLUSIONS ....................................................................................... 148
5. REFERENCES ............................................................................................ 149

GENERAL CONCLUSION ........................................................................... 156

SCIENTIFIC RESULTS CONCERNING THE PRESENT PhD THESIS .............. 157
PARTICIAPATION IN EVENTS, CONGRESSES, AND EXHIBITIONS ............... 159
COLLABORATION IN SCIENTIFIC INITIATION PROJECT ............................. 160
UNDERGRADUATE CLASSES TAUGHT IN HIGHER EDUCATION ............... 161

ANNEXES ...................................................................................................... 162
PRESENTATION

In 2,500 BC, the famous philosopher Hippocrates could not have been more precise in the prediction of food trends and preferences in the current world when he said: "Let the food be your medicine and the medicine be your food" (Khan et al., 2011). Thus, some authors emphasize that a functional food should promote beneficial effects in a satisfactory way to one or more target functions in the body, contributing to the improvement of health and reducing the risk of disease development, besides basic nutrition (Jiménez-Colmenero et al., 2010). Among the functional foods stand out probiotics, prebiotics, and synbiotics.

The feed ingredients present in a formulation might positively contribute to an interaction between the probiotic microorganism and its carbon source (prebiotic) through previous in vivo adaptation. In some cases, a competitive advantage in relation to the development of the probiotic strain in function of the synbiotic effect originated by the availability of prebiotic as a nutrient source was observed. Besides, this effect can be targeted to specific regions of the large and small intestine. The adequate consumption of products containing probiotics and prebiotics may further enhance the beneficial effects of both through a synergistic combination between a known strain and its substrate (Holzapfel & Schillinger 2002; Bielecka et al., 2002).

In the last years, several studies have been performed to evaluate the effect of probiotic microorganisms and prebiotic ingredients on the host’s health. However, information about the beneficial effects promoted by these microorganisms on the parameters related to the metabolic syndrome (MetS) is still not clear. In addition, few studies have evaluated the effect of probiotic microorganisms on the health when incorporated in unconventional food products, such as aerated desserts like mousse, particularly when these products also contain prebiotic ingredients.

Thus, the idea of adapting a synbiotic product developed by our research group in order to produce a new dessert with no added sugar and reduced fat content and to test it on volunteers with MetS has become a promising research target.
The present thesis is organized in the form of scientific papers divided in the following chapters:

**Chapter 1: “Probiotics, Prebiotics, and Metabolic Syndrome”** - This section aims to report the beneficial effects of the supplementation of probiotics and/or prebiotics on parameters related to metabolic syndrome.

**Chapter 2: “Texture profile and sensory acceptance of a synbiotic diet aerated mousse containing Lactobacillus acidophilus La-5, inulin, fructooligosaccharides, and sucralse”** - This section aims to evaluate the effect of Lactobacillus acidophilus La-5, inulin, fructooligosaccharides, and sucralse on the instrumental texture profile and the sensory acceptance of a synbiotic diet mousse during 112 days of storage at -18 °C compared to a non-synbiotic diet mousse and another one containing sucrose used as a control.

**Chapter 3: “Effect of the consumption of a synbiotic diet mousse containing Lactobacillus acidophilus La-5 by individuals with metabolic syndrome: a randomized controlled trial”** - This section aims to assess the impact of a synbiotic diet dessert (mousse) containing L. acidophilus La-5 and the prebiotic ingredients inulin and fructooligosaccharides on anthropometric, biochemical, inflammatory, haematological, and immunological parameters of volunteers with metabolic syndrome.

**Chapter 4: “Microencapsulation of Lactobacillus acidophilus La-5 using inulin as coating agent by spray drying and its survival under in vitro simulated gastrointestinal conditions”** - This section aims to optimize the spray drying conditions for the microencapsulation of Lactobacillus acidophilus La-5, within a inulin concentrate matrix, applying it in a synbiotic diet mousse and evaluate his survival under simulated gastrointestinal conditions.
Chapter 1
Probiotics, Prebiotics, and Metabolic Syndrome

ABSTRACT

Several studies in the literature have contributed even more to the better understanding of bioactive compounds like the probiotic microorganisms and/or the prebiotic fibers on the modulation of the intestinal microbiota and subsequent positive effects on the host’s health. Therefore, this review aimed to discuss the main benefits of the supplementation with probiotic and prebiotic and their effects on different risk factors for the development of metabolic syndrome (MetS). A better understanding of the daily supplementation of probiotics and prebiotics regarding the mechanisms involved on the modulation of the intestinal microbiota and the immune system of patients suffering from this metabolic disorder is necessary to establish the efficiency of possible biomarkers that could contribute for the clinical trials needed for an approved health claim. Although the results might be promising, the integrity of probiotics and prebiotics on the intestinal microbiota becomes critical for its modulation, contributing for the prevention and management of MetS components in clinical practice.

Keywords: Functional food; Bioactive compounds; Dysbiosis; Gut microbiota; Human health.
1. INTRODUCTION

Due to their diverse beneficial effects promoted to health, consumers are increasingly interested in incorporating bioactive compounds to their diets as a functional ingredient (Vo & Kim, 2012). Among these bioactive compounds, probiotics, prebiotics and synbiotics foods stand out as the most profitable in the functional food market (Cruz et al., 2010).

According to Hill et al. (2014), the International Scientific Association for Probiotics and Prebiotics (ISAPP) recently proposed a consensus statement on the proper use of the term probiotic: “live micro-organisms that, when administered in adequate amounts, confer a health benefit on the host”. The recommendation for probiotic foods was established based on the daily portion of viable microorganisms that must be ingested, with the minimum stipulated from $10^8$ to $10^9$ Colony Forming Units/day (CFU/day), even though smaller concentrations may be accepted provided the manufacturer proves their effectiveness (ANVISA, 2016). A similar daily intake of viable probiotic cells per serving portion ($10^9$ CFU/day) is recommended by the public health agency of Canada (Health Canada, 2009) and the Italian Health Ministry (Ministero della Salute, 2013).

The health benefits attributed to the ingestion of probiotic cultures that mostly stand out are: control of the intestinal microbiota; stabilization of the intestinal microbiota after the use of antibiotics; promotion of the gastrointestinal endurance to colonization by pathogens; decrease in the count of pathogens resulting from the production of short-chain fatty acids, bacteriocins, and other antimicrobial compounds; modulation of the immune system; increased absorption of mineral salts and vitamin production; and constipation relief (Saad, 2006).

Prebiotic ingredients are also added to food formulations in order to develop products with functional claims that would attract consumers concerned about health (Hutkins et al., 2016). According to ISAPP, prebiotics are currently defined as “substrates that are
selectively used by host microorganisms, conferring a health benefit” (Gibson et al., 2017). The presence of prebiotic on the gastrointestinal tract induces the development and/or metabolic activation of beneficial microorganisms residing on the intestinal microbiota through the selectivity of the substrate (Martinez et al., 2015).

Synbiotic is a nutritional supplementation composed by a simultaneous addition of probiotics and of prebiotics in a food matrix which might lead to a synergic activity (Vrese & Schrezenmeir, 2008; Wu et al., 2016). This interaction in vivo might be favoured by an adaptation of the probiotic to prebiotic before the consumption, which in some cases can result in a competitive advantage for the microorganism (Saad et al., 2011). According to Kolida and Gibson (2011), a synergistic action occurs when the prebiotic aims to improve survival and growth of the probiotic in the host. On the other hand, a complementary action occurs when the prebiotic used selectively increases the concentrations of the beneficial components of the microbiota.

Much is known about the benefits of probiotic microorganisms and/or the prebiotic fibres on the human body. However, information regarding the beneficial effects promoted by these microorganisms and fibres on the parameters that characterize the metabolic syndrome (MetS) are still not clear. Thus, the aim of this review was to report studies on the beneficial effects of the supplementation of probiotics and/or prebiotics to improve the parameters related to MetS.

2. METABOLIC SYNDROME

MetS is a term suggested by the World Health Organization (WHO) in 1998 to universally relate factors that favour a set of metabolic abnormalities associated with the development of coronary heart disease, stroke and cardiovascular mortality (Afsana et al.
Medical disorders stemming from the prevalence of MetS increased in the late 20th century, becoming significant issues worldwide (Chou & Fang, 2010). Some researchers reported that it reaches 1 in 5 adults and is considered a new millennium epidemic that will affect the lives of millions of people around the world (Bhatnagar et al., 2011). Many factors can be considered in MetS development process as a consequence of the multi-process lifestyle, perinatal programming and (epi-) genetic pathway (Graf & Ferrari, 2016). Although some therapies have been reported, changes in dietary habits and lifestyle are, undoubtedly, the most important non-pharmacological factors for the prevention and treatment of this syndrome (Kim et al., 2016; Scavuzzi et al., 2015).

According to the National Cholesterol Education Program, Adult Treatment Panel III (NCEP/ATP III) (Grundy et al., 2005), MetS is characterized by the occurrence of at least three of the following five factors: 1) abdominal obesity (waist circumference of ≥ 88 cm for women and ≥ 102 cm for men); 2) high triglycerides (≥ 150 mg/dL); 3) reduced high-density lipoprotein cholesterol (HDL-C) (< 50 mg/dL for women and < 40 mg/dL for men); 4) high blood pressure (systolic ≥ 130 mmHg and diastolic ≥ 85 mmHg); 5) high fasting glucose (≥ 100 mg/dL).

Factors related to MetS assist in developing preventive approaches when metabolic disorders are detected before the onset of chronic diseases (Martin et al., 2016). It may be induced through a non-healthy diet with high fat that results in dyslipidemia, high blood pressure, hyperglycaemia, as well as insulin resistance (Mostafa et al., 2016; Robberecht et al., 2017), increasing the incidence of chronic non-communicable diseases (Bitzur et al., 2016; Monroy-Muñoz et al., 2017). In addition, determination of these parameters is necessary for a treatment that aims to reduce cardiovascular morbidity as a prevention method (Eckel et al., 2010; Westerink et al., 2016).
Obesity, a component of MetS, has been considered its major driving force, leading to both cardiometabolic risk and insulin resistance (Giugliano et al., 2008; Westerink et al., 2016). Moreover, according to Org et al. (2015), atherosclerosis risk factors are associated to levels of insulin resistance, bile acid metabolism, and inflammatory processes. These researches reported also that the metabolites derived from the intestinal microbiota contribute to the development of atherosclerosis and cholesterol metabolism through alternative metabolic pathways. According to Hand et al. (2016), the dyslipidaemia process and the cellular composition of the adipose tissue can also be influenced by the immune system of a metabolically active microbiota.

Through the increased load of free fatty acids coupled with insulin stimulation of hepatic lipogenesis, the synthesis of hepatic triglycerides, very low density lipoprotein cholesterol (VLDL-C) and steatosis becomes modulated by liver (Boden, 2008).

MetS is characterized by increased renal clearance and hepatic uptake of HDL-C, influencing low levels of HDL-C and increased levels of triglycerides (Gallagher et al., 2011). Although there are considerable differences in the mechanisms of excessive distribution of abdominal adipose tissue, the clinical diagnosis of MetS does not distinguish between increased amounts of subcutaneous and visceral fat (Eckel et al., 2005).

Inappropriate activation of the renin-angiotensin system due to the insulin resistance process may induce excess aldosterone and glomerular hypertension (Chou & Fang, 2010). In addition, many researchers associate insulin resistance with the development of metabolic diseases, while cardiologists relate it to cardiometabolic morbidity and mortality in individual patients (Genser et al., 2016). Insulin resistance could also be attributed to problems in specific substrate receptors and tyrosine phosphorylation in the liver of rats fed a high-fat diet (Eckel et al., 2005). In addition, insulin resistance is also related to the accumulation of lipids in insulin-sensitive tissues, so-called ectopic fat deposition (Karpe et al., 2011; Yki-Järvinen,
2002), mediated by modulation of the function/expression of the transporter proteins (Karpe et al., 2011; Holloway et al., 2008). Among these risk factors associated with MetS, an experiment conducted with 499 American non-diabetic Eastern American volunteers suggested that mechanisms related to hyperglycaemia and hypertension are independent of central adiposity or insulin resistance (Boyko et al., 2010). The composition of the intestinal microbiota exerts a major influence on the loss of function of the toll-like receptor-5 (TLR-5) (Hartstra et al., 2016). It has been identified that insulin resistance also induces a nonsense mutation in TLR-5 that induces the development of type 2 diabetes mellitus (Al-Daghri et al., 2013; Hartstra et al., 2016).

The process of hyperglycaemia may induce the generation of reactive oxygen that will result in lipid peroxidation that will further aggravate the Type 2 diabetes mellitus process (Vangaveti et al., 2016). It is one of the leading global causes of premature mortality due to a range of vision problems, renal dysfunction, disability, coronary heart disease, vascular disease, and physical and cognitive impairment (Noale et al., 2012). Physiologically it is observed that pancreatic islet B cells maintain glucose tolerance by their ability to overcome insulin resistance. However, this phenomenon does not occur in people with type 2 diabetes mellitus (Genser et al., 2016; Kahn, 2001).

Oxidative stress originated from metabolic overload (high caloric intake) can result in cardiovascular risk and low-grade of inflammation (Robberecht et al., 2016). Adipose cell enlargement leads to serial proinflammatory response on cells with reduced levels of adiponectin and increased levels of many cytokines and chemokines such as interleukins (IL) IL-6, IL-8, and monocyte chemoattractant protein-1 (MCP-1) (Gustafson et al., 2007).
3. THE INTESTINAL MICROBIOTA

The intestinal microbiota is a set of microorganisms that particularly colonize the gastrointestinal tract in a greater number than cells of the human body (Breban, 2016). That microbiota is directly associated with the host’s health as well as the aggravation of diseases, resultant of the great diversity of microorganisms, which makes it the most important environmental agent (Thakur et al., 2016). Although, cross-sectional studies and short-term intervention experiments have brought important information about the relationship of the intestinal microbiota and parameters that characterize the MetS, some approaches still are needed to evaluate certain parameters that are relatively important such as the interaction between host genetics, diet, and microbiota in the regulation of metabolism (Ussar et al., 2015).

According to Rosenbaum et al. (2015), some specific phyla that make up the intestinal microbiota might represent about 97% of the population of microorganisms such as Bacteroidetes (~0 to 25%), Firmicutes (~60 to 65%), Proteobacteria (~5 to 10%), and Actinobacteria (~3%).

However, according to Li et al. (2016), the process of colonization and establishment of microorganisms is complex and a function of the microorganism-microorganism and the microorganism-host relations. These researches stated that this process of colonization is so dynamic that not all bacteria are able to colonize an intestinal microbiota permanently.

Moreover, it is known that an unbalance of the microbiota (dysbiosis) may be a consequence of changes in the nitrogen cycle that would compromise its diversity and amount (Briskey et al., 2016). The dysbiosis process establishes a new proportion between the two phylum Firmicutes to Bacteroidetes on the intestinal microbiota of obese individuals (Ley et al., 2005; Martinez et al., 2016). The dysbiosis process is related to many chronic syndromes through the loss of normal functions provided by a commensal microbiota that would
attenuate the disease state (Frank et al., 2011). Thus, a diet rich in fat further influences the
dysbiosis process, favouring increased serum hepatic lipids, increased circulating
lipopolysaccharide (LPS), and intestinal barrier dysfunction (Norris et al., 2016). On the
another hand, dysbiosis aggravates even further the pathogenesis of chronic inflammatory
disease that remains unexplained to date (Bredan, 2016). Due to interactions between genetic
and environmental factors, the gut microbiota also contributes to the incidence of obesity,
diabetes, and MetS (Ussar et al., 2015).

According to He et al. (2016), the development of MetS is a direct association
between an interaction of the innate immune system and the intestinal microbiota. Recent
approaches are aimed at establishing intestinal homeostasis through a specific diet that can
restore the underlying immune system or possible changes in the microbiota (Thakur et al.,
2016). In addition, it was evidenced in experimental models that strain specificity on the gut
microbiota is important to attenuation of certain immune responses related to chronic
inflammation (Kang et al., 2016). Although the intestinal microbiota of adults presents
stability, it was observed that possible changes can occur due to diet, genotypic/epigenetic
composition, and immuno-metabolic function (Ling et al., 2016). As reported by Moran and
Shanahan (2014), different signalling pathways are used as a mean of communication
between the microbiota and host involving different classes of effector ligands required to
modulate the immune system.

Inflammatory biomarker presented in oxidative and endoplasmic stress induced by
diabetes aggravate the synthesis of β-cells influencing the levels of insulin sensitivity and
blood glucose homeostasis (Hasnain et al., 2014; He et al., 2016). It is important to emphasize that
the more invasive and inflammatory the composition of the intestinal microbiota is, the
greater are the changes in the immune environment adipose compartment from M2 to M1
macrophages that may contribute to the development of the MetS (Burcelin et al., 2012; Hand
et al., 2016). Besides, according to Breban (2016), it exerts anti-inflammatory effects on intestinal cells both by reducing nuclear factor kappa B (NF-κB) levels and synthesis of pro-inflammatory cytokines by the microbiota.

In addition, the diet may change the composition of the gut microbiota, influencing the physiopathology of nutritional disorders such as obesity, severe acute malnutrition, and anorexia nervosa (Alou et al., 2016). Intake of specific nutritional supplements contributes to the modification of the microbiota composition (Hussey & Bergman, 2014). The presence of prebiotics in the diet improves the growth of beneficial species, modifying their composition in a way that can promote beneficial effects on the host’s health (Alou et al., 2016). Interest of the consumer market in supplementing food with probiotic ingredients as an alternative medicine is growing, because it claims to induce a homeostasis of the inflammatory response as a result of the presence of these beneficial microorganisms in the gastrointestinal tract (Penga et al., 2014).

4. INFLUENCE OF PREBIOTICS AND/OR PROBIOTICS ON RELATED METABOLIC SYNDROME PARAMETERS

Scientific literature has pointed out, among nutritional therapies to prevent MetS, the consumption of products containing probiotics, prebiotics, and synbiotics (Scavuzzi et al., 2015). Some beneficial effects present in this review towards specific pathological conditions described in the scientific literature resulting from the supplementation with probiotics and/or prebiotics are shown in Table 1.
Table 1. Main effects described for the supplementation of probiotics and/or prebiotics on the human health.

| Clinical conditions                        | Study design                          | N (completed) | Intake vehicle | Dose and consumption period                                      | Effect                                                                 | Reference                          |
|-------------------------------------------|---------------------------------------|---------------|----------------|------------------------------------------------------------------|------------------------------------------------------------------------|------------------------------------|
| Abdominal pain                            | Randomized double-blind placebo-controlled trial | 93            | Tablets        | Lactobacillus reuteri DSM 17938 (10^9 CFU/g) for 4 weeks        | Decrease of abdominal pain                                              | Weizman et al., 2016               |
| Dyslipidaemia                             | Randomized double-blind placebo-controlled crossover trial | 37            | Capsules       | Bifidobacterium animalis subsp. lactis MB 2409 (DSM 23733), Bifidobacterium MB 109 (DSM 23731), and Bifidobacterium longum subsp. longum BL04 (DSM 23233), each at the dosage of 10^10 CFU for 12 weeks | Decrease of lipid profile                                                  | Guardamagna et al., 2014          |
| Gestational diabetes mellitus             | Randomized double-blind placebo-controlled trial | 60            | Capsules       | Lactobacillus acidophilus (2×10^9 CFU/g), Lactobacillus casei (2×10^9 CFU/g) and Bifidobacterium bifidum (2×10^9 CFU/g) for 6 weeks | Decrease glycemia levels, triglycerides, and very low-density lipoprotein cholesterol | Karamali et al., 2016               |
| Healthy                                   | Randomized double-blind placebo-controlled trial | 110           | Sachet         | Lactobacillus plantarum LP01 and Bifidobacterium breve BR03 (2.5×10^9 CFU/g), Bifidobacterium animalis subsp. lactis BS01 (5×10^9 CFU/g) for 30 days | Relief at the evacuation                                                    | Del Piano et al., 2010             |
| Postmenopausal women with metabolic syndrome | Randomized double-blind placebo-controlled trial | 24            | Fermented milk | Lactobacillus plantarum Lp-115 (1.25×10^8 CFU/g) for 12 weeks | Decrease glucose levels and homocysteine                                | Barreto et al., 2014               |
| Healthy                                   | Randomized double-blind placebo-controlled trial | 21            | Yoghurt and tablet | Bifidobacterium animalis DN-173 010 (2×10^9 CFU/g), Lactobacillus reuteri DSM 17918 (10^9 CFU/g), and Lactobacillus plantarum 299v (10^9 CFU/g) for 2 weeks | Glycemic homeostasis                                                      | Nilsson et al. 2016                |
| Patients with metabolic syndrome          | Randomized double-blind placebo-controlled trial | 51            | Fermented milk | Bifidobacterium animalis ssp. lactis HN019 (3.4×10^9 CFU/g) for 6 weeks | Decrease in body mass index measure, total cholesterol levels and low-density lipoprotein cholesterol | Bernini et al. 2016                |
| Irritable bowel syndrome                  | Randomized double-blind placebo-controlled multicentric trial | 30            | Fermented milk | Lactobacillus acidophilus La-5 (1.8×10^9 CFU/g) and Bifidobacterium animalis ssp. lactis BB-12 (2.5×10^9 CFU/g) and 2% dietary fiber Beneo Orafti Synergy1 (90% inulin, 10% oligofructose) for 7 weeks | Decrease of symptoms of irritable bowel syndrome                           | Matijasic et al., 2016             |
| Major depressive disorder                 | Randomized double-blind placebo-controlled trial | 40            | Capsules       | Lactobacillus acidophilus YAB (2×10^9 CFU/g), Lactobacillus casei TD7 (2×10^9 CFU/g), and Bifidobacterium bifidum B12 (2×10^9 CFU/g) for 8 weeks | Decrease serum insulin levels and homeostasis model of assessment of insulin resistance | Akkasheh et al. 2016               |
| Hypercholesterolemia                      | Randomized double-blind placebo-controlled trial | 32            | Capsules       | Lactobacillus acidophilus CHO-220 (10^9 CFU/g) and 0.2 g inulin for 12 weeks | Decrease of total cholesterol levels, high-density lipoprotein cholesterol, and very low-density lipoprotein cholesterol | Oon et al. 2010                    |
| Type 2 diabetes mellitus                  | Randomized double-blind placebo-controlled trial | 49            | Sachet         | 10 g chicory inulin enriched with fructooligosaccharides for 8 weeks | Glycemic homeostasis                                                      | Farhangi et al., 2016             |
| Type 2 diabetes mellitus                  | Randomized double-blind placebo-controlled trial | 49            | Sachet         | Daily dose of 10 g of fructooligosaccharides enriched inulin for 8 weeks | Improvements in immune system with increasing IL-4 (anti-inflammatory cytokine); reduction in IL-12 and IFN levels (inflammatory cytokines). | Dehghan et al. 2016               |
| Type 2 diabetes mellitus                  | Randomized double-blind placebo-controlled crossover trial | 102           | Packages       | Lactobacillus sporogenes (10^9 CFU/g), 0.1 g inulin and 0.05 g beta-carotene for 6 weeks | Decrease of serum insulin levels, homeostasis model of assessment of insulin resistance, triglycerides, very low-density lipoprotein cholesterol, and total cholesterol/high-density lipoprotein cholesterol | Asemi et al., 2016                 |
High levels of triglycerides and low levels of HDL-cholesterol contribute to the accumulation of fatty acids as visceral adiposity in subjects with MetS (Welty et al., 2016). Consequently, this clinical picture contributes to the aggravation of cardiovascular diseases (Tselios et al., 2016) and cerebrovascular accident (Shin et al., 2015). Song et al. (2014) correlated triglyceride and HDL-cholesterol levels with immunoglobulin M (IgM) synthesis in individuals with MetS. The blood test data from 10,015 participants, including immunological tests, showed increased triglycerides levels and decreased HDL-C levels correlating with the reduction of IgM levels in individuals with MetS.

Jones et al. (2012b) evaluated the influence of the daily intake of two capsules containing 2.9x10^9 CFU of L. reuteri NCIMB 30242 in a randomized, multi-centre, placebo-controlled design. The authors reported that the probiotic strain did not influence the glycaemia levels of 124 hypercholesterolemic volunteers during 9 weeks of intervention. On the other hand, Ejtahed et al. (2012) evaluated the glycaemia levels of 64 diabetic patients who consumed 300 g/day of probiotic yogurt containing 1.8x10^6 CFU/g of Bifidobacterium animalis subsp. lactis BB-12 and 1.9x10^6 CFU/g of Lactobacillus acidophilus La-5 for 6 weeks of supplementation. According to these researchers, the changes in the intestinal microbiota related to the presence of probiotic microorganisms possibly contributed to a reduction in glucose levels throughout the intervention period.

It has been shown that the supplementation of two prebiotics, inulin and fructooligosaccharides (FOS), in the diet of rats possibly contributed positively to the prevention of some metabolic disorders, such as arterial hypertension, hypertriglyceridemia, in addition to renal damage on the animals evaluated (Rault-Nania et al., 2008). As a result of their secondary metabolism, these microorganisms release short-chain fatty acids (SCFA), among them acetate and propionate, through complex metabolic pathways present in
numerous species belonging to the phyla Actinobacteria, Firmicutes, Bacteroidetes and others (Miremadi et al. 2016).

5. PREBIOTICS’ AND PROBIOTICS’ MECHANISMS OF ACTION ON THE HOST

The mechanism of action of probiotics on the host is not yet clearly elucidated. However, the literature has several studies with in vivo and in vitro models which support some hypotheses (Daliri & Lee, 2015). Although some mechanisms of action of probiotics, prebiotics, and synbiotics to reduce cholesterol levels are reported in the scientific literature (Bedani et al., 2015; Miremadi et al., 2014; Zhang et al., 2017), there is a consensus about the importance of the strain specificity in relation to its possible mechanisms of action for probiotic effects (Higashikawa et al., 2010; Ooi & Liong, 2010).

According to the literature, the main mechanism of action of prebiotics is their ability to reduce lipid levels in the bloodstream by the presence of SFCA synthesized in the intestinal microbiota (Miremadi et al., 2016). As a source of energy, these fibres stimulate the development of microorganisms in the microbiota that release bioactive compounds such as acetate, propionate, butyrate, isobutyrate, valerate, isovalerate, and caproate (Breban, 2016; Ooi & Ling, 2010; Fernández et al., 2016; Wang et al., 2012b). Thus, these SCFA can inhibit the synthesis of hepatic cholesterol and/or assist in the redistribution of cholesterol from the plasma to the liver (Al-Sheraji et al., 2012).

The modulation of hepatic cholesterol biosynthesis in the body begins by absorption of the SCFA in the gastrointestinal tract, where they are metabolised by the liver cells (Fernández et al., 2016; Wong et al., 2006). In turn, propionate and butyrate are also involved in the control of hepatic cholesterol synthesis that can lead to the reduction of plasma cholesterol levels (Trautwein et al., 1998). Thus, this can inhibit hepatic cholesterol synthesis.
and/or assist in the redistribution of cholesterol from plasma to liver (Al-Sheraji et al., 2012). Metabolism of cholesterol in the liver is a result of hepatic modulation that increases the levels of bile acids excretion, according to the presence of endogenous cholesterol (Ditscheid et al., 2005). The deconjugated bile salts are less absorbed along the intestinal lumen and excreted through the faeces after the hydrolysis process, resulting in free bile acids (Jones et al., 2012a; Kumar et al., 2012; Wang et al., 2012a). This process increases the demand for cholesterol molecules by the body as precursors for the synthesis of new bile salts (Begley et al., 2006). It is not entirely clear whether SCFA actually promotes beneficial effects to the host’s health by modulating the immune system by regulatory T (Tregs) and innate immune cells or by regulating other metabolic aspects (Hand et al., 2016).

Among the mechanisms responsible for the hypocholesterolemic effect, it has often been attributed to the assimilation and/or incorporation of the cholesterol molecule into the bacteria cell membrane during the microbial growth phase (Alhaj et al., 2010; Kumar et al., 2012). The binding of cholesterol to the cell surface can occur, independently of the physiological state of the cell (living or dead) (Kimoto et al., 2002). Nevertheless, it was clear in this research that some microorganisms in the growth phase can remove higher levels of cholesterol compared to the dead cell. Choi and Chang (2015) have demonstrated in an in vitro study that *L. plantarum* EM possesses a great ability to bind the cholesterol molecule to its cell surface, regardless of its viability. Thus, this mechanism of action reduces its absorption in the gastrointestinal tract after the assimilation of this lipid molecule on the cell surface (Lye et al., 2010).

Some studies indicate that the daily supplementation of *L. plantarum* and *L. casei* strains showed a potential anti-hypertensive effect in hypertensive volunteers (Naruszewicz et al., 2002; Nakajima et al., 1995). As observed by Lollo et al. (2015), probiotics have contributed to the reduction of blood pressure through the degradation of proteins from the
food matrix, mainly milk protein, releasing peptides with a hypotensive effect that act on the renin-angiotensin system.

Mechanisms of action of probiotics on the modulation of the immune system still require more investigation in order to carry out hypotheses that lead to a conclusion (Reid et al., 2016). A possible mechanism suggested by Tejada-Simon et al. (1999) is the influence of some components of the bacterial cell on the immunomodulatory activity in the lymphoid tissue. According to these researchers, cell membrane components such as peptidoglycans and endotoxic lipopolysaccharides (LPS) would be responsible for the signalling and translocation of antigens by the intestinal mucosal barrier. Hence, activation of an immune response by a non-pathogenic strain contributes to homeostasis, favouring an immunomodulatory reaction by the host's immune system (Kotzamanidis et al., 2010). Activation of certain immune defence cells such as dendritic cells and T-helper 1 lymphocytes have been modulated by *L. acidophilus* by the toll-like and proteoglycan receptor recognition of enterocytes (Daliri & Lee, 2015). Thus, the adhesion of probiotic strains on the intestinal epithelia in function of the hydrophobic affinity and autoaggregation of the cell surface can stimulate the immune responses in the gut-associated lymphoid tissue (GALT) through the strain antigen (Kotzamanidis et al., 2010). However, some interactions such as hydrophobic and autoaggregation of the cell surface can be impaired by exposure to the bile salts resulting from the digestive process (Burns et al., 2011). As observed by Thakur et al. (2016), among *Lactobacillus* strains, only *Lactobacillus casei* Lbs (MTCC5953) showed the ability to reduce the secretion of tumour necrosis factor alpha (TNF-α) and IL-6 after induction by the presence of LPS in an *in vivo* assay with rats. Besides, *L. rhamnosus* GG has the ability to modulate the immune system through the reduction in IL-8 levels induced by TNF-α (Zhang et al., 2005). Consequently, in addition to inhibiting the secretion of IL-8, this strain stimulates increased levels of nerve growth factor (NGF) (Ma et al., 2004).
6. CONCLUSIONS

In this review article, we have described that numerous non-transmissible chronic diseases result from the process of intestinal dysbiosis, thus, evidencing the importance of the function of the intestinal microbiota on the health of the host through an organized system. Besides, beneficial association between modulation of the intestinal microbiota and prevention of the components related with MetS through a daily diet composed of foods containing probiotic strains and prebiotic fibres are showing promising results. A better understanding of the mode of action of probiotics ingredients and/or prebiotics in clinical trials are required for their application, aiming at beneficial effects of their supplementation on the human health. Therefore, studies have shown that a regular diet with these bioactive compounds promotes beneficial effects on the MetS-related parameters.
7. REFERENCES

Afsana, F., Latif, Z. A., Haq, M., Ahmed, T., Habib, S. H., & Mahtab, H. (2010). Characteristics of different parameters of metabolic syndrome in subjects undergoing coronary angiogram and their association with peripheral vascular disease. *Diabetes & Metabolic Syndrome: Clinical Research & Reviews*, 4, 220–225.

Akkasheh, G., Kashani-Poor, Z., Tajabadi-Ebrahimi, M., Jafari, P., Akbari, H., Taghizadeh, M., Memarzadeh, M. R., Asemi, Z., & Esmaillzadeh, A. (2016). Clinical and metabolic response to probiotic administration in patients with major depressive disorder: A randomized, double-blind, placebo-controlled trial. *Nutrition*, 32, 315–320.

Al-Daghri, N. M., Clerici, M., Al-Attas, O., Forni, D., Alokail, M. S., Alkharfy, K. M., Sabico, S., Mohammed, A. K., Cagliani, R., & Sironi, M. (2013). A nonsense polymorphism (R392X) in TLR5 protects from obesity but predisposes to diabetes. *Journal of Immunology*, 190, 3716-3720.

Al-Sheraji, S. H., Ismail, A., Manap, M. Y., Mustafa, S., Yusof, R. M., & Hassan, F. A. (2012). Hypocholesterolemic effect of yoghurt containing *Bifidobacterium pseudocatenulatum* G4 or *Bifidobacterium longum* BB536. *Food Chemistry*, 135, 356-361.

Alhaj, O. A., Kanekanian, A. D., Peters, A. C., & Tatham, A. S. (2010). Hypocholesterolemic effect of *Bifidobacterium animalis* subsp. *lactis* (Bb12) and trypsin casein hydrolysate removal of cholesterol via attachment to cellular surface. *Food Chemistry*, 123, 430-435.

Alou, M. T.; Lagier, J-C, & Raoult, D. (2016). Diet influence on the gut microbiota and dysbiosis related to nutritional disorders. *Human Microbiome Journal*, 1, 3–11.

Al-Sheraji, S. H., Ismail, A., Manap, M. Y., Mustafa, S., Yusof, R. M., & Hassan, F. A. (2012). Hypocholesterolemic effect of yoghurt containing *Bifidobacterium*
pseudocatenulatum G4 or Bifidobacterium longum BB536. *Food Chemistry*, 135, 356-361.

ANVISA (2016). Probióticos. Retrieved from: http://portal.anvisa.gov.br/informacoes-tecnicas13?p_p_id=101_INSTANCE_FXrpx9qY7FbU&p_p_col_id=column-2&p_p_col_pos=1&p_p_col_count=2&_101_INSTANCE_FXrpx9qY7FbU_groupId=219201&_101_INSTANCE_FXrpx9qY7FbU_urlTitle=probioticos&_101_INSTANCE_FXrpx9qY7FbU_struts_action=%2Fasset_publisher%2Fview_content&_101_INSTANCE_FXrpx9qY7FbU_assetEntryId=2864062&_101_INSTANCE_FXrpx9qY7FbU_type=content. Access: Jan 18th, 2017.

Asemi, Z., Alizadeh, S-A., Ahmad, K., Goli, M., & Esmaillzadeh, A. (2016). Effects of beta-carotene fortified synbiotic food on metabolic control of patients with type 2 diabetes mellitus: A double-blind randomized cross-over controlled clinical trial. *Clinical Nutrition*, 35, 819-825.

Barreto, F. M., Simão, A. N. C., Morimoto, H. K., Lozovoy, M. A. B., Dichi, I., & Miglioranza, L. H. S. (2014). Beneficial effects of *Lactobacillus plantarum* on glycemia and homocysteine levels in postmenopausal women with metabolic syndrome. *Nutrition*, 30, 939–942.

Bedani, R., Rossi, E. A., Cavallini, D. C. U., Pinto, R. A., Vendramini, R. C., Augusto, E. M., Abdalla, D. S. P., & Saad, S. M. I. (2015). Influence of daily consumption of Synbiotic soy-based product supplemented with okara soybean by-product risk factors for cardiovascular diseases. *Food Research International*, 73, 142-148.

Begley, M., Hill, C., & Gahan, C. G. M. (2006). Bile Salt Hydrolase Activity in Probiotics. *Applied and Environmental Microbiology*, 72, 1729-1738.

Bernini, L. J., Simão, A. N. C., Alfieri, D. F., Lozovoy, M. A. B., Mari, N. L., Souza, C. H.
B., Dichi, I., & Costa, G. N. (2016). Beneficial effects of *Bifidobacterium lactis* on lipid profile and cytokines in patients with metabolic syndrome: A randomized trial. Effects of probiotics on metabolic syndrome. *Nutrition*, 32, 716–719.

Bhatnagar, M. K., Arora, S., Singh, V., & Bhattacharjee, J. (2011). Assessment of insulin resistance using surrogate markers in patients of metabolic syndrome. *Diabetes & Metabolic Syndrome: Clinical Research & Reviews*, 5, 29–32.

Bitzur, R., Brenner, R., Maor, E., Antebi, M., Ziv-Baran, T., Segev, S., Sidi, Y., & Kivity, S. (2016). Metabolic syndrome, obesity, and the risk of cancer development. *European Journal of Internal Medicine*, 34, 89–93.

Boden G. (2008). Obesity and free fatty acids. *The Medical clinics of North America*, 37, 635-646.

Boyko, E. J., Doheny, R. A., Mcneely, M. J., Kahn, S. E., Leonetti, D. L., & Fujimoto, W. Y. (2010). Latent class analysis of the metabolic syndrome. *Diabetes Research and Clinical Practice*, 89, 88-93.

Breban, M. (2016). Gut microbiota and inflammatory joint diseases. *Joint Bone Spine*, 83, 645–649.

Briskey, D., Tucker, P. S., Johnson, D. W., & Coombes, J. S. (2016). Microbiota and the nitrogen cycle: Implications in the development and progression of CVD and CKD. *Nitric Oxide*, 57, 64-70.

Bukowska, H., Pieczul-Mróz, J., Chelstowski, K., & Naruszewicz, M. (1997). Effect of *Lactobacillus plantarum* (pro viva) on LDL-cholesterol and fibrinogen levels in subjects with moderately elevated cholesterol. *Atherosclerosis*, 134, 325, 1997.

Burcelina, R., Garidoua, L., & Pomié, C. (2012). Immuno-microbiota cross and talk: The new paradigm of metabolic diseases. *Seminars in Immunology*, 24, 67–74.
Burns, P., Reinheimer, J., & Vinderola, G. (2011). Impact of bile salt adaptation of *Lactobacillus delbrueckii* subsp. *lactis* 200 on its interaction capacity with the gut. *Research in Microbiology*, 162, 782-790.

Cameron, A. J., Magliano, D. J., Zimmet, P. Z., Welborn, T., & Shaw, J. E. (2007). The Metabolic Syndrome in Australia: Prevalence using four definitions. *Diabetes Research and Clinical Practice*, 77, 471–478.

Choi, E. A., & Chang, H. C. (2015). Cholesterol-lowering effects of a putative probiotic strain *Lactobacillus plantarum* EM isolated from kimchi. *LWT - Food Science and Technology*, 62, 210-217.

Chou, C-L., & Fang, T-C. (2010). Incidental Chronic Kidney Disease in Metabolic Syndrome. *Tzu Chi Medical Journal*, 22, 11-17.

Cruz, A. G., Cadena, R. S., Walter, E. H. M., Mortazavian, A. M., Granato, D., Faria, J. F., & Bolini, H. M. A. (2010). Sensory Analysis: Relevance for Prebiotic, Probiotic, and Synbiotic Product Development. *Comprehensive Reviews in Food Science and Food Safety*, 9, 358-373.

Kim, D., Yoon, S.-J., Lim, D.-S., Gong, Y.-H., Ko, S., Lee, Y.-H., Lee, H.S., Park, M.-S., Kim, K.-H., & Y.A. Kim. (2016). The preventive effects of lifestyle intervention on the occurrence of diabetes mellitus and acute myocardial infarction in metabolic syndrome. *Public Health*, 139, 178-182.

Daliri, E. B-M., & Lee, B. H. (2015). New perspectives on probiotics in health and disease. *Food Science and Human Wellness*, 4, 56–65.

Dehghan, P., Farhangi, M. A., Tavakoli, F., Aliasgarzadeh, A., & Akbari, A. M. (2016). Impact of prebiotic supplementation on T-cell subsets and their related cytokines, anthropometric features and blood pressure in patients with type 2 diabetes mellitus: A
randomized placebo-controlled Trial. *Complementary Therapies in Medicine*, 24, 96–102.

Del Piano, M., Carmagnola, S., Anderloni, A., Andorno, S., Ballarè, M., Balzarini, M., Montino, F., Orsello, M., Pagliarulo, M., Sartori, M., Tari, R., Sforza, F., & Capurso, L. (2010). The Use of Probiotics in Healthy Volunteers With Evacuation Disorders and Hard Stools A Double-blind, Randomized, Placebo-controlled Study. *Journal of Clinical Gastroenterology*, 44, S30-S34.

Ditscheid, B., Keller, S., & Jahreis, G. (2005). Cholesterol Metabolism is Affected by Calcium Phosphate Supplementation in Humans. *The Journal of Nutrition*, 135, 1678-1682.

Eckel, R. H., Alberti, K. G., Grundy, S. M., & Zimmet, P. Z. (2010). The metabolic syndrome. *Lancet*, 375, 181-183.

Eckel, R. H., Grundy, S. M., & Zimmet, P. Z. (2005). The metabolic syndrome. *Lancet*, 365, 1415–1428.

Ejtaheh, H. S., Mohtadi-Nia, J., Homayouni-Rad, A., Niafar, M., Asghari-Jafarabadi, M., & Mofid, V. (2012). Probiotic yogurt improves antioxidant status in type 2 diabetic patients. *Nutrition*, 28, 539–543.

Farhangia, M. A., Javid, A. Z., & Dehghan, P. (2016). The effect of enriched chicory inulin on liver enzymes, calcium homeostasis and hematological parameters in patients with type 2 diabetes mellitus: A randomized placebo-controlled trial. *Primary Care Diabetes*, 10, 265–271.

Fernández, J., Redondo-Blanco, S., Gutiérrez-del-Río, I., Miguélez, E. M., Villar, C. J., & Lombó, F. (2016). Colon microbiota fermentation of dietary prebiotics towards short-chain fatty acids and their roles as anti-inflammatory and antitumour agents: A review.
Journal of Functional Foods, 25, 511–522.

Frank, D. N., Zhu, W., Sartor, R. B., & Li, E. (2011). Trends in Microbiology, 19, 427-434.

Gallagher, E. J., Leroith, D., & Karnieli, E. (2011). The metabolic syndrome--from insulin resistance to obesity and diabetes. The Medical Clinics of North America, 95, 855-873.

Genser, L., Mariolo, J. R. C., Castagneto-Gissey, L., Panagiotopoulos, S., & Rubino, F. (2016). Obesity, Type 2 Diabetes, and the Metabolic Syndrome: Pathophysiologic Relationships and Guidelines for Surgical Intervention. Surgical Clinics of North America, 96, 681–701.

Gibson, G. R., Hutkins, R., Sanders, M. E., Prescott, S. L., Reimer, R. A., Salminen, S. J., Scott, K., Stanton, C., Swanson, K. S., Cani, P. D., Verbeke, K., & Reid, G. (2017). Expert consensus document: The International Scientific Association for Probiotics and Prebiotics (ISAPP) consensus statement on the definition and scope of prebiotics. Nature Reviews Gastroenterology & Hepatology, 14, 491-502.

Gibson, G. R., Probert, H. M., Loo, J. V., Rastall, R. A., & Roberfroid, M. B. (2004). Dietary modulation of the human colonic microbiota: updating the concept of prebiotics. Nutrition Research Reviews, 17, 259–275.

Gibson, G. R., Scott, K. P., Rastall, R. A., Tuohy, K. M., Hotchkiss, A., Dubert-Ferrandon, A., Gareau, M., Murphy, E., F., Saulnier, D., Loh, G., Macfarlane, S., Delzenne, N., Ringel, Y., Kozianowski, G., Dickmann, R., Lenoir-Wijnkoop, I., Walker, C., & Buddington, R. (2010). Dietary prebiotics: current status and new definition. Food Science and Technology Bulletin Functional Foods, 7, 1–19.

Giugliano, D., Ceriello, A., & Esposito, K. (2008). Are there specific treatments for the metabolic syndrome? The American Journal of Clinical Nutrition, 87, 8-11.

Graf, C., & Ferrari, N. (2016). Metabolic Syndrome in Children and Adolescents. Visceral
Grundy, S. M., Cleeman, J. I., Daniels, S. R., Donato, K. A., Eckel, R. H., Franklin, B. A.,
Gordon, D. J., Krauss, R. M., Savage, P. J., Smith Jr, S. C., Spertus, J. A., & Costa, F.
(2005). Diagnosis and Management of the Metabolic Syndrome an American Heart
Association/National Heart, Lung, and Blood Institute Scientific Statement. Circulation,
112, 2735-2752.

Guardamagna, O., Amaretti, A., Emilio, P., Raimondi, S., Abello, F., Caglieri, P., & Rossi,
M. (2014). Bifidobacteria supplementation: Effects on plasma lipid profiles in
dyslipidemic children. Nutrition, 30, 831–836.

Gustafson, B., Hammarstedt, A., Andersson, C. X., & Smith, U. (2007). Inflamed Adipose
Tissue A Culprit Underlying the Metabolic Syndrome and Atherosclerosis.
Arteriosclerosis, Thrombosis, and Vascular Biology, 27, 2276-2283.

Hand, T. W., Ivan, V-C, Ridaura, V. K., & Belkaid, Y. (2016). Linking the Microbiota,
Chronic Disease, and the Immune System. Trends in Endocrinology & Metabolism, 27,
831–843.

Hartstra, A. V., Nieuwdorp, M., & Herrema, H. (2016). Interplay between gut microbiota, its
metabolites and human metabolism: Dissecting cause from consequence. Trends in Food
Science & Technology, 57, 233-243.

Hasnain, S. Z., Borg, D. J., Harcourt, B. E., Tong, H., Sheng, Y. H., Ng, C. P., Das, I., Wang,
R., Chen, A. C-H., Loudovaris, T., Kay, T., Thomas, H. E., Whitehead, J. P., Forbes, J.
M., Prins, J. B., & McGuckin, M. A. (2014). Glycemic control in diabetes is restored by
therapeutic manipulation of cytokines that regulate beta cell stress. Nature Medicine, 20,
1417–1426.

He, C., Shan., Y., & Song, W. (2016). Targeting gut microbiota as a possible therapy for
diabetes. *Nutrition Research*, 35, 361–367.

Health Canada (2009) Guidance document – The use of probiotic microorganisms in food. Retrieved from: http://www.hc-sc.gc.ca/fn-an/alt_formats/hpfb-dgpsa/pdf/legislation/probiotics_guidance-orientation_probiotiques-eng.pdf. Access: May 25th, 2016.

Higashikawa, F., Noda, M., Awaya, T., Nomura, B. S. K., Oku, H., & Sugiyama, M. (2010). Improvement of constipation and liver function by plant-derived lactic acid bacteria: A double-blind, randomized trial. *Nutrition*, 26, 367–374.

Hill, C., Guarner, F., Reid, G., Gibson, G. R., Merenstein, D. J., Pot, B., Morelli, L., Canani, B. R., Flint, H. J., Salminen, S., Calder, P. C., & Sanders, M. E. (2014). The International Scientific Association for Probiotics and Prebiotics consensus statement on the scope and appropriate use of the term probiotic. *Nature reviews. Gastroenterology & Hepatology*, 11, 506–514.

Holloway, G. P., Luiken, J. J., Glatz, J. F., Spriet, L. L., & Bonen A. (2008). Contribution of FAT/CD36 to the regulation of skeletal muscle fatty acid oxidation: an overview. *Acta physiologica*, 194, 293–309.

Huang, C-H., Shen, C-C., Liang, Y-C., & Jan, T-R. (2016). The probiotic activity of *Lactobacillus murinus* against food allergy. *Journal of Functional Foods*, 25, 231–241.

Hussey, S, & Bergman, M. (2014). The Gut Microbiota and Effects on Metabolism. *Pathobiology of Human Disease: A Dynamic Encyclopedia of Disease Mechanisms*, 508-526.

Hutkins, R. W., Krumbeck, J. A., Bindels, L. B., Cani, P. D., Fahey Jr, G., Goh, J. Y., Hamaker, B., Martens, E. C., Mills, D. A., Rastal, R. A., Vaughan, E., & Sanders, M. E. (2016). Prebiotics: why definitions matter. *Current Opinion in Biotechnology*, 37, 1-7.
Jones, M. L., Martoni, C. J., Parent, M., & Prakash, S. (2012a). Cholesterol-lowering efficacy of a microencapsulated bile salt hydrolase-active Lactobacillus reuteri NCIMB 30242 yoghurt formulation in hypercholesterolemic adults. *British Journal of Nutrition*, 107, 1505–1513.

Jones, M. L., Martoni, C. J., Pietro, E. D., Simon, R. R., & Prakash, S. (2012b). Evaluation of clinical safety and tolerance of a Lactobacillus reuteri NCIMB 30242 supplement capsule: A randomized control trial. *Regulatory Toxicology and Pharmacology*, 63, 313-320.

Kahn R. (2007). Metabolic syndrome: Is it a syndrome? Does it matter? *Circulation*, 115, 1806-1810.

Kahn, S. E. (2001). Clinical review 135: the importance of beta-cell failure in the development and progression of type 2 diabetes. *The Journal of Clinical Endocrinology & Metabolism*, 86, 4047–4058.

Kang, Y. B., Cai, Y., & Zhang, H. (2016). Gut microbiota and allergy/asthma: From pathogenesis to new therapeutic strategies. *Allergologia et Immunopathologia*, 45, 305-309.

Karamali, M.; Dadkhah, F.; Sadrkhanlou, M.; Jamilian, M.; Ahmadi, S.; Tajabadi-Ebrahimi, M.; Jafari, P.; & Asemi, Z. (2016). Effects of probiotic supplementation on glycaemic control and lipid profiles in gestational diabetes: A randomized, double-blind, placebo-controlled trial. *Diabetes & Metabolism*, 42, 234–241.

Karpe, F., Dickmann, J. R., & Frayn, K. N. (2011). Fatty Acids, Obesity, and Insulin Resistance: Time for a Reevaluation. *Diabetes*, 60, 2441-2449.

Kim, D., Yoon, S.-J., Lim, D.-S., Gong, Y.-H., Ko, S., Lee, Y.-H., Lee, H.S., Park, M.-S., Kim, K.-H., & Y.A. Kim. (2016). The preventive effects of lifestyle intervention on the
occurrence of diabetes mellitus and acute myocardial infarction in metabolic syndrome. 

*Public Health*, 139, 178-182.

Kimoto, H., Ohmomo, S., & Okamoto, T. (2002). Cholesterol Removal from Media by *Lactococci*. *Journal Dairy of Science*, 85, 3182-3188.

Kotzamanidis, C., Kourelis, A., Litopoulou-Tzanetaki, E., Tzanetakis, N., & Yiangou, M. (2010). Evaluation of adhesion capacity, cell surface traits and immunomodulatory activity of presumptive probiotic *Lactobacillus* strains. *International Journal of Food Microbiology*, 140, 154–163.

Kumar, M., Nagpal, R., Kumar, R., Hemalatha., Verma, V., Kumar, A., Chakraborty, C., Singh, B., Marotta, F., Jain, S., & Yadav, H. (2012). Cholesterol-Lowering Probiotics as Potential Biotherapeutics for Metabolic Diseases. *Experimental diabetes research*, 2012, 1-14.

Ley, R. E., Bäckhed, F., Turnbaugh P., Lozupone, C. A., Knight, R. F., & Gordon, J. I. (2005). Obesity alters gut microbial ecology. *Proceedings of the National Academy Sciences of the United States of America*, 102, 11070–11075.

Li, D., Wang, P., Wang, P., Hu, X., & Chen, F. (2016). The gut microbiota: A treasure for human health. *Biotechnology Advances*, 34, 1210–1224.

Ling, Q. L., Ting, L. H., Lei, Z., Chen, F. Q., & Ping, J. W. (2015). Effect of the Gut Microbiota on Obesity and Its Underlying Mechanisms: an Update. *Biomedical and Environmental Sciences*, 28, 839-847.

Lollo, P. C. B., Morato, P. N., Moura, C. S., Almada, C. N., Felicio, T. L., Esmerino, E. A., Barros, M. E., Amaya-Farfan, J., Sant'Ana, A. S., Raices, R. R. S., Silva, M. C., & Cruz, A. G. (2015). Hypertension parameters are attenuated by the continuous consumption of probiotic Minas cheese. *Food Research International*, 76, 611–617.
Luke, J. N., Brown, A., Daniel, M., O’Dea, K., Best, J. D., Jenkins, A. J., Wang, Z., McDermott, R. A., Wang, Z., & Rowley, K. G. (2013). The metabolic syndrome and CVD outcomes for a central Australian cohort. *Diabetes Research and Clinical Practice*, 100, 70–73.

Lye, H.-S., Rahmat-Ali, G. R., & Liong, M.-T. (2010). Mechanisms of cholesterol removal by lactobacilli under conditions that mimic the human gastrointestinal tract. *International Dairy Journal*, 20, 169–175.

Ma, Y., Liu, J., Shi, H., & Yu, L. (2016). Isolation and characterization of anti-inflammatory peptides derived from whey protein. *Journal of Dairy Science*, 99, 6902-6912.

Martin, A., Neale, E. P., Batterham, M., & Tapsell, L. C. (2016). Identifying metabolic syndrome in a clinical cohort: Implications for prevention of chronic disease. *Preventive Medicine Reports*, 4, 502–506.

Martinez, K. B., Pierre, J. F., & Chang, E. B. (2016). The Gut Microbiota: The Gateway to Improved Metabolism. *Gastroenterology Clinics of North America*, 45, 601–614.

Martinez, R. C. R., Bedani, R., & Saad, S. M. I. (2015). Scientific evidence for health effects attributed to the consumption of probiotics and prebiotics: an update for current perspectives and future challenges. *British Journal of Nutrition*, 114, 1993–2015.

Matijašić, B. B., Obermajer, T., Lipoglavšek, L., Sernel, T., Locatelli, I., Kos, M. Šmid, A., & Rogelj, I. (2016). Effects of synbiotic fermented milk containing *Lactobacillus acidophilus* La-5 and *Bifidobacterium animalis* ssp. *lactis* BB-12 on the fecal microbiota of adults with irritable bowel syndrome: A randomized double-blind, placebo-controlled trial. *Journal of Dairy Science*, 99, 1–14.

Ministero della Salute (2013). Commissione unica per la nutrizione e la dietetica – Guidelines on probiotics and prebiotics. Retrieved from:
Miremadi, F., Sherkat, F., & Stojanovska, L. (2016). Hypocholesterolaemic effect and anti-hypertensive properties of probiotics and prebiotics: A review. *Journal of Functional Foods*, 25, 497–510.

Monroy-Muñoz, I. E., Angeles-Martinez, J., Posadas-Sánchez, R., Villarreal-Molina, T., Alvarez-León, E., Flores-Dominguez, C., Cardoso-Saldana, G., Medina-Urrutia, A., Juárez-Rojas, J. G., Posadas-Romero, C., & Alarcon, G. V. (2017). *PLA2G2A* polymorphisms are associated with metabolic syndrome and type 2 diabetes mellitus. Results from the genetics of atherosclerotic disease Mexican study. *Immunobiology*, 222, 967–972.

Moran, C. P., & Shanahan, F. (2014). Gut microbiota and obesity: Role in aetiology and potential therapeutic target. *Best Practice & Research Clinical Gastroenterology*, 28, 585-597.

Mostafa, D. K., Nasra, R. A., Zahran, N., & Ghoneim, M. T. 2016. Pleiotropic protective effects of Vitamin D against high fat diet-induced metabolic syndrome in rats: One for all. *European Journal of Pharmacology*, 792, 38–47.

Nakajima, K., Hata, Y., Osono, Y., Hamura, M., Kobayashi, S., & Watanuki, M. (1995). Antihypertensive effect of extract of *Lactobacillus casei* in patients with hypertension. *Journal of Clinical Biochemistry and Nutrition*, 18, 181–187.

Naruszewicz, M., Johansson, M-L., Zapolska-Downar, D., & Bukowska, H. (2002). Effect of *Lactobacillus plantarum* 299v on cardiovascular disease risk factors in smokers. *American Journal of Clinical Nutrition*, 76, 1249–1255.

Nilsson, A., Johansson-Boll, E., Sandberg, J., & Björck, I. (2016). Gut microbiota mediated
benefits of barley kernel products on metabolism, gut hormones, and inflammatory markers as affected by co-ingestion of commercially available probiotics: a randomized controlled study in healthy subjects. *Clinical Nutrition ESPEN*, 15, 49-56.

Noale, M., Maggi, S., Zanoni, S., Limongi, F., Zambon, S., Crepaldi, G., & ILSA working group. The metabolic syndrome, incidence of diabetes and mortality among the elderly: The Italian Longitudinal Study of Ageing. *Diabetes & Metabolism*, 38, 135–141.

Norris, G. H., Jiang, C., Ryan, J., Porter, C. M., & Blesso, C. N. (2016). Milk sphingomyelin improves lipid metabolism and alters gut microbiota in high fat diet-fed mice. *Journal of Nutritional Biochemistry*, 30, 93–101.

Ooi, L-G., & Liong, M-T. (2010). Cholesterol-Lowering Effects of Probiotics and Prebiotics: A Review of in Vivo and in Vitro Findings. *International Journal of Molecular Sciences*, 11, 2499-2522.

Org, E., Mehrabian, M., & Lusis, A. J. (2015). Unraveling the environmental and genetic interactions in atherosclerosis: Central role of the gut microbiota. *Atherosclerosis*, 241, 387-399.

Penga, J., Narasimhan, S., Marchesi, J. R., Benson, A., Wong, F. S., & Wena, L. (2014). Long term effect of gut microbiota transfer on diabetes development. *Journal of Autoimmunity*, 53, 85–94.

Rault-Nania, M., Demougeot, C., Gueux, E., Berthelot, A., Dzimira, S., Rayssiguier, Y., Rock, E., & Mazur, A. (2008). Inulin supplementation prevents high fructose diet-induced hypertension in rats. *Clinical Nutrition*, 27, 276-282.

Reid, G. (2016). Probiotics: definition, scope and mechanisms of action. *Best Practice & Research Clinical Gastroenterology*, 30, 17-25.

Robberecht, H., De Bruyne, T., & Hermans, N. (2017). Biomarkers of the metabolic
syndrome: Influence of minerals, oligo-and trace elements. *Journal of Trace Elements in Medicine and Biology*, 43, 23-28.

Rosenbaum, M., Knight, R., & Leibel, R. L. (2015). The gut microbiota in human energy homeostasis and obesity. *Trends in Endocrinology and Metabolism*, 26, 493-501.

Saad, S. M. I. (2006). Probióticos e prebióticos: o estado da arte. *Brazilian Journal of Pharmaceutical Sciences*, 42, 1-16.

Scavuzzi, B. M., Miglioranza, L. H. S., Henrique, F. C., Paroschi, T. P., Lozovoy, M. A. B., Simaão, A. N. C., & Dichi, I. (2015). The role of probiotics on each component of the metabolic syndrome and other cardiovascular risks. *Expert Opin Ther Targets*, 19, 1127-1138.

Shin J, Cho KH, Choi Y, Lee SG, Park E-C, & Jang S-I. (2016). Combined effect of individual and neighborhood socioeconomic status on mortality in patients with newly diagnosed dyslipidemia: A nationwide Korean cohort study from 2002-2013. *Nutrition, Metabolism and Cardiovascular Diseases*, 26, 207–215.

Song, K., Du, H., Zhang, Q., Wang, C., Guo, Y., Wu, H., Liu, L., Jia, Q., Wang, X., Shi, H., Sun, S., & Niu, K. (2014). Serum Immunoglobulin M Concentration Is Positively Related to Metabolic Syndrome in an Adult Population: Tianjin Chronic Low-Grade Systemic Inflammation and Health (TCLSIH) Cohort Study. *PLoS One*, 9, 88701.

Tejada-Simon, M. V., Lee, J. H., Ustunol, Z., & Pestka, J. J. (1999). Ingestion of Yogurt Containing *Lactobacillus acidophilus* and Bifidobacterium to Potentiate Immunoglobulin A Responses to Cholera Toxin in Mice. *Journal of Dairy Science*, 82, 649-660.

Thakur, B. K., Saha, P., Banik, G., Saha, D. R., Grover, S., Batish, V. K, & Das, S. (2016). Live and heat-killed probiotic *Lactobacillus casei* Lbs2 protects from experimental
colitis through Toll-like receptor 2-dependent induction of T-regulatory response.

*International Immunopharmacology*, 36, 39–50.

Trautwein, E. A., Rieckhoff, D., & Erbersdobler, H. F. (1998). Dietary Inulin Lowers Plasma Cholesterol and Triacylglycerol and Alters Biliary Bile Acid Profile in Hamsters. *The Journal of Nutrition*, 128, 1937-1943.

Tselios, K., Koumaras, C., Gladman, D. D., & Urowitz, M. B. (2016). Dyslipidemia in systemic lupus erythematosus: just another comorbidity?. *Seminars in Arthritis and Rheumatism*, 45, 604-610.

Ussar, S., Griffin, N. W., Bezy, O., Fujisaka, S., Vienberg, S., Softic, S., Deng, L., Bry, L., Gordon, J. I., & Kahn, C. R. (2016). Interactions between Gut Microbiota, Host Genetics and Diet Modulate the Predisposition to Obesity and Metabolic Syndrome. *Cell Metabolism*, 22, 516–530.

Vangaveti, V. N., Jansen, H., Kennedy, R. L., & Malabu, U. H. (2016). Hydroxyoctadecadienoic acids: Oxidised derivatives of linoleic acid and their role in inflammation associated with metabolic syndrome and cancer. *European Journal of Pharmacology*, 785, 70–76.

Vo, T.-S., & Kim, S-K. (2012). Fucoidans as a natural bioactive ingredient for functional foods. *Journal of Functional Foods*, 5, 16 –27.

Vrese, M., & Schrezenmeir, J. (2008). Probiotics, prebiotics, and synbiotics. *Advances in biochemical engineering/biotechnology*, 111, 1–66.

Wang, C-Y., Wu, S-J., Fang, J-Y., Wang, Y-P., & Shyu, Y-T. (2012a). Cardiovascular and intestinal protection of cereal pastes fermented with lactic acid bacteria in hyperlipidemic hamsters. *Food Research International*, 48, 428–434.

Wang, J., Zhang, H., Chen, X., Chen, Y., Menghebilige, & Bao, Q. (2012b). Selection of
potential probiotic lactobacilli for cholesterol-lowering properties and their effect on cholesterol metabolism in rats fed a high-lipid diet. *Journal of Dairy Science*, 95, 1645–1654.

Weizman, Z., Abu-Abed, J., & Binsztok, M. (2016). *Lactobacillus reuteri* DSM 17938 for the Management of Functional bdominal Pain in Childhood: A Randomized, Double-Blind, Placebo-Controlled Trial. *The Journal of Pediatrics*, 174, 160-164.

Welty, F. K., Alfaddagh, A., & Elajami, T. K. (2016). Targeting inflammation in metabolic syndrome. *Translational Research*, 167, 257-280.

Westerink, N. L., Nuver, J., Lefrandt, J. D., Vrieling, A. H., Gietema, J. A., & Walenkamp, A. M. E. (2016). Cancer treatment induced metabolic syndrome: improving outcome with lifestyle. *Critical Reviews in Oncology/Hematology*, 108, 128-136.

Wong, J. M. W., de Souza, R., Kendall, C. W. C., Emam, A., & Jenkins, D. J. A. (2006). Colonic health: Fermentation and short chain fatty acids. *Journal of Clinical Gastroenterology*, 40, 235–243.

Wu, X-D., Liu, M-M, Liang, X., Hu, N., & Huang, W. (2016). Effects of perioperative supplementation with pro-/synbiotics on clinical outcomes in surgical patients: A meta-analysis with trial sequential analysis of randomized controlled trials. *Clinical Nutrition*. In press. Doi: http://dx.doi.org/10.1016/j.clnu.2016.10.015.

Yki-Järvinen, H. (2002). Ectopic fat accumulation: an important cause of insulin resistance in humans. *Journal of the Royal Society of Medicine*, 95, 39–45.

Zhang, F., Qiu, L., Xu, X., Liu, Z., Zhan, H, Tao, X., Shah, P. N., & Wei, H. (2017). Beneficial effects of probiotic cholesterol-lowering strain of *Enterococcus faecium* WEFA23 from infants on diet-induced metabolic syndrome in rats. *Journal of Dairy Science*, 100, 1618–1628.
Zhang, L., Li, N., Caicedo, R., & Neu, J. (2005). Alive and dead *Lactobacillus rhamnosus* GG decrease tumor necrosis factor-alpha-induced interleukin-8 production in Caco-2 cells. *Journal of Nutrition*, 135, 1752-1756.
Chapter 2
Texture profile and sensory acceptance of a synbiotic diet aerated mousse containing *Lactobacillus acidophilus* La-5, inulin, fructooligosaccharides, and sucralose

**ABSTRACT**

This study aimed at evaluating the effects of *Lactobacillus acidophilus* La-5, inulin, fructooligosaccharides (FOS), sucralose, and time of storage on pH variation, and instrumental texture profile of a synbiotic diet mousse (SDM) during 112-day storage at -18 °C, compared to a non-synbiotic diet mousse (PDM) and another formulation of synbiotic non-diet mouse (CSM) on sensory acceptance. SDM pH throughout the storage period was slightly lower than that of PDM. SDM showed a total energy value about 20% lower than PDM. Hardness and gumminess of SDM increased and cohesiveness decreased throughout storage, while adhesiveness and springiness kept relatively stable. PDM showed lower acceptability after storage than CSM and SDM, probably due to its higher powdered milk content and absence of inulin and FOS. These results suggest that the presence of pro- and prebiotics, as well as the storage time, although causing significant changes in SDM instrumental texture profile, did not exert any appreciable influence on its sensory acceptability, and that sucralose could be a good sucrose substitute in mousses.

**Keywords:** Instrumental texture profile; Sensory performance; Probiotic; Prebiotic; Mousse.
1. INTRODUCTION

The modern lifestyle is often taken into account in developing new foods. Therefore, the search for attractive and healthier products has become a challenge for the food industry (Komatsu, Buriti, & Saad, 2008). Thus, research efforts aim at modifying the technological properties of food macromolecules to develop products able to promote improvements in the quality of consumer’s life.

According to Hill et al. (2014), a consensus declaration on the scope and the proper use of the term ‘probiotics’ has recently given by the International Scientific Association for Probiotics and Prebiotics (ISAPP) as “live micro-organisms that, when administered in adequate amounts, confer a health benefit on the host”. Probiotics have in fact attracted special attention because of their nutritional and functional properties, and a number of studies have been developed aiming to clarify the mechanisms of action of these strains in the human body (Daliri & Lee, 2015; Kemgang, Kapila, Shanmugam, Reddi, & Kapila, 2016; Reid, 2016; Shah, 2007; Vasiljevic & Shah, 2008). As a result, similar daily intake of viable probiotic cells per serving portion (10⁹ CFU/day) is recommended by the Canadian Public Health Agency (Health Canada, 2009) and the Italian Health Ministry (Ministero della Salute, 2013).

The incorporation of probiotic cultures into frozen desserts has been performed in different studies with the aim of diversifying the types of probiotic foods on the market (Cruz, Antunes, Souza, Faria, & Saad, 2009). Dairy desserts are widely consumed worldwide by several groups of consumers, including children and elderly, in different meals, environments, and occasions (Buriti & Saad, 2014), and such a large consumption is mainly influenced by the nutritional and sensory characteristics of these products (Tárrega & Costell, 2007; Ares, Giménez, & Gámbaro, 2009; Ferraz et al., 2012).
Lactobacillus are lactic acid bacteria in rod form and many species are present on the mucosal surfaces of animals (Hymes, Johnson, Barrangou & Klaenhammer, 2016). These microorganisms are widely used in the development of dairy products (Gebara, Ribeiro, Chaves, Gandara, & Gigante, 2015). Lactobacillus acidophilus La-5 stands out for playing an important role in the modulation of the intestinal microbiota, suppression of harmful bacteria, hypcholesterolemic effect, and immune tolerance (Anderson & Gilliland, 1999; Medellin-Penä & Griffiths, 2009; Zhao et al., 2015).

Prebiotic ingredients are also added to food formulations in order to develop products with functional claims that would attract consumers concerned about health (Hutkins et al., 2016). According to ISAPP, prebiotics are currently defined as “substrates that are selectively used by the host micro-organisms, conferring a health benefit” (Gibson et al., 2017). According to Wang (2009), these ingredients contribute significantly to the improved sensory characteristics of products, such as taste and flavour, as well as their structural stability during the processing period, in terms of heat, pH, and conditions favouring the Maillard reaction.

Inulin is being increasingly used in the food industry owing to its technological characteristics, especially as a fat substitute, as well as to increase the food fibre content (Barclay, Ginic-Markovic, Cooper, Petrovsky, & 2010; Bitzios, Fraser, & Haddock-Fraser, 2011; Gunnarsson, Svensson, Johansson, Karakashev, & Angelidaki, 2014; Khuenpeta et al., 2017). Moreover, the bifidogenic effect of inulin can be prolonged by an increase either in its solubility or the degree of polymerization of its chain (Pompei et al., 2008). FOS is a fairly soluble fibre, which is marketed either as a viscous syrup (containing 75% of total solids) or as a powder (up to 95% purity). In its pure form, it has a sweetness of about 30-35% compared to sucrose, combining well with delicate flavour and reducing sweetener aftertaste (Franck, 2008).
Synbiotics are nutritional supplements composed of both probiotics and prebiotics (Moumita et al., 2017; Vrese & Schrezenmeir, 2008; Wu, Liu, Liang, Hu, & Huang, 2016). According to Kolida and Gibson (2011), a synergistic activity occurs in a food matrix when the prebiotic aims to improve survival and growth of the probiotic in the host, whereas a complementary action occurs when the prebiotic selectively increases the concentrations of beneficial components of the microbiota.

It is known that many commercialized desserts contain high levels of sucrose, a sugar which is readily metabolized by the body. Its consumption has been associated with many diseases; therefore, its low intake or substitution by non-caloric sweeteners is recommended (Morais, Lima, Morais, & Bolini, 2015).

Sucralose is a sweetener derived from sucrose through the selective substitution of three hydroxyl groups by chlorine atoms, and therefore non-caloric and widely used by the food industry (Magnuson, Roberts, & Nestmann, 2017). This sweetener has a sweetening power of approximately 600 times greater than sucrose (Rodriguez Furlán, Baracco, Zaritzky, & Campderrós, 2016).

Finally, the freezing process may contribute to maintain cell vitality along the period of the product storage, reducing the probiotic mortality rate when compared to storage above 0 °C (Magariños, Selaive, Costa, Flores, & Pizarro, 2007).

The objective of this study was to evaluate the effect of *Lactobacillus acidophilus* La-5, inulin, FOS, sucralose, and time of storage on instrumental texture profile and sensory acceptance of a synbiotic diet mousse (SDM) during 112-days of storage at -18 °C, compared to a non-synbiotic diet mousse (PDM) and another containing sucrose used as a control (CSM).
2. MATERIALS AND METHODS

2.1. Production of synbiotic diet mousse

The aerated SDM was prepared as an adaptation of a low-calorie formulation developed by Buriti, Castro, and Saad (2010a,b) and characterized by Komatsu et al. (2013), which will be referred here as CSM, only used to evaluate sensory acceptability (Table 1).

Table 1. Ingredients employed in the production of synbiotic diet mousse (SDM), and non-synbiotic diet mousse (PDM), and control synbiotic mousse (CSM).

| Ingredients (g/100 g)                          | SDM     | PDM     | *CSM  |
|------------------------------------------------|---------|---------|-------|
| Skimmed milk†                                   | 61.7    | 61.7    | 59.3  |
| Skimmed milk powder‡                             | 4.0     | 14.0    | 4.0   |
| Sucrose§                                        | -       | -       | 11.0  |
| Sucralose¶                                      | 1.1     | 1.1     | -     |
| FOS§                                            | 6.0     | -       | 6.0   |
| Inulin§                                         | 4.0     | -       | 4.0   |
| Pasteurized and frozen guava pulp¶              | 20.0    | 20.0    | 12.5  |
| Stabilizer/emulsifier§                           | 2.8     | 2.8     | 2.8   |
| Lactic acid§                                     | 0.4     | 0.4     | 0.4   |
| *Lactobacillus acidophilus* La-5†               | 0.05    | -       | 0.05  |
| Total                                          | 100.0   | 100.0   | 100.0 |

†Paulista (Danone, Guaratinguetá, SP, Brazil); ‡Molico (Nestlé, Araçatuba, SP, Brazil); §União (Cosan, Limeira, SP, Brazil); ¶Sucralose (Línea Sucralose, São Paulo, SP, Brazil); †Beneo P95 (Orafti, Oreye, Belgium); ‡Beneo HP (Orafti); §Icefruit-Maisa (Icefruit Comércio de Alimentos, Tatuí, SP, Brazil); †Cremodan Mousse 30 (Danisco, Cotia, SP, Brazil); ‡Purac (Purac Sínteses, Rio de Janeiro, RJ, Brazil; 85g/100g food-grade solution); †Strain La-5 (Christian Hansen, Hoersholm, Denmark). *Previously developed non-diet sucrose-containing formulation (Buriti et al., 2010a,b; Komatsu et al., 2013), which was only used to evaluate sensory acceptability.

For the preparation of both SDM and CSM, a commercial freeze-dried direct-to-vat probiotic culture of *L. acidophilus* La-5 was used, which was stored frozen (-18±2 °C). Powdered skimmed milk and FOS were dissolved in ultra-high temperature (UHT) skimmed
milk one day before product preparation in order to make the dissolution of these ingredients easier. The resulting pre-mixture was stored under refrigeration at 4 °C until the addition of the remaining ingredients. One portion (40 mL) of this pre-mixture was sterilized at 121 °C/15 min and employed, the next day, for the activation of the probiotic culture for 120 min at 37 °C (Komatsu et al., 2013).

The other ingredients listed in Table 1 were added and mixed until complete mass uniformity in a 6 kg-mixer, model UMMSK-12 (Geiger, Pinhais, PR, Brazil). The resulting mixture was pasteurized in the same mixer at 85 °C for 5 min, allowed cooling to 40 °C and supplemented with milk containing the activated probiotic culture. Then, the mixture was kept in refrigerator (5 °C) for subsequent aeration at a temperature between 10 and 15 °C in a 20 L-planetary mixer, model 20 (Irmãos Amadio Ltda., São Paulo, SP, Brazil), during which its volume increased by 80-85%. Afterwards, the mousse was transferred to a manual filler, model IQ81-A (Intelimaq Máquinas Inteligentes, São Paulo, SP, Brazil), and then packed in polypropylene plastic pots for food with 75 mm diameter, 42 mm height and 100 mL capacity (Tries Aditivos Plásticos, São Paulo, SP, Brazil), which were sealed with aluminium cover in a sealer, model 1968 (Delgado Metalúrgica, Cotia, SP, Brazil). Figure 1 schematically illustrates the main steps of SDM manufacture.
2.2. Determination of pH and microbiological parameters

The pH values were determined on quadruplicate samples (four different pots of the same trial) using a pH meter Orion Model Three Stars (Thermofisher Scientific, Waltham, USA) equipped with a penetration electrode type for solid foods and semi-solid.

The counts of *L. acidophilus* La-5 were monitored during the production process and along the storage frozen period. For this purpose, 25 g portions of quadruplicate mousses samples (four different pots of the same trial) were collected in aseptic condition and added to 225 mL of 0.5% NaCl solution, using a Bag Mixer 400 (Interscience, St. Nom, France).
Samples were serially diluted in 0.1 peptone water solution, and seeded in MRS agar, modified by the addition of a maltose solution (50% w/v) using the pour plate method and with incubation at 37 °C for 48 h, as proposed by the International Dairy Federation (IDF, 1995).

Aliquots of 1 mL of each sample dilution were transferred to Petrifilm™ EC (3M Microbiology) and Petrifilm™ YM (3M Microbiology) plates for counting of coliforms and Escherichia coli, molds and yeasts, all according to the manufacturer's instructions. The Petrifilm™ EC plates were incubated at 35-37 °C for 24 h, while Petrifilm™ YM plates were incubated at 20-25 °C for 3 to 5 days.

2.3. Chemical composition and total energy value of mousses

Portions of SDM and PDM previously submitted to the whole storage period were also analysed in triplicate for their chemical composition and total energy value (TEV). For this purpose, the solid contents of 5.0 g mousse samples were determined by drying at 70 °C in a vacuum oven equipment, model 440/A (Nova Ética, Vargem Grande Paulista, SP, Brazil), according to Instituto Adolfo Lutz (2005). The protein content was determined by measuring the nitrogen content of mousses through the micro Kjeldahl method and multiplying by a conversion factor of 6.38, according to the AOAC official methods 690.52 (AOAC, 2003). The lipid content was quantified by the method of Soxhlet, and that of ash, or fixed mineral residue, was determined gravimetrically by incineration of 2.0 g of sample at 550 °C (Instituto Adolfo Lutz, 2005). Finally, the percentage of carbohydrates (excluding total dietary fibre) was calculated as the difference to obtain 100 % of the total composition (ANVISA, 2003).

The contents of these macronutrients were converted into TEV (kJ 100/g) through the Atwater factors and energy from all components (16.74 kJ/g × x g proteins/100 g + 16.74
kJ/g × y g carbohydrates/100 g + 6.28 kJ/g × z g fructans/100 g + 37.66 kJ/g × t g total lipids/100 g) (Roberfroid, 1999, 2005; ANVISA, 2003; FAO, 2003).

2.4. Instrumental texture profile

Texture profile analysis (TPA) was carried out in samples collected during a storage period of 112 days by double compression test at room temperature, using an aluminium cylinder with 25 mm diameter (P25) fixed to a texture analyser, model TA-XT2 (Stable Micro Systems, Haslemere, UK), and employing a distance of 10 mm and a penetration speed of 1 mm/s. To avoid any interference of freezing with hardness analysis (Muse & Hartel, 2004), diet mousses were transferred from the freezer to a refrigerator at 4±1 °C where they remained for 6 h before testing. The following texture parameters were determined: hardness, cohesiveness, adhesiveness, springiness, and gumminess. Data were collected and analysed through the Texture Expert for Windows software, version 1.20 (Stable Micro Systems).

Samples of mousses stored at -18±2 °C were collected in quintuplicate, thawed at 4 °C and analysed for instrumental texture parameters one day after their manufacture and after 7, 35, 56, 84, and 112 days.

2.5. Sensory evaluation

The present study was conducted according to the guidelines laid down in the Declaration of Helsinki. The protocol followed for sensory analysis of mousses was approved by the Research Ethics Committees of the School of Pharmaceutical Sciences of the University of São Paulo, São Paulo, SP, Brazil (CAAE 30539214.6.0000.0067) and of the University Hospital, São Paulo, SP, Brazil (Protocol Number 663.138). The sensorial evaluation was conducted on samples of the three mousse formulations stored at -18 °C for 7,
35, 56, 84, and 112 days and thawed at 4 °C, 2 h before the start of sensory sections. Samples were codified with 3 random digits and distributed among participants for their individual evaluation.

Sensory acceptability tests were performed by voluntary consumers, using a structured 9-point hedonic scale (1 = dislike extremely; 9 = like extremely) for overall acceptability (Hough, 2010), and allowing the judge to indicate what was the sensory characteristics that he liked most or least.

Thirty untrained adults participated in each of the five sensory analysis sections, giving a total of 150 consumers, of which 50.0% were female and 50.0% male, with ages between 18 and 60 years (mean age of 24.4±7.4 years). Healthy volunteers were mostly undergraduate and graduate students and University of São Paulo employees. Criteria of exclusion included people with history of allergic manifestation, food intolerance or chronic diseases such as diabetes, hypothyroidism, hyperthyroidism, hypertension or others, flu or indisposed people, people making medical treatment or having a cold, and people that were in contact with strong smelling materials, foods or cosmetics less than 1 h before.

In particular, texture, appearance, odour, and taste were evaluated, which are the main sensory attributes chosen by consumers to assess quality and characteristics of a food (Afoakwa, Paterson, Fowler, & Viera, 2009).

## 2.6. Statistical analyses

Variance homogeneity for each set of data was verified, using the Hartley, Cochran, and Bartlett tests. The Student $t$ test was used to determine statistically significant differences ($p<0.05$) between two means when a homogeneous variance was observed. Results were compared by the analysis of variance (ANOVA) using the Tukey’s test, considering a
significance level of $p<0.05$. When normal distribution was not found, we employed the nonparametric Kruskal-Wallis test followed by the Dunn’s test.

3. RESULTS AND DISCUSSION

3.1. Viability of the probiotic microorganism

Some studies emphasized the importance of previously testing the compatibility between probiotic microorganism and prebiotic ingredient, in order to provide a positive interaction that could contribute to increased microbial viability throughout storage (Alves et al., 2013; Peredo, Beristain, Pascual, Azuara, & Jimenez, 2016; Sathyabama, Ranjith, Bruntha, Vijayabharathi, & Brindha, 2014). L. acidophilus La-5 population in the diet synbiotic mousse (SDM) remained above 7.8 log CFU/g (results not shown) during the 112 day-long storage at -18±2 °C, with no significant differences ($p>0.05$) in its viability.

Such L. acidophilus La-5 viability in SDM was higher than that previously observed in a sucrose-based synbiotic mousse either after 14 days of refrigerated storage (6 log CFU/g) or after 112 days of frozen storage (>7 log CFU/g) (Buriti, Castro, & Saad, 2010b). The post-acidification process, attributed to a fermentation process of the probiotic strain at refrigerated storage, reduces the pH value due of the generation of organic acids, which could impair the viability of the strain, therefore reducing of its population (Settachaimongkon et al., 2016; Shah, 2000). On the other hand, Moura et al. (2016) reported higher counts of the same probiotic (8.62-8.92 log CFU/g) in a sucrose-based dairy dessert after 15 days of refrigerated storage. In that study, the effect of post-acidification may be minimized by the absence of inulin in the formulation of this probiotic dessert, since some Lactobacillus strains have genes for the activity of β-fructofuranosidase responsible for the fermentation of inulin-type fructans (Bielecka, Biedrzycka, & Majkowska, 2002; Hopkins, Cummings, & Macfarlane, 1998;
Makras, Van Acker, & De Vuyst, 2005). In the present study, the frozen storage preserved the L. acidophilus La-5 populations above 7.8 log CFU/g during 112 days.

No microbial contaminants were detected in frozen mousses during storage, likely due to the good manufacturing practices employed during production and storage of mousses (data not shown).

3.2. pH variation

The mean pH values of both diet mousses are listed in Table 2. It can be seen that the pH of SDM was significantly lower (p<0.05) than that of PDM throughout the whole storage period. Besides, the addition of skimmed milk powder in both formulations may contribute to the buffering effect due to the presence of proteins and phosphates (Antunes, Cazetto, & Bolini, 2005; Buriti, Castro, & Saad, 2010a). This fact may explain the higher pH values in PDM.
Table 2. Mean pH values (standard deviation) of non-synbiotic diet mousse (PDM) and synbiotic diet mousse (SDM) stored at $-18\pm2$ °C for up to 112 days.

| Storage (days) | PDM        | SDM        |
|---------------|------------|------------|
| 1             | 6.40 (0.01) $^{Aa}$ | 5.85 (0.02) $^{Ba}$ |
| 7             | 6.37 (0.02) $^{Aab}$ | 5.82 (0.01) $^{Bab}$ |
| 35            | 6.28 (0.03) $^{Abc}$ | 5.80 (0.03) $^{Babc}$ |
| 56            | 6.26 (0.01) $^{Acd}$ | 5.71 (0.03) $^{Bbcd}$ |
| 84            | 6.22 (0.02) $^{Acd}$ | 5.68 (0.09) $^{Bcd}$ |
| 112           | 6.18 (0.02) $^{Ad}$  | 5.66 (0.02) $^{Bd}$  |

Different uppercase letters in the same line indicate statistically significant differences ($p<0.05$) between the two diet mousse formulations after the same storage period. Different lowercase letters in the same column indicate statistically significant differences ($p<0.05$) between different storage periods.

3.3. Chemical composition and total energy value

The chemical composition, the energy contribution of macronutrients, and the TEV of both diet mousses formulations are listed in Table 3.
Table 3. Chemical composition, energy contribution of macronutrients, and total energy values (TEV) of synbiotic diet mousse (SDM) and non-synbiotic diet mousse (PDM) referred to 100 g of mousses (dry weight).

|                | PDM                | SDM                |
|----------------|--------------------|--------------------|
| **Composition (g/ 100 g)** |                    |                    |
| Ash            | 1.42 (0.17) B      | 0.90 (0.06) A      |
| Proteins       | 8.55 (0.33) B      | 6.77 (0.37) A      |
| Simple carbohydrates | 17.53 (1.01) B    | 10.24 (0.97) A    |
| Fructans       | 0.00 B             | 9.63 A-*           |
| Lipids         | 0.12 (0.04) A      | 0.22 (0.05) A      |
| Moisture       | 72.38 (1.84) A     | 72.24 (1.59) A     |
| **Total**      | 100.00             | 100.00             |
| **Energetic value (kJ/ 100 g)** |                    |                    |
| Proteins       | 143.09 (5.52)      | 113.30 (6.67)      |
| Lipids         | 4.52 (2.26)        | 8.28 (2.07)        |
| Simple carbohydrates | 293.24 (16.90)    | 171.38 (31.07)    |
| Fructans       | 0.00               | 60.46              |
| TEV            | 440.85 (11.42)     | 353.42 (27.91)     |

Values expressed as averages (standard deviation). TEV: Total Energy Value. *Estimate based on information given by the supplier (Orafti) for the prebiotic ingredients (Beneo P95 and Beneo HP). Different uppercase letters in the same line indicate statistically significant differences ($p<0.05$) between the two diet formulations.
There were no significant differences ($p>0.05$) between lipids, and moisture contents of formulations, while those of ash, carbohydrates, and proteins were significantly higher ($p<0.05$) in PDM, possibly due to its higher percentage (14% w/w) of powdered skimmed milk (Table 1). Similar results were observed by other researchers. To provide just a few examples, Morais, Lima, Morais, and Bolini (2015) observed protein levels between 6.7 to 7.1% for milk chocolate desserts containing different sweeteners (sucrose, sucralose, aspartame, neotame or stevia), but higher ash content (from 1.7 to 2.1%), while Komatsu et al. (2013) reported protein and ash contents in the ranges 4.4-8.0% and 0.8-1.0%, respectively, for milk guava mousses using inulin as fat replacer and/or whey as a food supplement.

TEVs of PDM (440.85 kJ/100g) and SDM (353.42 kJ/100g) were 10.8 and 28.5% lower, respectively, than that of CSM (494.0 kJ/100g), due to the high sucrose content of the control mousse (11%). Therefore, according to the Brazilian legislation, both non-synbiotic and synbiotic formulations proposed in this study can be considered not only diet, for they contained less than 0.5 g of free sugars like sucrose, fructose, and glucose (dextrose) and/or fats per 100 g of product, but also as “zero”, with TEVs < 400 kcal/100 g (1674 kJ/100 g) (ANVISA, 1998).

### 3.4. Texture profile analysis

The texture profiles of both the synbiotic and non-synbiotic mousses stored at -18 °C are illustrated in Figure 2. One can see that hardness and gumminess of SDM increased and cohesiveness decreased significantly throughout storage ($p<0.05$), while adhesiveness and springiness kept almost the same ($p>0.05$) until 112 and 84 days, respectively. On the other hand, PDM hardness did not vary significantly during storage ($p>0.05$), while gumminess, cohesiveness, springiness, and adhesiveness gradually decreased with time ($p<0.05$).
Figure 2. Instrumental texture profiles of mousse formulations: (■) non-synbiotic diet mousse; (□) synbiotic diet mousse. Different uppercase letters indicate statistically significant differences ($p<0.05$) between the two diet mousse formulations for the same storage time. Different lowercase letters indicate statistically significant differences ($p<0.05$) among different storage times for the same mousse formulation. *Absolute values of adhesiveness in module.
In addition, hardness of PDM was relatively stable along the whole storage period ($p>0.05$), while that of SDM increased significantly ($p<0.05$) after 84-days storage. Opposite to what was observed for the diet mousses was reported by Borreani, Llorca, Quiles, and Hernando (2017). According to these researchers, occurred a general decrease in the hardness of formulations of dairy desserts containing skimmed milk powder either enriched with liquid cream. It is noteworthy to take in mind, in this regard, that a relatively constant hardness along storage, like that observed for PDM, is a desirable property in any food, because it suggests that the stored product preserved the main features of the original formulation (Maruyama, Cardarelli, Buriti, & Saad, 2006).

According to Cardarelli, Aragon-Alegro, Alegro, Castro, and Saad (2008), mousse particles take a long time to settle stably at low temperature, owing to the low mobility of air bubbles in the intrinsic structure. It has been suggested that the hardness of inulin-containing foods can be promoted by the ability of this prebiotic to interact with water molecules and milk protein fraction (Gokavi, Zhang, Huang, Zhao, & Guo, 2005), thus forming larger aggregates (Tárrega & Costel, 2006). Moreover, prebiotic incorporation in different products improved their hardness (Oliveira, Perego, Oliveira, & Converti, 2011; Shoaib et al., 2016). Thus, the higher hardness observed in the present study for PDM lacking in inulin compared with SDM may be ascribed to its significantly higher content of powdered skimmed milk (Table 1).

SDM adhesiveness was significantly higher ($p<0.05$) than that of PDM, probably due to the presence of FOS, which are more hygroscopic than inulin (Tonon et al., 2009; Franck, 2002). For the same reason, while PDM adhesiveness showed a statistically significant decrease at the end of storage, it remained almost unchanged for SDM ($p>0.05$) (Figure 2). Such a stability in SDM adhesiveness is consistent with the one observed by Buriti, Castro, and Saad (2010b) for a FOS-containing synbiotic guava mousse stored in the same way. On
the contrary, a progressive increase in this parameter was observed either in synbiotic chocolate mousses stored for only 28 days (Cardarelli, Aragon-Alegro, Alegro, Castro, & Saad, 2008) or in different formulations of probiotic dessert after 28 days of storage (Frederico et al., 2016).

Springiness and cohesiveness along storage were always similar in both mousses \( (p>0.05) \), and their values at the end of storage were significantly lower than at the start \( (p<0.05) \). These results suggest that neither FOS nor inulin significantly contributed to these properties. It is surprising that the presence of inulin did not significantly influence SDM cohesiveness, taking into account that the addition of this prebiotic to whey protein suspensions (Herceg, Režec, Lelas, Krešić, & Franetović, 2007) and dairy desserts (Lobato, Grossmann, & Benassi, 2009) led to a reduction of this parameter, as a possible consequence of inulin ability to form hydrogen bonds with proteins and to reduce surface tension and stability of these systems.

The well-known aggregating effect not only of inulin but also of FOS is evident in the behaviour of gumminess along storage, which decreased significantly \( (p<0.05) \) in PDM, whereas increased \( (p<0.05) \) in SDM that contained both. Finally, the significantly higher gumminess of PDM compared with SDM can be ascribed to its higher content of powdered skimmed milk.

### 3.5. Sensory analysis

According to Table 4, which summarizes the results of sensory analysis, there was no statistically significant difference \( (p>0.05) \) between the average scores attributed by consumers to SDM and CSM throughout the whole storage period at low temperature.
Table 4. Mean scores of sensory acceptability (standard deviation) attributed by consumers to non-synbiotic diet mousse (PDM), synbiotic diet mousse (SDM), and control synbiotic mousse (CSM) stored at -18±2 °C for up to 112 days.

| Storage (days) | PDM       | SDM       | CSM       |
|---------------|-----------|-----------|-----------|
| 7             | 5.9 (1.4) A | 6.9 (1.1) B | 7.5 (0.9) B |
| 35            | 6.0 (1.5) A | 7.0 (1.4) B | 7.7 (1.0) B |
| 56            | 6.4 (1.5) A | 6.8 (1.6) AB | 7.6 (1.3) B |
| 84            | 6.5 (1.3) A | 6.7 (1.3) A | 6.8 (1.6) A |
| 112           | 5.8 (2.2) A | 6.7 (1.5) AB | 7.5 (0.9) B |

Different uppercase letters indicate statistically significant differences ($p<0.05$) among the three diet mousse formulations for the same storage time.

The low powdered skimmed milk content (4%) and the presence of both probiotic and prebiotics (inulin and FOS) in SDM may have been responsible for its low hardness, low gumminess and high adhesiveness (Figure 2), resulting in a better acceptability ($p<0.05$) in comparison with PDM (Table 4) during the entire storage period. Some ingredients such as inulin and protein concentrates are often used in the development of milk desserts not only to substitute fat, but also to provide special functional and nutritional properties to products (Bayarri, Gozález-Tomás, Hernando, Lluch, & Costell, 2011; Morais et al., 2016). In this regard, Cardarelli, Aragon-Alegro, Alegro, Castro, and Saad (2008) reported that the simultaneous addition of *L. paracasei* subsp. *paracasei* LBC 82 and inulin directly improved the main sensory characteristics of chocolate mousses, i.e., texture, colour and flavour, when compared to a control lacking in these ingredients.

The satisfactory acceptability of acceptability of both mousses suggests that sucralose may be considered a good substitute for sucrose in dairy products, thus confirming previous observations (Brito & Bolini, 2010). This result is consistent with the observation of very
similar characteristics of dairy desserts supplemented with sucralose or other sweeteners such as aspartame, neotame, and stevia (Morais, Lima, Morais, and Bolini, 2015).

The mean scores attributed to CSM, ranging from 6.8 to 7.7, were lower than those reported by Buriti, Castro, and Saad (2010b) for the same guava mousse (7.6 to 8.0) stored exactly in the same way, but having lower contents inulin (2.0%), which suggests some influence of these contents in the taste of the final product.

Among the criteria used for assigning scores, texture was the most appreciated attribute among consumers for both PDM and SDM, while flavour was the one that stood out for CSM (results not shown). However, odour was the least rated attribute for the three formulations.

The relative frequencies of scores assigned to mousses after all storage times (7, 35, 56, 84, and 112 days) are illustrated in Figure 3.
Figure 3. Relative frequencies of scores assigned to mousses in all storage times. 1, dislike extremely; 2, dislike very much; 3, dislike moderately; 4, dislike slightly; 5, neither like or dislike; 6, like slightly; 7, like moderately; 8, like very much; 9, like extremely. (□) Non-synbiotic diet mousse; (■) Synbiotic diet mousse; (■■) Control synbiotic mousse.
PDM received scores between 4 and 9 after all storage times, and the score 7 was the one attribute with the highest frequency (around 45%), whereas scores 4, 5 and 9 those with the lowest one (around 5%). SDM received scores between 5 and 9 after 7 and 56 days of storage, but the score 8 was by far the most frequent one (around 35%) after all storage periods. CSM showed slightly higher scores (between 6 and 9) after 7, 35 and 112 days of storage, and the score 7 was the most frequent one (around 50%), whereas scores 6 and 9 the less frequent ones (both approximately 10%). In general, it can be concluded that CSM was the mousse that had, on average, the best scores throughout the whole storage period, followed by SDM, whereas PDM was the one that consumers liked less.
4. CONCLUSIONS

The present study evaluated the effects of *Lactobacillus acidophilus* La-5, inulin, fructooligosaccharides (FOS), sucralose, and time of storage on pH variation, and instrumental texture profile of a synbiotic diet mousse (SDM), when compared to a non-synbiotic diet mousse (PDM) and to a sucrose-containing control synbiotic mousse (CSM) on sensory acceptance. The dietary symbiotic mousse stored at -18 °C showed a *L. acidophilus* La-5 population greater than 7.5 log CFU/g over a 112 day-long storage. SDM showed lower pH values than PDM. Regarding the instrumental texture, SDM hardness and gumminess increased and cohesiveness decreased throughout storage (*p*<0.05), while adhesiveness and springiness remained almost stable. On the other hand, PDM hardness did not vary significantly, while gumminess, cohesiveness, springiness and adhesiveness gradually decreased along storage. In addition, sensory acceptability of all formulations was satisfactory throughout storage, with average scores from 6.7 to 7.0 for SDM, 5.8 to 6.5 for PDM, and 6.8 to 7.7 for CSM. The low powdered skimmed milk content and the presence of both probiotic and prebiotics (inulin and FOS) in SDM may have been responsible for its better acceptability compared with PDM. These results demonstrate that the presence of *Lactobacillus acidophilus* La-5, sucralose, inulin and FOS, as well as the time of storage, were responsible for significant changes in SDM instrumental texture profile, but not for its sensory acceptability, and that sucralose could be a good sucrose substitute in mousses.
5. REFERENCES

Afoakwa, E. O., Paterson, A., Fowler, M., & Viera, J. (2009). Microstructure and mechanical properties related to particle size distribution and composition in dark chocolate. *International Journal of Food Science and Technology, 44*, 111-119.

Alves, L. L., Richards, N. S. P. S., Mattanna, P., Andrade, D. F., Rezer, A. P. S., Milani, L. I. G., Cruz, A. G., & Faria, J. A. F. (2013). Cream cheese as a synbiotic food carrier using *Bifidobacterium animalis* Bb-12 and *Lactobacillus acidophilus* La-5 and inulin. *International Journal of Dairy Technology, 66*, 63-69.

Anderson, J. W., & Gilliland, S. E. (1999). Effect of fermented milk (yogurt) containing *Lactobacillus acidophilus* L1 on serum cholesterol in hypercholesterolemic humans. *Journal of the American College of Nutrition, 18*, 43–50.

Antunes, A. E. C., Cazetto, T. F., & Bolini, H. M. A. (2005). Viability of probiotic microorganisms during storage, post acidification and sensory analysis of fat-free yogurts with added whey protein concentrate. *International Journal of Dairy Technology, 58*, 169-173.

ANVISA (1998). Aprova o regulamento técnico referente a alimentos para fins especiais. Diário Oficial da União, Brasília, March 30th, 1998. Retrieved from http://portal.anvisa.gov.br/wps/wcm/connect/2a1d950047458eca97dbd73fbc4c6735/PORTARIA_29_1998.pdf?MOD=AJPERES.

ANVISA (2003). Resolução RDC N° 360, de 23 de dezembro de 2003. Aprova regulamento técnico sobre rotulagem nutricional de alimentos embalados, tornando obrigatória a rotulagem nutricional. Diário Oficial da União, Brasília, December 26th, 2003. Retrieved from
AOAC (2003). Official methods of analysis (17th ed., 2.rev). (pp. 121-123). Gaithersburg, MD, USA: AOAC International.

Ares, G., Giménez, A., & Gámbaro, A. (2009). Consumer perceived healthiness and willingness to try functional dairy desserts: Influence of ingredient, ingredient name and health claim. *Food Quality and Preference*, 20, 50–56.

Barclay, T., Ginic-Markovic, M., Cooper, P., & Petrovsky, N. (2010). Inulin – a versatile polysaccharide with multiple pharmaceutical and food chemical uses. *Journal of Excipients and Food Chemicals*, 1, 27-50.

Bayarri, S., Gozález-Tomás, L., Hernando, I., Lluch, M. A., & Costell, E. (2011). Texture perceived on inulin-enriched low-fat semisolid dairy desserts. Rheological and structural basis. *Journal of Texture Studies*, 42, 174-184.

Bielecka, M., Biedrzycka, E., & Majkowska, A. (2002). Selection of probiotics and prebiotics for synbiotics and confirmation of their in vivo effectiveness. *Food Research International*, 35, 125–131.

Bitzios, M., Fraser, I., & Haddock-Fraser, J. (2011). Functional ingredients and food choice: Results from a dual-mode study employing means-end-chain analysis and a choice experiment. *Food Policy*, 36, 715–725.

Borreani, J., Llorca, E., Quiles, A., & Hernando, I. (2017). Designing dairy desserts for weight management: Structure, physical properties and *in vitro* gastric digestion. *Food Chemistry*, 220, 137–144.

Brito, C. A. K., & Bolini, H. M. A. (2010). Sensory profile of sweeteners in guava nectar. *Alimentos e Nutrição* Araraquara, 20, 561-572.
Buriti, F. C. A., & Saad, S. M. I. (2014). Chilled milk-based desserts as emerging probiotic and prebiotic products. *Critical Reviews in Food Science and Nutrition*, 54, 139-150.

Buriti, F. C. A., Castro, I. A., & Saad, M. I. (2010b). Effects of refrigeration, freezing and replacement of milk fat by inulin and whey protein concentrate on texture profile and sensory acceptance of synbiotic guava mousses. *Food Chemistry*, 123, 1190–1197.

Buriti, F. C. A., Castro, I. A., & Saad, S. M. I. (2010a). Viability of *Lactobacillus acidophilus* in synbiotic guava mousses and its survival under in vitro simulated gastrointestinal conditions. *International Journal of Food Microbiology*, 137, 121–129.

Cardarelli, H. R., Aragon-Alegro, L. C., Alegro, J. H. A., Castro, I. A., & Saad, S. M. I. (2008). Effect of inulin and *Lactobacillus paracasei* on sensory and instrumental texture properties of functional chocolate mousse. *Journal of the Science of Food and Agriculture*, 88, 1318-1324.

Cruz, A. G., Antunes, A. E. C., Souza, A. L. O. P., Faria, J. A. F., & Saad, S. M. I. (2009). Ice cream as a probiotic food carrier. *Food Research International*, 42, 1233-1239.

Daliri, E. B. M., & Lee, B. H. (2015). New perspectives on probiotics in health and disease. *Food Science and Human Wellness*, 4, 56-65.

FAO (2003). Food energy e Methods of analysis and conversion factors. Report of a technical workshop. FAO food and nutrition paper 77. Rome: Food and Agriculture Organization of the United Nations. Retrieved from http://www.fao.org/DOCREP/006/Y5022E/Y5022E00.HTM.

Ferraz, J. L., Cruz, A. G., Cadena, R. S., Fritas, M. Q., Pinto, U. M., Carvalho, C. C., Faria, J. A. F., & Bolini, H. M. A. (2012). Sensory acceptance and survival of probiotic bacteria in ice cream produced with different overrun levels. *Journal of Food Science*, 71, s24-s28.
Franck, A (2008). Food applications of prebiotics. In: Gibson, G.R.; Roberfroid, M.B. *Handbook of prebiotics* (pp. 437-448). CRC: Boca Raton.

Franck, A. (2002). Technological functionality of inulin and oligofructose. *British Journal of Nutrition*, 87, S287–S291.

Frederico, C., Pinto, T. B., Castro, E. M., Suguimoto, H. H., Santana, E. H. W., Alegro, L. C. A., & Souza, C. H. B. (2016). Probiotic dairy dessert supplemented with whey protein concentrate: effect on the viability of *Lactobacillus acidophilus*, on texture, physicochemical and sensory features. *Journal of Food and Nutrition Research*, 55, 48–56.

Gebara, C., Ribeiro, M. C. R., Chaves, K. S., Gandara, A. L. N., & Gigante, M. L. (2015). Effectiveness of different methodologies for the selective enumeration of *Lactobacillus acidophilus* La5 from yoghurt and Prato cheese. *LWT - Food Science and Technology*, 64, 508-513.

Gibson, G. R., Hutkins, R., Sanders, M. E., Prescott, S. L., Reimer, R. A., Salminen, S. J., Scott, K., Stanton, C., Swanson, K. S., Cani, P. D., Verbeke, K., & Reid, G. (2017). Expert consensus document: The International Scientific Association for Probiotics and Prebiotics (ISAPP) consensus statement on the definition and scope of prebiotics. *Nature Reviews| Gastroenterology & Hepatology*, 14, 491-502.

Gibson, G. R., Probert, H. M., Loo, J. V., Rastall, R. A., & Roberfroid, M. B. (2004). Dietary modulation of the human colonic microbiota: updating the concept of prebiotics. *Nutrition research reviews*, 17, 259–275.

Gibson, G. R., Scott, K. P., Rastall, R. A., Tuohy, K. M., Hotchkiss, A., Dubert-Ferrandon, A., Gareau, M., Murphy, E., F., Saulnier, D., Loh, G., Macfarlane, S., Delzenne, N., Ringel, Y., Kozianowski, G., Dickmann, R., Lenoir-Wijnduin, I., Walker, C., &
Buddington, R. (2010). Dietary prebiotics: current status and new definition. *Food Science and Technology Bulletin Functional Foods*, 7, 1–19.

Gokavi, S., Zhang, L., Huang, M. K., Zhao, X., & Guo, M. (2005). Oat-based synbiotic beverage fermented by *Lactobacillus plantarum, Lactobacillus paracasei* ssp. *Casei*, and *Lactobacillus acidophilus*. *Journal of Food Science*, 70, M216-M223.

Gunnarsson, I. B., Svensson, S. E., Johansson, E., Karakashev, D., & Angelidaki, I. (2014). Potential of Jerusalem artichoke (*Helianthus tuberosus* L.) as a biorefinery crop. *Industrial crops and products*, 56, 231-240.

Health Canada (2009) Guidance document – The use of probiotic microorganisms in food. Retrieved from: http://www.hc-sc.gc.ca/fn-an/alt_formats/hpfb-dgpsa/pdf/legislation/probiotics_guidance-orientation_probiotiques-eng.pdf. Access: May 25th, 2016.

Herceg, Z., Režec, A., Lelas, V., Krešić, G., & Franetović, M. (2007). Effect of carbohydrates on the emulsifying, foaming and freezing properties of whey protein suspensions. *Journal of Food Engineering*, 79, 279-286.

Hill, C., Guarner, F., Reid, G., Gibson, G. R., Merenstein, D. J., Pot, B., Morelli, L., Canani, B. R., Flint, H. J., Salminen, S., Calder, P. C., & Sanders, M. E. (2014). The International Scientific Association for Probiotics and Prebiotics consensus statement on the scope and appropriate use of the term probiotic. *Nature reviews Gastroenterology & Hepatology*, 11, 506–514.

Hopkins, M. J., Cummings, J. H., & Macfarlane, G. T. (1998). Inter-species differences in maximum specific growth rates and cell yields of bifidobacteria cultured on oligosaccharides and other simple carbohydrate sources. *Journal of Applied Microbiology*, 85, 381–386.
Hough, G. *Sensory shelf-life estimation of food products*. CRC Press, Boca Raton, 2010.

Hutkins, R. W., Krumbeck, J. A., Bindels, L. B., Cani, P. D., Fahey Jr, G., Goh, J. Y., Hamaker, B., Martens, E. C., Mills, D. A., Rastal, R. A., Vaughan, E., & Sanders, M. E. (2016). Prebiotics: why definitions matter. *Current Opinion in Biotechnology*, 37, 1-7.

Hymes, J. P., Johnson, B. R., Barrangou, R., & Klaenhammer, T. R. (2016). Functional analysis of an s-layer-associated fibronectin-binding protein in *Lactobacillus acidophilus* NCFM. *Applied & Environmental Microbiology*, 82, 2676-2685.

Instituto Adolfo Lutz. *Métodos químicos e físicos para análise de alimentos*. 4 ed., Brasília: Ministério da Saúde, 2005. 1018p.

International Dairy Federation. *Fermented and non-fermented milk products. Detection and enumeration of Lactobacillus acidophilus*. Culture media. Bulletim of the IDF 306. Brussels: IDF, 1995.

Kemgang, T. S., Kapila, S. K., Shanmugam, V. P., Reddi, S., & Kapila, R. (2016). Fermented milk with probiotic *Lactobacillus rhamnosus* S1K3 (MTCC5957) protects mice from salmonella by enhancing immune and nonimmune protection mechanisms at intestinal mucosal level. *The Journal of Nutritional Biochemistry*, 30, 62-73.

Khuenpet, K., Fukuoka, M., Jittanit, W., & Sirisanseeyakul, S. (2017). Spray drying of inulin component extracted from Jerusalem artichoke tuber powder using conventional and ohmic-ultrasonic heating for extraction process. *Journal of Food Engineering*, 194, 67-78.

Kolida, S., & Gibson, G. R. (2011). Synbiotic in health and disease. *Annual review of food science and technology*, 2, 373-393.
Komatsu, T. R., Buriti, F. C. A., & Saad, S. M. I. (2008). Inovação, persistência e criatividade superando barreiras no desenvolvimento de alimentos probióticos. Revista Brasileira de Ciências Farmacêuticas, 44, 329-347.

Komatsu, T. R., Buriti, F. C. A., Silva, R. C., Lobo, A. R., Colli, C., Gioielli, L. A., & Saad, S. M. I. (2013). Nutrition claims for functional guava mousses produced with milk fat substitution by inulin and/or whey protein concentrate based on heterogeneous food legislations. LWT – Food Science and Technology, 50, 755-765.

Krystyjan, M., Ciesielski, W., Khachatryan, G., Sikora, M., & Tomasik, P. (2015). Structure, rheological, textural and thermal properties of potato starch – Inulin gels. LWT – Food Science and Technology, 60, 131-136.

Lobato, L. P., Grossmann, M. V. E., & Benassi, M. T. (2009). Inulin addition in starch-based dairy desserts: instrumental texture and sensory aspects. Food Science and Technology International, 15, 317-323.

Magariños, H., Selaive, S., Costa, M., Flores, M., & Pizarro, O. (2007). Viability of probiotic microorganisms (Lactobacillus acidophilus La-5 and Bifidobacterium animalis subsp. Lactis Bb-12) in ice cream. International Journal of Dairy Technology, 60, 128-134.

Magnuson, B. A., Roberts, A., & Nestmann, E. R. (2017). Critical review of the current literature on the safety of sucralose. Food and Chemical Toxicology, 106, 324-355.

Makras, L., Van Acker, G., & De Vuyst, L. (2005). Lactobacillus paracasei subsp. paracasei 8700:2 degrades inulin-type fructans exhibiting different degrees of polymerization. Applied and Environmental Microbiology, 71, 6531–6537.

Maruyama, L. Y., Cardarelli, H. R., Buriti, F. C. A., & Saad, S. M. I. (2006). Textura instrumental de queijo petit-suisse potencialmente probiótico: influência de diferentes combinações de gomas. Ciência e Tecnologia de Alimentos, 26, 386-393.
Medellin-Peña, M. J., & Griffiths, M. W. (2009). Effect of molecules secreted by Lactobacillus acidophilus strain La-5 on Escherichia coli O157:H7 colonization. Applied and Environmental Microbiology, 75, 1165–1172.

Ministero della Salute (2013). Commissione unica per la nutrizione e la dietetica – Guidelines on probiotics and prebiotics. Retrieved from: http://www.salute.gov.it/imgs/C_17_pubblicazioni_1016_allegato.pdf. Access: May 24th, 2016.

Morais, E. C., Esmerino, E. A., Monteiro, R. A., Pinheiro, C. M., Nunes, C. A., Cruz, A.G., & Bolini, H. M.A. (2016). Prebiotic Low Sugar Chocolate Dairy Desserts: Physical and Optical Characteristics and Performance of PARAFAC and PCA Preference Map. Journal of Food Science, 81, S156-S164.

Morais, E. C., Lima, G. C., Morais, A. R., & Bolini, H. M. A. (2015). Prebiotic and diet/light chocolate dairy dessert: Chemical composition, sensory profiling and relationship with consumer expectation. LWT – Food Science and Technology, 62, 424-430.

Moumita, S., Goderska, K., Johnson, E. M., Das, B., Indira, D., Yadav, R., Kumari, S., & Jayabalan, R. (2017). Evaluation of the viability of free and encapsulated lactic acid bacteria using in-vitro gastro intestinal model and survivability studies of synbiotic microcapsules in dry food matrix during storage. LWT – Food Science and Technology, 77, 460-467.

Moura, C. S., Lollo, P. C. B., Morato, P. N., Esmerino, E. A., Margalho, L. P., Santos-Junior, V. A., Coimbra, P. T., Cappato, L. P., Silva, M. C., Garcia-Gomes, A. S., Granato, D., Bolini, H. M. A., Sant’Ana, A. S., Cruz, A. G., & Amaya-Farfan, J. (2016). Assessment of antioxidant activity, lipid profile, general biochemical and immune system responses
of Wistar rats fed with dairy dessert containing *Lactobacillus acidophilus* La-5. *Food Research International*, 90, 275–280.

Muse, M. R., & Hartel, R. W. (2004). Ice cream structural elements that affect melting rate and hardness. *Journal of Dairy Science*, 87, 1–10.

Oliveira, R. P. S, Perego, P., Oliveira, M. N., & Converti, A. (2011). Effect of inulin as a prebiotic to improve growth and counts of a probiotic cocktail in fermented skim milk. *LWT-Food Science and Technology*, 44, 520–523.

Peredo, A. G., Beristain, C. I., Pascual, L. A., Azuara, E., & Jimenez, M (2016). The effect of prebiotics on the viability of encapsulated probiotic bacteria. *LWT – Food Science and Technology*, 73, 191-196.

Pompei, A., Cordisco, L., Raimondi, S., Amaretti, A., Pagnoni, U. M., Matteuzzi, D., & Rossi, M. (2008). *In vitro* comparison of the prebiotic effects of two inulin-type fructans. *Anaerobe*, 14, 280-286.

Reid, G. (2016). Probiotics: definition, scope and mechanisms of action. *Best Practice & Research Clinical Gastroenterology*, 30, 17–25.

Roberfroid, M. B. (1999). Caloric value of inulin and oligofructose. *Journal of Nutrition*, 129, 1436S-1437S.

Roberfroid, M. B. (2005). Inulin-type fructans: functional food ingredients. Boca Raton: CRC, 359p.

Sathyabama, S., Ranjith, M., Bruntha, P., Vijayabharathi, R., & Brindha, V. (2014). Co-encapsulation of probiotics with prebiotics on alginate matrix and its effect on viability in simulated gastric environment. *LWT-Food Science and Technology*, 57, 419-425.
Settachaimongkon, S., van Valenberg, H. J. F., Gazi, I., Nout, M. J. R., van Hooijdonk, T. C. M., Zwietering, M. H., & Smid, E. J. (2016). Influence of Lactobacillus plantarum WCFS1 on post-acidification, metabolite formation and survival of starter bacteria in set-yoghurt. Food Microbiology, 59, 14-22.

Shah, N. P. (2000). Probiotic bacteria: Selective enumeration and survival in dairy foods. Journal of Dairy Science, 83, 894-907.

Shah, N. P. (2007). Functional cultures and health benefits. International Dairy Journal, 17, 1262-1277.

Shoaib, M., Shehzad, A., Omar, M., Rakha, A., Raza, H., Sharif, H. R., Shakeel, A., Ansari, A., & Niazi, S. (2016). Inulin: Properties, health benefits and food applications. Carbohydrate Polymers, 147, 444–454.

Tárrega, A., & Costell, E. (2006). Effect of inulin addition on rheological and sensory properties of fat-free starch-based dairy desserts. International Dairy Journal, 16, 1104-1112.

Tonon, R. V., Brabet, C., Pallet, D., Brat, P., & Hubinger, M. D. (2009). Physicochemical and morphological characterisation of açaí (Euterpe oleracea Mart.) powder produced with different carrier agents. International Journal of Food Science and Technology, 44, 1950–1958.

US CFR (2010). Nutrition labeling of food. Title 21, section 101.9. Retrieved from http://www.accessdata.fda.gov/scripts/cdrh/cfdocs/cfcfr/CFRSearch.cfm?fr¼101.9. Acess: May 24th, 2016.

Vrese, M., & Schrezenmeir, J. (2008). Probiotics, prebiotics, and synbiotics. Advances in Biochemical Engineering/Biotechnology, 111, 1–66.
Wang Y. (2009). Prebiotics: present and future in food science and technology. *Food Research International, 42*, 8-12.

Wu, X-D., Liu, M-M, Liang, X., Hu, N., & Huang, W. (2016). Effects of perioperative supplementation with pro-/synbiotics on clinical outcomes in surgical patients: A meta-analysis with trial sequential analysis of randomized controlled trials. *Clinical Nutrition. In press*. Doi: http://dx.doi.org/10.1016/j.clnu.2016.10.015.

Zhao, Y., Jiang, L., Liu, T., Wang, M., Cao, W., Bao, Y., & Qin, J. (2015). Construction and immunogenicity of the recombinant *Lactobacillus acidophilus* pMG36e-E0-LA-5 of bovine viral diarrhea virus. *Journal of Virological Methods*, 225, 70-75.
Chapter 3
Effect of the consumption of a synbiotic diet mousse containing *Lactobacillus acidophilus* La-5 by individuals with metabolic syndrome: a randomized controlled trial

ABSTRACT

This study aimed to evaluate the impact of a synbiotic diet mousse containing *Lactobacillus acidophilus* La-5 and the prebiotics inulin and fructooligosaccharides on the health of volunteers with metabolic syndrome (MetS). In a randomized, double-blind, placebo-controlled trial, forty-five volunteers with MetS were assigned into two groups, each receiving 40 g/day of: synbiotic diet mousse (SDM) (n=23) and placebo diet mousse (PDM) without pro- and prebiotics (n=22). Anthropometric and blood pressure measurements, biochemical, haematological, inflammatory, and immunologic parameters were measured at the beginning and after 8 weeks of intervention. The daily intake of the SDM and the PDM led to significant reductions of total cholesterol and HDL-cholesterol, as well as of immunoglobulins (A and M), and interleukin-1β in both groups (*p*<0.05). These results suggest that the presence of the probiotic and prebiotic ingredients in the diet mousse did not exert any additional effects on the health of volunteers with MetS.

Keywords: Probiotic; Prebiotic; Clinical trial; Metabolic Syndrome; Mousse.
1. INTRODUCTION

The metabolic syndrome (MetS) has received a great deal of attention from the scientific community in recent years. This is largely influenced by the increase in the prevalence of MetS in the last two decades especially in countries with increased calorie consumption and decreased physical activities (Mazidi et al., 2016). In general, MetS is a group of risk factors comprising obesity (particularly abdominal obesity), insulin resistance, atherogenic dyslipidaemia, and hypertension, which are associated with increased risk of cardiovascular disease (CVD) and type 2 diabetes mellitus (Grundy et al., 2005; Kakafika et al., 2006). Moreover, subjects with these features usually show prothrombotic and proinflammatory states (Grundy et al., 2005). Clinical and epidemiological studies have indicated that low-grade inflammation may contribute to the development of metabolic disorders associated with obesity (Cani & Hul, 2015). In this sense, MetS is known to be a low grade systemic inflammatory condition (Synetos et al., 2016).

It has been shown that an intestinal dysbiosis which could also be associated to MetS. In this context, a number of studies using animal models and clinical trials have reported a relationship between the composition of the intestinal microbiota and MetS risk factors, including obesity and diabetes (Larsen et al., 2010; Ley et al., 2005; Tremaroli & Bäckhed, 2012). In general, the microbiota associated with obese individuals has been characterized by an increased Firmicutes/Bacteroidetes ratio (Ley et al., 2006; Jonkers, 2016; Turnbaugh et al., 2009). Nevertheless, according to Scavuzzi et al. (2015), there is still no consensus as to the mechanisms relating intestinal microbiota modifications and the potential metabolic changes. On the other hand, these researchers reported that mechanisms possibly involve gut barrier alterations and low-grade inflammation.
The MetS may have several origins; however, diet and lifestyle are considered important aspects that may influence the susceptibility of humans to MetS (Kovatcheva-Datchary & Arora, 2013). Since, dietary approaches to manipulate the intestinal microbiota, in particular the use of probiotic microorganisms and/or prebiotic compounds, have demonstrated health-improving effects on the host. These approaches were proposed for MetS management (Bernini et al. 2016; Kovatcheva-Datchary & Arora, 2013; Scavuzzi et al., 2015). Nonetheless, it is noteworthy that studies evaluating the impact of probiotics on obesity-related inflammation are limited and especially based on animal studies (de Moreno de LeBlanc & Perdigon, 2010; Gøbel et al., 2012).

Some researchers reported beneficial effects of the consumption of probiotic, prebiotic, and synbiotic products on parameters related to MetS (Barreto et al., 2014; Bernini et al., 2016; Gøbel et al., 2012). Akkasheh et al. (2016) observed significant decreases in serum insulin concentrations and the homoeostasis model of assessment of insulin resistance (HOMA-IR) after the daily consumption of one probiotic capsule containing *Lactobacillus acidophilus* YAB, *Lactobacillus casei* TD₂, and *Bifidobacterium bifidum* B12 during 8 weeks. Studies have also investigated the possible role of probiotic bacteria and prebiotic fibres on different risk factors of MetS, such as the reduction of cardiovascular disease (CVD) risk (Al-Sheraji et al., 2012; Gøbel et al., 2012). Along these lines, a meta-analysis of randomized controlled trials conducted by Guo et al. (2011) showed that the consumption of probiotics led to a decrease in the total cholesterol and the LDL-C in individuals with high, borderline high, and normal cholesterol levels.
Recently, inflammatory processes have also been considered as biomarkers in clinical trials with MetS patients (Brito-Luna et al., 2016; Karaman et al., 2015; Panahi et al., 2016). Barreto et al. (2014) observed that the consumption of fermented milk containing *Lactobacillus plantarum* Lp 115 led to a significant decrease in IL-6 levels in patients with MetS after 90 days of study.

It is noteworthy that probiotic beneficial effects, as well as mechanisms of action, are considered as strain specific. In addition, it has been suggested that different food formats in which the probiotic bacteria are incorporated may influence their functionality, and, consequently, their potential health effects (Forssten, Sindelar, & Ouwehand, 2011; Sanders & Marco, 2010). Besides, there are indications that synbiotic products may be more effective than either probiotics or prebiotics alone (Sanders & Marco, 2010).

To the best of our knowledge, no study is available in the scientific literature on the impact of a synbiotic diet dessert on subjects with MetS. The aim of this study was therefore to assess the impact of a synbiotic diet dessert (mousse) containing *L. acidophilus* La-5 and the prebiotic ingredients inulin and fructooligosaccharides (FOS) on biochemical (plasmatic glucose, TC, HDL-C, LDL-C, TG, and insulin), inflammatory (TNF-α, CD40, IL-1β, IL-6, IL-8, IL-10, and IL-12), haematological (erythrocytes, leukocytes, lymphocytes, erythrocytes, neutrophils, eosinophils, monocytes, and haemoglobin), and immunological (IgA, IgE, IgG, and IgM) parameters of volunteers with MetS.
2. SUBJECTS AND METHODS

2.1. Production of synbiotic and placebo diet mousses

The diet desserts were produced under suitable hygiene and sanitation criteria at the Laboratory of Food Technology of the Department of Biochemical and Pharmaceutical Technology of the School of Pharmaceutical Sciences of the University of São Paulo (SP, Brazil), according to the method described by Buriti, Castro, and Saad (2010). The amounts of ingredients employed in the production of the diet desserts shown in Table 1, while Table 2 lists their macronutrient composition and energy contribution.

Table 1. Amounts of ingredients employed in the production of synbiotic diet mousse (SDM) and placebo diet mousse (PDM).

| Ingredients (g/100 g) | SDM  | PDM  |
|-----------------------|------|------|
| Skimmed milk¹         | 61.7 | 61.7 |
| Skimmed milk powder²  | 4.0  | 14.0 |
| Sucralose³            | 1.1  | 1.1  |
| Pasteurized and frozen guava pulp⁴ | 20.0 | 20.0 |
| Emulsifier/stabilizer⁵ | 2.8  | 2.8  |
| FOS⁶                  | 6.0  | 0.0  |
| Inulin⁷               | 4.0  | 0.0  |
| Lactic acid⁸          | 0.4  | 0.4  |
| *Lactobacillus acidophilus* La-5⁹ | 0.05 | 0.0  |
| **Total**             | 100.0| 100.0|

¹Paulista (Danone, Guaratinguetá, SP, Brazil); ²Molico (Nestlé, Araçatuba, SP, Brazil); ³Sucralose (Línea Sucralose, São Paulo, SP, Brazil); ⁴Icefruit Comércio de Alimentos (Icefruit Comércio de Alimentos, Tatuí, SP, Brazil); ⁵Cremodan Mousse 30 (Danisco, Cotia, SP, Brazil); ⁶Beneo P95 (Orafti, Oreye, Belgium); ⁷Beneo HP (Orafti); ⁸Purac (Purac Sínteses, Rio de Janeiro, RJ, Brazil; 85 g/100 g food-grade solution); ⁹Strain La-5 (Christian Hansen, Hoersholm, Denmark).
Table 2. Chemical composition, energy contribution of macronutrients, and total energy values (TEV) of synbiotic diet mousse (SDM) and placebo diet mousse (PDM) in 100 g of whole mousses (dry weight).

| Composition (g/ 100g) | SDM      | PDM      |
|-----------------------|----------|----------|
| Ash                   | 0.90 (0.06) B | 1.42 (0.17) A |
| Proteins              | 6.77 (0.37) B | 8.55 (0.33) A |
| Simple carbohydrates  | 10.24 (0.97) B | 17.53 (1.01) A |
| Fructans              | 9.63 B,* | 0.00 A |
| Lipids                | 0.22 (0.05) A | 0.12 (0.06) A |
| Moisture              | 72.24 (1.59) A | 72.38 (1.84) A |
| Total                 | 100.0 | 100.0 |

Energetic value (kJ/ 100 g)

|                | SDM       | PDM       |
|----------------|-----------|-----------|
| Proteins       | 113.30 (6.67) | 143.09 (5.52) |
| Lipids         | 8.28 (2.07)   | 4.52 (2.26)   |
| Simple carbohydrates | 171.38 (31.07) | 293.24 (16.90) |
| Fructans       | 60.46      | 0.00      |
| TEV            | 353.42 (27.91) | 440.85 (11.42) |

Values are expressed as mean (standard deviation). Different uppercase letters in the same line indicate statistically significant differences ($p<0.05$) between the two diet formulations. *Estimate based on information given by the supplier (Orafti) for the prebiotic ingredients (Beneo P95 and Beneo HP).

Diet desserts were packaged in polypropylene plastic pots for food products (100 mL of capacity) (Tries Aditivos Plásticos, São Paulo, Brazil) in portions of 40 g. The pots were sealed with metallic covers with varnish in a sealer (Delgo Metalúrgica, Cotia, Brazil). The products were stored frozen (-18 °C) and delivered to each volunteer in plastic vials labelled
with the dates of manufacture and expiration. Microbiological analyses of the synbiotic product showed that the average population of *L. acidophilus* La-5 ranged between 9.2 and 9.5 log CFU (colony-forming units) per daily serving portion (40 g) during the experimental period. Therefore, the probiotic population was above the minimum recommended level (6 log CFU/g) suggested for beneficial health effects (Health Canada, 2009; Champagne et al., 2011; Ministero della Salute, 2013). Coliforms, *Escherichia coli*, and yeasts and moulds were not detected during the products’ storage period.

### 2.2. Participants

Sixty subjects with MetS, aged between 19 and 65, were recruited (August 2014 up to June 2015) from the ambulatory of the University Hospital (São Paulo, SP, Brazil). The present study was conducted according to the guidelines laid down in the Declaration of Helsinki and approved by the Research Ethical Committees involving humans of the School of Pharmaceutical Sciences of the University of São Paulo (CAAE 30539214.6.0000.0067) and of the University Hospital (Protocol Number 663.138). All subjects provided written consent form before participating in the study. According to the National Cholesterol Education Program, Adult Treatment Panel III (NCEP/ATP III) (Grundy et al., 2005), the subjects were eligible for the study if they had at least three of the following five factors: 1) abdominal obesity (waist circumference of ≥ 88 cm for women and ≥ 102 cm for men); 2) high TG levels (≥150 mg/dL); 3) low HDL-C levels (<50 mg/dL for women and <40 mg/dL for men); 4) high blood pressure (systolic ≥ 130 mmHg and diastolic ≥ 85 mmHg); 5) high fasting glucose levels (≥100 mg/dL). The exclusion criteria were thyroid, renal, hepatic, gastrointestinal or oncological disease and use of drugs (including hormone replace therapy) that interfere with the lipids and/or glycaemic profile.
2.3. Study design

The present study was a randomized, double-blind, placebo-controlled trial in which subjects with MetS were randomly divided into two groups: group S (synbiotic group - individuals who consumed 40 g/d of SDM; n=23) and group P (placebo group - individuals who consumed 40 g/d of PDM; n=22). The participants were paired by age, gender, ethnicity, and consumption of antihypertensive drugs (Simão et al., 2013). Throughout the study (8 weeks), the subjects were encouraged to maintain their lives as they normally would, with no change in their usual diets or physical activity. However, the volunteers were instructed to avoid the consumption of probiotic and prebiotic products during the 7 days that preceded the beginning of the intervention (run-in).

2.4. Anthropometric, heart rate, and laboratory blood analysis

Fasting blood samples, anthropometric, heart rate, and blood pressure measurements were collected at baseline (T0) and at the end of week 8 (T8). Body mass index (kg/m²) was calculated as body weight (kg) divided by squared height (m). Waist circumference was determined using a tape measure. After the subjects had been seated for five minutes, three blood pressure measurements, obtained at one-minute intervals, were recorded. The average of the last two measurements was used. These clinical and anthropometric parameters were measured according to Mill et al. (2013).

After fasting for 12 h, blood samples were drawn from the forearm vein into Vacutainer tubes (Becton Dickinson, Rutherford, USA). Samples were immediately centrifuged at 3000 rpm for 15 min at 4 °C (Eppendorf, Hamburg, Germany), and the serum was collected and stored at -80 °C until the analysis. The plasmatic glucose levels and the serum levels of TC, HDL-C, LDL-C, TG, IgA, IgE, IgG, and IgM were assayed by an
automated biochemical analyser (Labmax 240, Tokyo, Japan), using specific enzyme kits (Labtest Diagnostics, Lagoa Santa, GO, Brazil). Plasma insulin level was determined by chemiluminescence microparticle immunoassay (Architect, Abbott Laboratory, IL, USA). TNF-α, CD40, IL-1β, IL-6, IL-8, IL-10, and IL-12 were evaluated using commercially available immunoassay kit #HCYTMAG-60K (Millipore, Billerica, MA, USA) with a series of magnetic beads and the MAGPIX system (Luminex, Austin, TX, USA). Haematological parameters were evaluated at the University Hospital Clinical Laboratory of the University of São Paulo through an automated haematology analyser (Sysmex-XT 2000i, Kobe, Japan), using routine analysis based on electrical impedance (erythrocytes), flow cytometry (leukocytes, lymphocytes, erythrocytes, neutrophils, eosinophils, and monocytes) and colorimetric (haemoglobin) methods.

2.5. Statistical analysis

The chi-squared test was used to evaluate the differences between synbiotic and placebo groups with respect to the gender, ethnicity, consumption of antihypertensive drugs, and student-t test to age. The Mann-Whitney test was performed to compare differences among parameters of groups at baseline and differences across treatment groups (intergroup changes). The Wilcoxon matched pairs test was performed to verify changes from baseline (intragroup changes). Data were presented as median (25%-75%), and the significance was declared when the p-value was <0.05. Statistical analyses were carried out using the Statistica version 12.0 (Statsoft Inc, Tulsa, USA) and GraphPad Prism version 3.0 (GraphPad Software Inc, La Jolla, USA) programs.
3. RESULTS AND DISCUSSION

The present study evaluated the impact of a synbiotic diet mousse containing *L. acidophilus* La-5 and the prebiotic ingredients inulin and FOS on some biochemical, haematological, inflammatory, and immunological parameters of subjects with MetS through a randomized, double-blind, and placebo-controlled trial.

In general, the two experimental groups were similar (Table 3) since there were no significant differences between the synbiotic and the placebo groups related to age, gender, ethnicity, and the consumption of antihypertensive drugs at baseline (*p > 0.05*).

**Table 3.** General characteristics of the participants of the placebo and synbiotic groups at the beginning of the study.

| Parameters                  | Group P (n=22) | Group S (n=23) | *p*  |
|-----------------------------|---------------|---------------|------|
| Gender (M/F)                | (10/12)       | (13/10)       | 0.4578 |
| Antihypertensive (yes/no)   | (6/16)        | (5/18)        | 0.6659 |
| Non-Caucasian/Caucasian     | (11/11)       | (10/13)       | 0.6611 |
| Age (years)                 | 49.5 (39.5-59.5) | 47.0 (41.0-53.0) | 0.4674 |

Values are expressed as median (25%-75%). Group P: Placebo group; Group S: Synbiotic group. M/F: male/female.

During the period of daily diet mousse consumption (from T0 to T8), there were no significant differences for anthropometric and haematological parameters, systolic and diastolic blood pressure levels, heart rate, glucose, TG, LDL-C, TC/HDL-C and LDL-C/HDL-C ratios, insulin, TNF-α, CD40, IL-8, IL-10, IL-12, and IgG (Tables 4, 5, and 6) for both groups. The exceptions were verified for haemoglobin (Hb) levels (*p = 0.0356*), IgE (*p = 0.0451*), and IL-6 (*p = 0.0396*), since the placebo group showed a decrease in these parameters after 8 weeks of the study (Table 5 and 6). In relation to the other parameters, there were significant reductions in TC, HDL-C, IgA, IgM, and IL-1β for both groups.
throughout the experimental period (Table 4 and 6). Comparing the median differences (T8 to T0) between the two groups, the trend for LDL-C decrease was higher in group S (15.0 mg/dL) (p=0.0606) than in group P (2.5 mg/dL) (p=0.1292). Nevertheless, regarding inter-group changes, no significant differences were verified for all parameters at baseline and after 8 weeks of diet dessert consumption (p>0.05).
Table 4. Clinical and biochemical parameters at baseline (T0) and after 8 weeks (T8) of mousse consumption.

| Parameters       | Groups | T0              | T8              | p     |
|------------------|--------|-----------------|-----------------|-------|
| Weight (kg)      | P      | 87.8 (61.9-96.5) | 88.1 (78.1-97.3) | 0.6158 |
|                  | S      | 84.6 (59.9-99.3) | 84.0 (72.2-100.5) | 0.5392 |
| BMI (kg/m²)      | P      | 33.9 (29.1-37.1) | 33.9 (29.0-37.4) | 0.5536 |
|                  | S      | 30.7 (28.0-33.4) | 30.9 (28.6-33.1) | 0.3764 |
| WC (cm)          | P      | 101.9 (94.5-112.8) | 103.0 (96.0-113.8) | 0.8552 |
|                  | S      | 99.0 (91.5-112.2) | 97.5 (91.0-109.5) | 0.6671 |
| SBP (mm Hg)      | P      | 130.0 (115.5-139.5) | 127.0 (115.0-137.5) | 0.9759 |
|                  | S      | 133.0 (127.0-142.0) | 131.0 (127.0-142.0) | 0.6089 |
| DBP (mm Hg)      | P      | 81.5 (74.0-89.0) | 80.0 (74.0-87.0) | 0.3543 |
|                  | S      | 82.0 (73.0-91.0) | 82.0 (77.0-89.0) | 0.7779 |
| Heart rate (bmp) | P      | 77.0 (65.8-86.2) | 76.0 (65.5-85.3) | 0.6017 |
|                  | S      | 71.0 (66.0-78.0) | 70.0 (66.0-76.0) | 0.4885 |
| Glucose (mg/dL)  | P      | 94.5 (89.0-99.0) | 91.5 (79.0-96.0) | 0.1469 |
|                  | S      | 95.0 (88.0-99.0) | 95.0 (83.0-101.0) | 0.2592 |
| TG (mg/dL)       | P      | 127.0 (93.5-163.0) | 120.0 (75.5-168.0) | 0.5645 |
|                  | S      | 123.0 (89.0-159.0) | 131.0 (102.0-194.0) | 0.2511 |
| TC (mg/dL)       | P      | 183.5 (149.5-211.5) | 160.0 (133.0-209.5) | 0.0023 |
|                  | S      | 203.0 (194.0-229.0) | 189.0 (168.0-206.0) | 0.0064 |
| LDL-C (mg/dL)    | P      | 109.0 (87.5-133.0) | 106.5 (74.0-137.5) | 0.1292 |
|                  | S      | 123.0 (103.0-137.0) | 108.0 (103.0-118.0) | 0.0606 |
| HDL-C (mg/dL)    | P      | 46.0 (37.0-51.0) | 43.0 (35.5-48.5) | 0.0054 |
|                  | S      | 48.0 (38.0-60.0) | 44.0 (38.0-51.0) | 0.0050 |
| TC/HDL-C         | P      | 4.0 (3.5-5.2) | 4.1 (3.4-4.6) | 0.0785 |
|                  | S      | 4.2 (4.0-5.1) | 4.3 (3.7-4.9) | 0.4702 |
| LDL-C/HDL-C      | P      | 2.4 (2.2-3.0) | 2.5 (2.1-2.7) | 0.6321 |
|                  | S      | 2.5 (2.3-3.1) | 2.6 (2.1-2.9) | 0.8137 |
| Insulin (µU/mL)  | P      | 12.3 (8.5-17.5) | 11.9 (8.4-16.7) | 0.7086 |
|                  | S      | 13.3 (8.7-18.4) | 12.3 (9.1-16.2) | 0.0830 |

Values are expressed as median (25%-75%). Wilcoxon matched pairs test was performed to verify changes from the baseline (intragroup changes). Mann-Whitney was performed to compare differences at baselines and across treatments groups (intergroup changes). The differences were significant for p<0.05 and p<0.01. No differences between groups were found. BMI: body mass index; WC: waist circumference; SBP: systolic blood pressure; DBP: diastolic blood pressure; TG: triglycerides; TC: total cholesterol; LDL-C: low-density lipoprotein cholesterol; HDL-C: high-density lipoprotein cholesterol; TC/HDL-C: total cholesterol to HDL-cholesterol ratio; LDL-C/HDL-C: LDL-cholesterol to HDL-cholesterol ratio; IgA: immunoglobulin A; IgM: immunoglobulin M. Group P: individuals who consumed the placebo product (n=22); Group S: individuals who consumed the synbiotic diet mousse (n=23). T0: baseline; T8: 8 weeks of daily consumption of diet desserts.
Table 5. Haematological parameters at baseline (T0) and after 8 weeks (T8) of mousse consumption.

| Parameters      | Groups | T0                  | T8                  | p   |
|-----------------|--------|---------------------|---------------------|-----|
| Haemoglobin (g/dL) |        |                     |                     |     |
| P               | 14.5 (13.1-15.3) | 13.9 (13.0-15.1) | 0.0356              |     |
| S               | 14.6 (13.3-15.6) | 14.7 (13.2-15.7) | 0.8771              |     |
| Leukocytes (mm³) |        |                     |                     |     |
| P               | 7160.0 (6025.0-9275.0) | 7060.0 (5910.0-9875.0) | 0.6083          |     |
| S               | 6960.0 (5730.0-7570.0) | 6830.0 (6270.0-7970.0) | 0.3989          |     |
| Lymphocytes (mm³) |        |                     |                     |     |
| P               | 2124.0 (1960.0-2511.0) | 2148.0 (1775.0-2598.0) | 0.9935       |     |
| S               | 2241.0 (1869.0-2760.0) | 2351.0 (1871.0-2871.0) | 0.0528       |     |
| Erythrocytes (mm³) |      |                     |                     |     |
| P               | 5.02x10⁶ (4.59x10⁶-5.38x10⁶) | 4.98x10⁶ (4.41x10⁶-5.31x10⁶) | 0.2392      |     |
| S               | 4.93x10⁶ (4.70x10⁶-5.29x10⁶) | 5.08x10⁶ (4.75x10⁶-5.34x10⁶) | 0.4479      |     |
| Neutrophils(mm³) |        |                     |                     |     |
| P               | 4429 (3087-5652) | 4176 (3209-5990) | 0.7640              |     |
| S               | 3783 (2854-4413) | 3953 (2700-4655) | 0.5894              |     |
| Eosinophils (mm³) |      |                     |                     |     |
| P               | 190.0 (120.5-255.5) | 194.0 (137.5-294.5) | 0.1605          |     |
| S               | 160.0 (100.0-314.0) | 162.0 (120.0-277.0) | 0.9454          |     |
| Monocytes (mm³)  |        |                     |                     |     |
| P               | 549.5 (446.0-679.9) | 531.5 (469.0-642.0) | 0.7029       |     |
| S               | 592.0 (500.0-709.0) | 577.0 (542.0-700.0) | 0.7553       |     |

Values are expressed as median (25%-75%). Wilcoxon matched pairs test was performed to verify changes from baseline (intragroup changes). Mann-Whitney was performed to compare differences at baselines and across treatments groups (intergroup changes). The differences were significant for p < 0.05 and p<0.01. No differences between groups were found. Group P: individuals who consumed the placebo product (n=22); Group S: individuals who consumed the synbiotic diet mousse (n=23). T0: baseline; T8: 8 weeks of daily consumption of diet desserts.
Bernini et al. (2016) verified that the daily ingestion of fermented milk containing glucose, TNF rate, anthropometric, and various laboratory blood parameters (TG, LDL) between treatment baseline and T8 values were expressed as median (25%-75%). Mann-Whitney matched pairs test was performed to verify changes from baseline (intragroup changes). We did not find any effect of the intervention with SDM on blood pressure, heart rate, anthropometric, and various laboratory blood parameters (TG, LDL-C, TC/HDL, insulin, glucose, TNF-α, CD40, IL-8, IL-10, IL-12, and IgG) assessed in the present study. Similarly, Bernini et al. (2016) verified that the daily ingestion of fermented milk containing...
Bifidobacterium animalis ssp. lactis HN019 by patients with MetS did not cause any significant changes in blood pressure, glucose, WC, TG, HDL-C, insulin, and HOMA-IR. Nevertheless, the authors observed a significant reduction in BMI, TC, and LDL-C in the probiotic group compared to the baseline and the control group values.

On the other hand, in our study a significant reduction of TC and HDL-C levels was observed for both groups after 8 weeks of intervention. It is noteworthy that the TC decrease was higher in the placebo group compared to the synbiotic group (reductions of 23.5 and 14.0 mg/dL, respectively). A possible explanation for this result may be related to the differences found in the food matrix of the PDM and the SDM, in that former product presented 14.0% of skimmed milk powder (non-fat solids source), while the SDM only 4.0% (Table 1).

In this sense, during the intervention period of 8 weeks, the placebo and the synbiotic groups ingested, respectively, 0.14 and 0.04 g/day of skimmed milk powder. Some evidence suggests a possible interaction of the dietary calcium with fatty acids through the formation of chelates during the process of lipids digestion, resulting in a reduction of the absorption of some fatty acids by the precipitation and excretion of the salts formed in faeces (Cominetti, Marreiro, & Cozzolino, 2012; Jolma et al., 2003; Vaskonen et al., 2002). Thus, the highest content of calcium in PDM compared to SDM might have exerted a greater influence on the lipid profile of volunteers. Indeed, Barreto et al. (2014) attributed the reduction of cholesterol levels in the placebo group after 90 days of intervention with unfermented milk (not containing probiotic and prebiotic) to calcium and magnesium.

Although the LDL-C reduction was not statistically significant, there was a higher tendency (p=0.0606) of reduction of this parameter in the group S (around 12%) when compared to group P (around 2%). Several hypotheses have been proposed to explain the potential cholesterol-lowering effects of probiotics and/or prebiotics including the production of short chain fatty acids resulting from fermentation of prebiotics, incorporation of
cholesterol into the cell membrane, dissociation of bile salts by specific hydrolases, and conversion of cholesterol into coprostanol by desconjugated bile (Ishimwe et al., 2015).

It is important to point out that the findings of different studies on probiotic and prebiotic hypocholesterolemic effect are still controversial. For instance, studies developed by Ahn et al. (2015) and Jung et al. (2015) did not show any effect of the probiotic strains *Lactobacillus curvatus* HY7601 and *L. plantarum* KY1032 on TC, HDL-C, and LDL-C levels of subjects with triglyceridemia (without diabetes) and overweight, respectively. However, a meta-analysis of randomized controlled trials revealed that the consumption of probiotics has positive health effects on TC and LDL-C in volunteers with high, borderline high and normal cholesterol levels (Guo et al., 2011).

Regarding the haematological parameters, we observed a significant reduction ($p<0.05$) in the Hb level only in the placebo group after 8 weeks of study. However, no significant difference was observed between the groups at the end of the intervention period. Studies suggest a relationship between Hb levels and the risk of developing MetS (Chuang et al., 2016; Hu, Kuo, & Wu, 2016). It is important to emphasize that hypertrophy and hyperplasia are characteristic features of obesity and lead to a reduction in the blood supply to adipocytes, due to the adipocytes enlargement. This reduction causes a tissue hypoxia, leading to metabolic changes, besides stimulating erythropoietin production and Hb synthesis (Chuang et al., 2016). In this sense, the Hb levels may be correlated to MetS and used to predict this syndrome in subjects (Chuang et al., 2016). Past studies showed that among various CVD risk factors associated with Hb levels are white blood cell counts, cigarette smoking, diastolic blood pressure, and serum albumin (Shimakawa & Bild, 1993).

Regarding proinflammatory cytokines, the present study showed that PDM as well as SDM consumption led to a reduction in IL-1β after 8 weeks. On the other hand, a significant decrease in the IL-6 levels was found only in the placebo group. Nevertheless,
there were no significant differences between the experimental groups after 8 weeks of intervention. Further studies are necessary to investigate the role of each mousse ingredient on the inflammatory parameters of MetS subjects. However, it is noteworthy that lactic acid bacteria, including probiotic strains, differ in their immunomodulatory properties regarding their differences in their cytokine profile and regulatory T cell responses (Ashraf et al., 2014).

Studies have suggested a great potential for immune and inflammatory response associated with daily supplementation with lactobacilli strains (Akoğlu et al., 2015; Matsusaki et al., 2016; Štofilová et al., 2016). Nevertheless, a double-blind, randomized, placebo-controlled trial conducted by Tonucci et al. (2017) showed that the intake of fermented goat milk containing *L. acidophilus* La-5 and *Bifidobacterium animalis* Bb-12 did not influence the IL-6 levels in subjects with type 2 diabetes mellitus after 6 weeks of intervention.

Additionally, an immunostimulatory effect of the bioactive peptides resulting from the digestive process of milk proteins was suggested by Solieri, Rutella, and Tagliazucchi (2015), since milk proteins, particularly casein, are precursors of biologically active peptides. Besides, these researchers reported that bioactive peptides can be released from milk proteins by gastrointestinal digestion or by enzymatic hydrolysis during food processing and fermentation. Moreover, they may exert several beneficial properties, including the fact that immunomodulation, and immunomodulatory peptides can increase immune cell functions, such as lymphocyte proliferation, natural killer cell activity, antibody synthesis, and cytokine regulation (Singh, Vij, & Hati, 2014). In this context, the effect of the diet mousses studied, in particular the placebo product, on the reduction of the IL-1β and IL-6 levels might be related to an increased formation of bioactive peptides in the products. As mentioned before, the amount of milk proteins in the placebo product was higher compared to the synbiotic product. Bioactive peptides may inhibit inflammatory biomarkers such as IL-1β, cyclooxygenase-2, and TNF-α mRNA expression (Ma et al., 2016).
Regarding the immunoglobulins, we observed a significant reduction in IgM and IgA levels for both experimental groups studied. According to Gonzalez-Quintela et al. (2007), high levels of IgA may represent an important immunological marker for the prevalence of obesity and MetS. In addition, these researchers reported an association between serum levels of IL-6 and IgA between people with this profile of metabolic abnormalities. In the present study, IL-6 and IgA levels showed a significant reduction ($p<0.05$) in the placebo group.

According to Song et al. (2014), IgM is reactive to several autoantigens and is implied to be important for autoimmunity, suggesting that this immunoglobulin may be a potential risk factor for MetS. In this context, these researchers designed a cross-sectional study with around one thousand subjects to evaluate the relationship between IgM and MetS. The results showed that IgM may be a useful predictive factor for MetS in an adult population. Although further studies are required to explain the exact mechanisms of IgM in MetS, we could observe a significant reduction in IgM levels in both experimental groups after 8 weeks of study.

In the present study, a significant decrease in IgE levels was only verified in the group that received the placebo product. Evidence suggests that high levels of IgE in plasma or tissues contribute to the activation of mast cells in the extracellular environment involved in the inflammation process and immunity (Madjene et al, 2015; Wang et al., 2013). Studies suggest the association between high levels of IgE and mast cells, which are important biomarkers for the development of type 2 diabetes mellitus in humans (Wang et al., 2011; Wang et al., 2017). Besides, Zhang and Shi (2012) related the mast cell presence to other diseases associated with MetS, including obesity, insulin resistance, hypertension, and dyslipidemia.
Some limitations of the present study, including the duration of the intervention and sample size, need to be considered to analyse the results obtained. Long-term interventions using a larger number of volunteers would be required to confirm the effects of the synbiotic product on anthropometric, biochemical, haematological, inflammatory, and immunological parameters. Moreover, we believe that the aggressive conditions of the gastrointestinal tract (GIT) (digestive agents present in the gastric and pancreatic secretions, as well as other physiological factors) may have affected the *L. acidophilus* La-5 survival and functionality, which could explain why the results of the synbiotic group were not so expressive in the present study. Buriti, Castro, and Saad (2010) demonstrated the low tolerance of *L. acidophilus* La-5, incorporated in a mousse similar to the one applied in the present study, to artificial gastrointestinal juice in an assay that simulated the GIT conditions. The survival of this probiotic strain was drastically reduced after 6 h of the in vitro assay. On the other hand, in a study conducted by our research group, we tested a synbiotic mousse containing *L. acidophilus* La-5 microencapsulated with inulin, where the probiotic strain showed a high survival rate (around 82%) when submitted to simulated gastrointestinal conditions, suggesting that the microencapsulation may be an alternative to increase the strain survival and potential health effects (unpublished data). This technology enables the development of more stable probiotic products, preserving the viability of microorganisms throughout processing, distribution, storage, and especially during the passage through the gastrointestinal tract (Amine et al., 2014). Nevertheless, further studies will be required to verify whether the mousse incorporated with microencapsulated *L. acidophilus* La-5 could have a greater influence on risk factors related to MetS. In brief, our results suggest that the presence of probiotic and prebiotic ingredients in the diet mousse did not significantly affect the parameters evaluated after 8 weeks of intervention in the volunteers with MetS.
4. CONCLUSION

The observations here reported suggest that daily consumption of either the synbiotic mousse or the placebo product contributed to the reduction of TC, HDL-C, IL-1β, IgA, and IgM in the volunteers with MetS. Therefore, these results suggest that the presence of probiotic and prebiotic ingredients in the diet mousse did not significantly influence the risk factors related to MetS. Further clinical studies are necessary to support the results here reported, such as a long-term experimental protocol and the inclusion of an evaluation of the intestinal microbiota to determine whether the synbiotic dessert might cause specific changes in the composition and/or activity of the intestinal microbiota of subjects with MetS.
5. REFERENCES

Ahn, H.-Y., Kim, M., Chae, J. S., Ahn, Y.-T., Sim, J.-H., Choi, II-D., Lee, S.-H., & Lee, J. H. (2015). Supplementation with two probiotic strains, *Lactobacillus curvatus* HY7601 and *L. plantarum* KY1032, reduces fasting TG and enhances apolipoprotein A-V levels in non-diabetic subjects with hypertriglyceridemia. *Atherosclerosis*, 241, 649-656.

Akkasheh, G., Kashani-Poor, Z., Tajabadi-Ebrahimi, M., Jafari, P., Akbari, H., Taghizadeh, M., Memarzadeh, M. R., Asemi, Z., & Esmailzadeh, A. (2016). Clinical and metabolic response to probiotic administration in patients with major depressive disorder: A randomized, double-blind, placebo-controlled trial. *Nutrition*, 32, 315–320.

Akoglu, B., Loytved, A., Nuiding, H., Zeuzem, S., & Faust, D. (2015). Probiotic *Lactobacillus casei* Shirota improves kidney function, inflammation and bowel movements in hospitalized patients with acute gastroenteritis – A prospective study. *Journal of Functional Foods*, 17, 305–313.

Al-Sheraji, S. H., Ismail, A., Manap, M. Y., Mustafa, S., Yusof, R. M., & Hassan, F. A. (2012). Hypocholesterolemic effect of yoghurt containing *Bifidobacterium pseudocatenulatum* G4 or *Bifidobacterium longum* BB536. *Food Chemistry*, 135, 356–361.

Amine, K. M., Champagne, C. P., Raymond, Y., St-Gelais, D., Britten, M., Fustier, P., Salmieri, S., & Lacroix, M. (2014). Survival of microencapsulated *Bifidobacterium longum* in Cheddar cheese during production and storage. *Food Control*, 37, 193-199.

Ashraf, R., Vasiljevic, T., Day, S. L., Smith, S. C., & Donkor, O. N. (2014). Lactic acid bacteria and probiotic organisms induce different cytokine profile and regulatory T cells mechanisms. *Journal of Functional Foods*, 6, 395–409.
Barreto, F. M., Simão, A. N. C., Morimoto, H. K., Lozovoy, M. A. B., Dichi, I., & Miglioranza, L. H. S. (2014). Beneficial effects of *Lactobacillus plantarum* on glycemia and homocysteine levels in postmenopausal women with metabolic syndrome. *Nutrition*, 30, 939–942.

Bernini, L. J., Simão, A. N. C., Alfieri, D. F., Lozovoy, M. A. B., Mari, N. L., Souza, C. H. B., Dichi, I., & Costa, G. N. (2016). Beneficial effects of *Bifidobacterium lactis* on lipid profile and cytokines in patients with metabolic syndrome: A randomized trial. Effects of probiotics on metabolic syndrome. *Nutrition*, 32, 716–719.

Brito-Luna, M. J., Villanueva-Quintero, D. G., Sandoval-Talamantes, A. k., Fatutis-Morris, M., Graciano-Machuca, O., Sanchez-Hernandez, P. E., & Alvarado-Navarro, A. (2016). Correlation of IL-12, IL-22, and IL-23 in patients with psoriasis and metabolic syndrome. Preliminary report. *Cytokine*, 85, 130-136.

Buriti, F. C. A., Castro, I. A., & Saad, S. M. I (2010). Viability of *Lactobacillus acidophilus* in synbiotic guava mousses and its survival under *in vitro* simulated gastrointestinal conditions. *International Journal of Food Microbiology*, 137, 121–129.

Cani, P. D., & Hul, M. V. (2015). Novel opportunities for next-generation probiotics targeting metabolic syndrome. *Current Opinion in Biotechnology*, 32, 21–27.

Champagne, C. P., Ross, R. P., Saarela, M., Hansen, K. F., & Charalampopoulos, D. (2011). Recommendations for viability assessment of probiotics as concentrated cultures and in food matrices. *International Journal of Food Microbiology*, 149, 185-193.

Chuang, T-J., Liu, J-S., Li, P-F., wen Chang, H., Hsieh, C-H., Chang, J-B., Hung, Y-J., Pei, D., Liang, Y-J., & Chen, Y-L. (2016). The relationships between hematogram and metabolic syndrome in elderly subgroups: A Taiwan cohort study. *Archives of Gerontology and Geriatrics*, 63, 59–66.
Cominetti, C., Marreiro, D. N., & Cozzolino, S. M. F. (2012). Minerais e obesidade. In: Cozzolino, S. M. F., 4 ed. *Biodisponibilidade de nutrientes*. Barueri: Manole, 2012. Cap.40, 971-1005.

De Moreno de LeBlanc A, & Perdigon G. (2010). The application of probiotic fermented milks in cancer and intestinal inflammation. *The Proceedings of the Nutrition Society*, 69, 421–428.

Forssten, S. D., Sindelar, C. W., & Ouwehand, A. C. (2011). Probiotics from an industrial perspective. *Anaerobe*, 17, 410–413.

Gøbel, R. J., Larsen, N., & Jakobsen, M., Mølgaard, C., & Michaelsen, K. F. (2012). Probiotics to adolescents with obesity: effects on inflammation and metabolic syndrome. *Journal of Pediatric Gastroenterology and Nutrition*, 55, 673-678.

Gonzalez-Quintel a, A., Alende, R., Gude, F., Campos, J., Rey, J., Meijide, L. M., Fernandez-Merino, C., & Vidal, C. (2008). Serum levels of immunoglobulins (IgG, IgA, IgM) in a general adult population and their relationship with alcohol consumption, smoking and common metabolic abnormalities. *Clinical and Experimental Immunology*, 151, 42–50.

Grundy, S. M., Cleeman, J. I., Daniels, S. R., Donato, K. A., Eckel, R. H., Franklin, B. A., Gordon, D. J., Krauss, R. M., Savage, P. J., Smith Jr, S. C., Spertus, J. A., & Costa, F. (2005). Diagnosis and Management of the Metabolic Syndrome an American Heart Association/National Heart, Lung, and Blood Institute Scientific Statement. *Circulation*, 112, 2735-2752.

Guo, Z., Liu, X. M., Zhang, Q. X., Shen, Z., Tian, F. W., Zhang, H., Sun, Z. H., & Zhang, H. P. (2011). Influence of consumption of probiotics on the plasma lipid profile: A meta-analysis of randomised controlled trials. *Nutrition, Metabolism & Cardiovascular Disease*, 21, 844–850.
Health Canada (2009) Guidance document – The use of probiotic microorganisms in food. Retrieved from: http://www.hc-sc.gc.ca/fn-an/alt_formats/hpfb-dgpsa/pdf/legislation/probiotics_guidance-orientation_probiotiques-eng.pdf. Access: May 25th, 2016.

Hu, Y-H., Kuo, S-W., & Wu, D-A. (2016). Relationships between Hemoglobin and Each Component of Metabolic Syndrome: A Special Focus on Elderly without Medication. *International Journal of Gerontology*, 10, 22-27.

Ishimwe, N., Daliri, E. B., Lee, B. H., Fang, F., & Du, G. (2015). The perspective on cholesterol-lowering mechanisms of probiotics. *Molecular Nutrition & Food Research*, 59, 94–105.

Jolma, P., Kööbi, P., Kalliovalkama, J., Kähönen, M., Fan, M., Saha, H., Helin, H., Lehtimäki, T., & Pörsti, I. (2003). Increased calcium intake reduces plasma cholesterol and improves vaso relaxation in experimental renal failure. *American Journal of Physiology Heart and Circulatory Physiology*, 285, H1882–H1889.

Jonkers, D. M. A. E. (2016). Role of microbes (probiotics and prebiotics). *Best Practice & Research Clinical Gastroenterology*, 6, 181-183.

Jung, S., Lee, Y. J., Kim, M., Kim, M., Kwak, J. H., Lee, J-W., Ahn, Y-T., Sim, J-H, & Lee, J-H. (2015). Supplementation with two probiotic strains, *Lactobacillus curvatus* HY7601 and *Lactobacillus plantarum* KY1032, reduced body adiposity and Lp-PLA 2 activity in overweight subjects. *Journal of Functional Foods*, 19, 744–752.

Kakafika, A. I., Liberopoulos, E. N., Karagiannis, A., Athyros, V. G., & Mikhailidis, D. P. (2006). Dyslipidaemia, hypercoagulability and the metabolic syndrome. *Current vascular pharmacology*, 4, 175-83.
Karaman, A., Aydin, H., Geçkinli, B., Çetinkaya, A., & Karaman, S. (2015). DNA damage is increased in lymphocytes of patients with metabolic syndrome. *Mutation Research, 782*, 30–35.

Kovatcheva-Datchary, P., & Arora, T. (2013). Nutrition, the gut microbiome and the metabolic syndrome. *Best Practice & Research Clinical Gastroenterology, 27*, 59–72.

Larsen, N., Vogensen, F. K., van den Berg, F. W. J., Nielsen, D. S., Andreasen, A. S., Pedersen, B. K., Al-Soud, W. A., Sørensen, S. J., Hansen, L. H., & Jakobsen, M. (2010). Gut Microbiota in Human Adults with Type 2 Diabetes Differs from Non-Diabetic Adults. *Plos One, 5*, e9085.

Ley, R. E., Bäckhed, F., Turnbaugh, P., Lozupone, C. A., Knight, R. D., & Gordon, J. I. (2005). Obesity alters gut microbial ecology. *PNAS, 102*, 11070–11075.

Ley, R. E., Turnbaugh, P. J., Klein, S., & Gordon, J. I. (2006). Microbial ecology: human gut microbes associated with obesity. *Nature, 44*, 1022-1023.

Ma, Y., Liu, J., Shi, H., & Yu, L. (2016). Isolation and characterization of anti-inflammatory peptides derived from whey protein. *Journal of Dairy Science, 99*, 6902-6912.

Madjene, L. C., Pons, M., Danelli, L., Claver, J., Ali, L., Madera-Salcedo, I. K., Kassas, A., Pellefigues, C., Marquet, F., Dadah, A., Attout, T., El-Ghoneimi, A., Gautier, G., Benhamou, M., Charles, N., Daugas, E., Launay, P., & Blank, U. (2015). Mast cells in renal inflammation and fibrosis: Lessons learnt from animal studies. *Molecular Immunology, 63*, 86–93.

Matsusaki, T., Takeda, S., Takeshita, M., Arima, Y., Tsend-Ayush, C., Oyunsuren, T., Sugita, C., Yoshida, H., Watanabe, W., & Kurokawa, M. (2016). Augmentation of T helper type 1 immune response through intestinal immunity in murine cutaneous herpes simplex
virus type 1 infection by probiotic *Lactobacillus plantarum* strain 06CC2. *International Immunopharmacology*, 39, 320–327.

Mazidi, M., Rezaie, P., Kengne, A. P., Mobarhan, M. G., & Ferns, G. A. (2016). Gut microbiome and metabolic syndrome. *Diabetes & Metabolic Syndrome: Clinical Research & Reviews*, 10S, S150-S157.

Mill, J. G., Pinto, K., Griep, R. H., Goulart, A., Foppa, M., Lotufo, P. A., Maestri, M. K., Ribeiro, A. L., Andreão, R. V., Dantas, E. M., Oliveira, I., Fuchs, S. C., Cunha, R. S., & Bensenor, I. M. (2013). Aferições e exames clínicos realizados nos participantes do ELSA-Brasil. *Revista de Saúde Pública*, 47, 54-62.

Ministero della Salute (2013). Commissione unica per la nutrizione e la dietetica – Guidelines on probiotics and prebiotics. Retrieved from: http://www.salute.gov.it/imgs/C_17_pubblicazioni_1016_allegato.pdf. Acess: May 24th, 2016.

Panahi, Y., Hosseini, M. S., Khalili, N., Naimi, E., Simental-Mendía, L. E., Majeed, M., & Sahebkar, A. (2016). Effects of curcumin on serum cytokine concentrations in subjects with metabolic syndrome: A post-hoc analysis of a randomized controlled trial. *Biomedicine & Pharmacotherapy*, 82, 578–582.

Sanders, M. E., & Marco, M. L. (2010). Food Formats for Effective Delivery of Probiotics. *Annual Review of Food Science and Technology*, 1, 65-85.

Scavuzzi, B. M., Miglioranza, L. H. S., Henrique, F. C., Paroschi, T. P., Lozovoy, M. A. B., Simão, A. N. C., & Dichi, I. (2015). The role of probiotics on each component of the metabolic syndrome and other cardiovascular risks. *Expert Opin Ther Targets*, 19, 1127-1138.
Shimakawa, T., & Bild, D. E. (1993). Relationship between hemoglobin and cardiovascular risk factors in young adults. *Journal of Clinical Epidemiology*, 46, 1257-1266.

Simão, T.N.C., Lozovoy, M.A.B., Simão, A.N.C., Oliveira, S.R., Venturini, D., Morimoto, H. K., & Dichi, I. (2013). Reduced-energy cranberry juice increases folic acid and adiponectin and reduces homocysteine and oxidative stress in patients with the metabolic syndrome. *British Journal of Nutrition*, 110, 1885–1894.

Singh, B. P., Vij, S., & Hati, S. (2014). Functional significance of bioactive peptides derived from soybean. *Peptides*, 54, 171–179.

Solieri, L., Rutella, G. S., & Tagliazucchi, D. (2015). Impact of non-starter lactobacilli on release of peptides with angiotensin-converting enzyme inhibitory and antioxidant activities during bovine milk fermentation. *Food Microbiology*, 51, 108-116.

Song, K., Du H., Zhang Q., Wang C., Guo Y., Wu H., Liu L., Jia Q., Wang X., Shi H., Sun S., & Niu K. (2014). Serum immunoglobulin M concentration is positively related to metabolic syndrome in an adult population: Tianjin Chronic Low-Grade Systemic Inflammation and Health (TCLSIH) Cohort Study. *PloS One*, 9, p.e88701.

Štofilová, J., Szabadosová, V., Hrěková, G., Salaj, R., Bertková, I., Hijová, E., Strojný, L., & Bomba, A. (2015). Co-administration of a probiotic strain *Lactobacillus plantarum* LS/07 CCM7766 with prebiotic inulin alleviates the intestinal inflammation in rats exposed to N, N-dimethylhydrazine. *International Immunopharmacology*, 24, 361–368.

Synetos, A., Papanikolaou, A., Toutouzas, K., Georgiopoulos, G., Karanasos, A., Drakopoulou, M., Latsios, G., Papaioannou, S., Tsiamis, E., & Tousoulis, D. (2016). Metabolic syndrome predicts plaque rupture in patients with acute myocardial infarction. An optical coherence study. *International Journal of Cardiology*, 209, 139–141.
Tonucci, L. B., Santos, K. M. O., Oliveira, L. L. O., Ribeiro, S. M. R., & Martino, H. S. D. (2017). Clinical application of probiotics in type 2 diabetes mellitus: A randomized, double-blind, placebo-controlled study. *Clinical Nutrition*, 36, 85-92.

Tremaroli, V., & Fredrik Bäckhed, F. (2012). Functional interactions between the gut microbiota and host metabolism. *Nature*, 489, 242-249.

Turnbaugh, P. J., Hamady, M., Yatsunenko, T., Cantarel, B. L., Duncan, A., Ley, R. E., Sogin, M. L., Jones, W. J., Roe, B. A., Affourtit, J. P., Egholm, M., Henrissat, B., Heath, A. C., Knight, R., & Gordon, J. I. (2009). A core gut microbiome in obese and lean twins. *Nature*, 457, 480–484.

Vaskonen, T., Mervaala., E., Sumuvuori, V., Seppänen-Laakso, T., & Karppanen, H. (2002). Effects of calcium and plant sterols on serum lipids in obese Zucker rats on a low-fat diet. *British Journal of Nutrition*, 87, 239–245.

Wang, Z., Shen, X-H., Feng, W-M., & Qiu, W. (2017). Mast cell specific immunological biomarkers and metabolic syndrome among middle-aged and older Chinese adults. *Endocrine Journal*, 64, 245-253.

Wang, Z., Zhang, H., Shen, X-H., Jin, K-L., Ye, G-F., Qian, L., Li, B., Zhang, Y-H., & Shi, G-P. (2011). Immunoglobulin E and Mast Cell Proteases Are Potential Risk Factors of Human Pre-Diabetes and Diabetes Mellitus. *Ploes One*, 6, e28962.

Wang, Z., Zhang, H., Shen, X-H., Jin, K-L., Ye, G-F., Qiu, W., Qian, Li., Li, B., Zhang, Y-H., & Shi, G-P. (2013). Increased levels of IgE in plasma or tissues may activate mast cells and increase mast cell mediators in the extracellular milieu. *Annals of Medicine*, 45, 220–229.

Zhang, J., & Shi, G. P. (2012). Mast cells and metabolic syndrome. *Biochimica et Biophysica Acta*, 1822, 14–20.
Chapter 4
Microencapsulation of *Lactobacillus acidophilus* La-5 using inulin as coating agent by spray drying and its survival under in vitro simulated gastrointestinal conditions

**ABSTRACT**

The objective of this study was the optimization of the spray drying process for the microencapsulation of *Lactobacillus acidophilus* La-5, using inulin as coating agent to increase its gastrointestinal survival. Microencapsulation process conditions were optimized at 80 mL/min, 82% and 10%, for feed flow, aspiration rate and inulin concentration, respectively. Subsequently, a synbiotic diet mousse (SDM) was produced with the addition both of the free and of the microencapsulated probiotic strain, and its *in vitro* gastrointestinal resistance was evaluated. The microencapsulated probiotic strain incorporated in mousse survived significantly better during the gastric phase: 5.68 log CFU/g (83.3%), the enteral phase I: 5.61 log CFU/g (82.3%), the enteral phase II: 5.56 log CFU/g (81.4%), in relation the other samples evaluated (*p*<0.05). Overall, these results confirm the appropriateness of the spray drying process to encapsulate the probiotic strain evaluated using inulin as coating agent and providing resistance to the microencapsulated microorganism.

**Keywords:** Probiotic; Prebiotic; Atomization; Gastrointestinal tolerance; Mousse.
1. INTRODUCTION

Microencapsulation of probiotic bacteria leads to cell protection against unfavorable conditions in the food matrix, as well as along the gastrointestinal tract (Würth et al., 2015). Microencapsulation technologies enable development of more stable probiotic products with the preservation of the viability of the microorganisms during processing, distribution, storage, and especially during the digestive process (Amine et al., 2014).

The microencapsulation technique through spray drying consists of forming a suspension containing microorganism and coating agents. Next, this suspension is nebulized with hot air or nitrogen (Encina et al., 2016; Venil et al., 2016). This process is convenient in terms of energy requirements, operating costs, and leads to high process yield and is often used for probiotic encapsulation (Pinto et al., 2015). In general, the prolonged viability of dehydrated probiotic culture after this process makes it a good investment for food industries (Peighambardoust et al., 2011).

Moreover, it is essential that the capsule is able to provide good protection against hydrochloric acid, which leads to damage of the probiotic cells (Cook et al., 2012; Pinto et al., 2015). The coating agent should not present cytotoxicity and anti-microbial activities, which would otherwise compromise the viability of the probiotic culture (Cook et al., 2012). Studies indicate that some encapsulating polymers such as gum arabic (Rajabi et al., 2015), gelatin (Gomez-Mascaraque et al., 2016b), pectin (Tamm et al., 2016), and inulin (Fritzen-Freire et al., 2012; Silva et al., 2016; Zamora-Vega et al., 2013) present a great potential as coating material. In fact, these materials promote conditions suitable for the microorganisms’ survival, increasing their stability during the storage period after the spray drying process (Salar-Behzadi et al., 2013).
Interaction between microorganisms and the polymer is an important factor during the choice of the coating agent (Anekella & Orsat, 2013). In addition, the microencapsulated probiotic ought to maintain viability in the product and its release in the gut has to occur in a controlled manner (Corona-Hernandez et al., 2013). Therefore, the objective of this study was the optimization of the spray drying conditions for the microencapsulation of *L. acidophilus* La-5, using inulin as coating agent. Survival of the microencapsulated microorganism incorporated in a synbiotic mousse to *in vitro* simulated gastrointestinal conditions was evaluated.

### 2. MATERIAL AND METHODS

#### 2.1. Microencapsulation of *Lactobacillus acidophilus* La-5 through spray drying

**2.1.1. Preparation of the encapsulanting solution**

Inulin HP (High Performance) (Beneo-Orafi, Oreye, Belgium) was used as coating agent. Inulin is a polysaccharide with a degree of polymerization (DP) above 23, with purity levels of 99.5%. The commercial freeze-dried probiotic culture of *L. acidophilus* La-5 (Christian Hansen, Hoersholm, Denmark), DVS type (direct vat set - for direct addition in milk), was added to a sterilized pre-mixture containing 6% (w/v) of fructooligosaccharides (FOS) (Beneo-Orafi, Oreye, Belgium) dissolved in UHT (ultra-high temperature) skimmed milk (COOP, Casalecchio di Reno, Italy). The suspension was then mixed for 120 minutes at 37 °C (Komatsu et al., 2013). The activated probiotic strain was inoculated into the suspension containing the coating agent in a ratio of 1:9 (v/v).
2.1.2. The spray drying process

The spray drying process was performed according to Fritzen-Freire et al. (2013) with some modifications in the process parameters. For the experiments, a Buchi B-290 Mini spray dryer (Buchi, Flawil, Switzerland) was used with air inlet temperature of 120 °C. Encapsulating agent solution containing *L. acidophilus* La-5 was maintained under magnetic stirring at room temperature before being used. A drying air flow rate of 55 m³/h and the compressor air pressure of 4 bar were used.

2.2. Optimization of spray drying process parameters through Box-Behnken experimental design

The response surface methodology and the Box-Behnken experimental design with three factors and three levels were chosen to optimize and investigate the influence of the process variables feed flow ($X_1$), aspiration rate ($X_2$), and inulin concentration ($X_3$) in terms of the survival rate after the spray drying process ($Y_1$), probiotic cell counts ($Y_2$), and survival rate in acidic conditions ($Y_3$). The complete design consisted of 15 experiments with three replicates (used to estimate experimental error) of the central point (Table 1).

| Factors          | Levels |
|------------------|--------|
|                  | -1     | 0     | +1    |
| $x_1$ Feed Flow (mL/min) | 4      | 7     | 10    |
| $x_2$ Aspiration rate (%) | 70     | 80    | 90    |
| $x_3$ Inulin concentration (%) | 10     | 15    | 20    |

*Table 1. Box–Behnken experimental design matrix employed.*
Response surface methodology was applied to further optimize probiotic microencapsulation. A quadratic polynomial model was fitted to each response following the equation given below:

\[ Y_i = \beta_0 + \beta_1 \sum X_i + \beta_{ii} \sum X_i^2 + \beta_{ij} \sum \sum X_i X_j \]  

(1)

where \( Y \) is the response, \( \beta_0 \) the constant, \( \beta_i \) the linear coefficient, \( \beta_{ii} \) the quadratic coefficient, and \( \beta_{ij} \) the interaction coefficient, whereas \( X_i \) and \( X_j \) are the independent variables (Ismail & Nampoothiri, 2010).

2.3. Microcapsules powder analysis

2.3.1. Count of microencapsulated and free cells of *Lactobacillus acidophilus* La-5

Counts of probiotic cells were determined by the standard plate count method, according to the methodology described by Gomez-Mascaraque et al. (2016a) with some modifications for the microencapsulated probiotic cells. The microcapsules obtained by spray drying (1.0 g) were re-suspended in a ratio of 1:9 with sterile peptone water (0.1% w/v) and kept under mixing for 3 minutes to release the cells. For the count of viable probiotic cells, samples were serially diluted in peptone water solution and seeded in MRS agar modified by the addition of maltose solution (50% w/v) using the pour plate method and with incubation at 37 °C for 48 h, as proposed by International Dairy Federation (IDF, 1995). The experiments were performed in triplicate. The survival rate (%) compared to the initial count before the spray drying was calculated according to Equation (2) (Guo et al., 2009; Pinto et al., 2015):

\[ \text{Survival rate (\%)} = \frac{\log \text{CFU/g } N}{\log \text{CFU/g } N_0} \]  

(2)
Where, \( N \) is the total viable count of probiotic strains after the spray drying process and \( N_0 \) is the total viable count of probiotic strains before the start of the process.

### 2.3.2. Survival of encapsulated probiotic strain in acid conditions

The survival rate in acidic conditions was evaluated according to Costa et al. (2017). Other adjustments were necessary and proceeded as follows: microencapsulated probiotic cells were added to a saline solution (0.5% w/v) with pH adjusted to 2.0-2.5 through the addition of a solution containing 1 N HCl (Merck, Darmstadt, Germany), without pepsin and lipase. The samples were incubated at 37 °C for 2 h. After the incubation period, the microencapsulated probiotic cells were released, and their viability was measured in triplicate using the method described in section 2.3.1.

### 2.3.3. Moisture content

The mean moisture content (% wet basis) resulting from the spray drying process was measured gravimetrically. A sample of known mass (0.5 g) was placed in an aluminum pan and dried in a hot air oven at 105 ± 2 °C for a period of 24 h. The sample was then removed and immediately weighed. Initial and final weights were used to calculate the moisture content on a wet basis. The experiments were performed in triplicate.

### 2.3.4. Microencapsulation yield

The microencapsulation yield was determined according to Gomez-Mascaraque et al. (2016a), using the Equation (3):

\[
\text{Microencapsulation yield (\%)} = \frac{\text{Mass of spray drying products recovered from collector}}{\text{Mass of solids in the processed suspension}} \times 100 \quad (3)
\]
2.3.5. Water solubility index, water absorption index and swelling capacity

The water solubility index (WSI) and the water absorption index (WAI) were determined according to Ahmed et al. (2010), by dissolving 1 g of product in 12 mL of water. The WSI and WAI were calculated according to Equations (4) and (5), respectively.

\[
\text{WSI} = \left( \frac{\text{DW}_{\text{sup}}}{\text{DW}_{\text{part}}} \right) \times 100 \quad (4)
\]

\[
\text{WAI} = \frac{\text{PW}}{\text{DW}_{\text{part}}} \quad (5)
\]

where \( \text{DW}_{\text{sup}} \) is the dry weight of the supernatant, \( \text{DW}_{\text{part}} \) is the initial weight of the microparticles (dry basis), and \( \text{PW} \) is the weight of the pellet after centrifugation.

The Equation (6) was applied according to Paini et al. (2015) using Equation (4) to determine the swelling capacity (SC):

\[
\text{SC} = \frac{\text{DW}_{\text{sup}}}{[\text{DW}_{\text{part}} \times (100-\text{WSI})]} \quad (6)
\]

2.4. Production of the Synbiotic Diet Mousse (SDM)

The aerated synbiotic diet mousse (SDM) was prepared according to the formulation developed by Buriti et al. (2010) and characterized by Komatsu et al. (2013). Table 2 shows the proportions of the ingredients used in the production of the SDM. For the preparation, a commercial freeze-dried DVS probiotic culture of \( \text{L. acidophilus} \) La-5 was used. Skimmed milk powder and FOS were dissolved in ultra-high temperature skimmed milk on the day before the product preparation in order to make the dissolution of these ingredients easier. The resulting pre-mixture was stored under refrigeration at 4 °C until the addition of the remaining ingredients. One portion (40 mL) of this pre-mixture was sterilized and employed for the
fermentation at 37 °C for 120 min, using the probiotic culture (Komatsu et al., 2013). The activated culture in milk was then, depending on the condition tested, either added directly to the further ingredients of the mixture (free culture) or after being added to a suspension containing the coating agent in a ratio 1:9 and microencapsulated as described above (section 2.1 - microencapsulated culture, obtained through the optimized spray drying process, as described in section 2.2).

**Table 2.** Proportions of the ingredients used in the production of the synbiotic diet mousse.

| Ingredient (g/100 g)                                  | Synbiotic diet mousse |
|------------------------------------------------------|-----------------------|
| Skimmed milk\(^1\)                                   | 61.7                  |
| Powdered skimmed milk\(^2\)                          | 4.0                   |
| Sucralose\(^3\)                                      | 1.1                   |
| FOS\(^4\)                                            | 6.0                   |
| Inulin\(^5\)                                         | 4.0                   |
| Pasteurized and frozen guava pulp\(^6\)              | 20.0                  |
| Stabilizer/emulsifier\(^7\)                          | 2.8                   |
| Lactic acid\(^8\)                                    | 0.4                   |
| *Lactobacillus acidophilus* La-5\(^9\)               | 0.05                  |
| Total                                                | 100.0                 |

\(^1\) Latte UHT scremato (COOP, Gmunden, Austrian); \(^2\) Latte scremato in polvere (Ristora, Montichiari, Italy); \(^3\) Sucralose (COOP, Casalecchio di Reno, Italy); \(^4\) Beneo P95 (Orafti, Oreye, Belgium); \(^5\) Beneo HP (Orafti); \(^6\) Fruteiro do Brasil (Nectarvis Processamento de Frutas, Ceará-Mirim, RN, Brazil); \(^7\) Cremodan Mousse 30 (Danisco, Cotia, SP, Brazil); \(^8\) Lactic acid (Sigma-Aldrich, Steinheim, Germany); \(^9\) Strain La-5 (Christian Hansen, Hoersholm, Denmark).

The other ingredients listed in Table 2 were added and mixed until becoming homogenous. The mixture obtained was pasteurized in the same mixer at 85 °C for 5 min, allowed to cool to 40 °C and supplemented with fermented milk containing the activated probiotic culture. The mixture was then kept refrigerated (4 °C) for subsequent aeration at a
temperature between 10 and 15 °C, during which its volume increased by 80-85%. Figure 1 schematically illustrates the main steps of the production of the SDM.

![Diagram](image)

**Figure 1.** The main steps of synbiotic diet mousse production.

2.5. **Survival of microencapsulated *Lactobacillus acidophilus* La-5 to *in vitro* simulated gastrointestinal conditions after storage**

Free cells were prepared according to Yonekura et al. (2014). The freeze-dried probiotic culture was transferred to MRS broth (Oxoid Ltd., Basingstoke, UK), and, under aerobic conditions, incubated for 48 h at 37 °C. The MRS broth, modified by the addition of a maltose solution (described in section 2.3.1), was centrifuged at 3000 ×g for 5 min in aseptic conditions. Supernatants were discarded, and cell pellets were washed with phosphate
buffered saline (Sigma-Aldrich, Steinheim, Germany), and re-centrifuged. After discarding the supernatants, the collected bacterial cell pellets were suspended in the drying carrier media. The preparation of free cells was performed in triplicate.

Microencapsulated and free cells were compared for their ability to survive in vitro digestion simulating the human gastric and enteric conditions, according to Liserre et al. (2007), with the modifications suggested by Buriti et al. (2010). Other adjustments were necessary and proceeded as follows.

The microencapsulated and the free probiotic cells (1 g) were placed in 9 mL (ratio of 1:9) of a saline solution (0.5% w/v). The first 2 h represented the gastric phase (pH 2.0–2.5), with a solution containing 1 N HCl (Merck, Darmstadt, Germany), pepsin (3 g/L) (from porcine stomach mucosa, Sigma-Aldrich, St Louis, USA), and lipase (0.9 mg/L) (Amano lipase G, from Penicillium camemberti, Sigma-Aldrich). Bile (10 g/L) (bovine bile, Sigma-Aldrich) and pancreatin (1 g/L) (pancreatin from porcine pancreas, Sigma-Aldrich) were added to the enteric I (4 h of total assay) and the enteric II (6 h of total assay) phases with the pH adjusted, respectively, to 4.5–5.5 and 6.5–7.5.

After the respective incubation periods, microencapsulated and free cells were removed, and the viability of the entrapped cells was measured in triplicates using the method described in section 2.3.1. The results were presented as log CFU/g of fresh probiotic culture. Each assay was performed in triplicate. The pH values of the samples at each step of the assay were monitored using a pH meter (Hanna Instruments, Woonsocket, USA).

2.6. Statistical analysis

The response surface modelling was conducted using the STATISTICA v.10.0 software (Statsoft Inc., Tulsa, OK, USA). The statistical analysis of the Box-Behnken model
and adjusted coefficient of determination ($R^2$) was performed through the analysis of variance (ANOVA), followed by the Tukey post-hoc test ($p<0.05$). The optimization was obtained using the methodology described by Balasubramani et al. (2015). The optimization techniques of the Design-Expert software (Version 7.0 Trial, Stat-Ease, Minneapolis, MN, USA) were used for the simultaneous optimization of the multiple responses. The desired goals for each variable and response were chosen. All of the independent variables were kept within the range, while the responses were either maximized or minimized.

3. RESULTS AND DISCUSSION

3.1. Box–Behnken experimental design of the spray drying conditions

The experimental design matrix along with the measured responses for all the 15 experiments is given in Table 3. The probiotic survival rate after spray drying ranged between 62.6% and 86.5% and its survival rate to acidic conditions ranged between 41.8% and 79.3%. Probiotic counts varied from log 6.3 CFU/g up to log 9.3 CFU/g. The moisture and microencapsulation yield ranged between 4.2% and 10.6% and from 81.5% to 98.2%, respectively. The water solubility index ranged between 36.9% and 74.0%, the water absorption index from 0.9 g/gDP to 2.0 g/gDP, and the swelling capacity from 0.059 g/gDP to 0.0310 g/gDP.

Khem et al. (2016) reported an average survival rate for *L. plantarum* A17 after spray drying from 34.7% to 82.8%, using whey protein isolate powder as coating agent and an inlet temperature between 90 °C and 130 °C. In another study, Fritzen-Freire et al. (2013) using different coating agents to encapsulate *Bifidobacterium animalis* subsp. *lactis* BB-12, by spray drying observed a survival rate of 70.6% and 75.7% in reconstituted skimmed milk.
with FOS and FOS-enriched inulin at 150 °C, respectively. Huang et al. (2016) verified approximated survival of 40.0% for *L. casei* microencapsulated with sweet protein at 140 °C.
Table 3. Box–Behnken experimental design matrix and responses.

| Run | Feed Flow (mL/min) | Aspiration rate (%) | Inulin concentration (%) | Survival rate after spray drying (%) | Survival rate to acid conditions (%) | Probiotic count (log UFC/g) | Moisture (%) | Microencapsulation yield (%) | Water solubility index (%) | Water absorption index (g/g DP) | Swelling capacity (g/g DP) | Swelling capacity (g/g DP) |
|-----|-------------------|---------------------|--------------------------|-------------------------------------|-------------------------------------|----------------------------|--------------|----------------------------|-------------------------------|----------------------------|---------------------------|---------------------------|
| 1   | 4 (-1)            | 70 (-1)             | 15 (0)                   | 64.86                               | 56.59                               | 6.68                      | 8.00         | 95.73                       | 51.50                         | 1.64                       | 0.0107                    |                           |
| 2   | 10 (+1)           | 70 (-1)             | 15 (0)                   | 73.51                               | 46.39                               | 7.68                      | 8.00         | 93.53                       | 38.76                         | 1.78                       | 0.0063                    |                           |
| 3   | 4 (-1)            | 90 (+1)             | 15 (0)                   | 62.57                               | 54.70                               | 6.33                      | 9.20         | 94.73                       | 51.80                         | 1.73                       | 0.0105                    |                           |
| 4   | 10 (+1)           | 90 (+1)             | 15 (0)                   | 75.57                               | 73.15                               | 7.82                      | 4.40         | 89.27                       | 44.89                         | 1.71                       | 0.0083                    |                           |
| 5   | 4 (-1)            | 80 (0)              | 10 (-1)                  | 77.26                               | 44.30                               | 8.41                      | 6.93         | 98.10                       | 57.73                         | 1.04                       | 0.0138                    |                           |
| 6   | 10 (+1)           | 80 (0)              | 10 (-1)                  | 86.49                               | 79.33                               | 9.30                      | 6.86         | 93.50                       | 44.41                         | 1.64                       | 0.0080                    |                           |
| 7   | 4 (-1)            | 80 (0)              | 20 (+1)                  | 64.50                               | 52.90                               | 6.57                      | 4.26         | 95.25                       | 67.37                         | 0.89                       | 0.0206                    |                           |
| 8   | 10 (+1)           | 80 (0)              | 20 (+1)                  | 76.22                               | 63.08                               | 7.95                      | 6.45         | 81.45                       | 73.95                         | 0.98                       | 0.0310                    |                           |
| 9   | 7 (0)             | 70 (-1)             | 10 (-1)                  | 73.77                               | 63.58                               | 7.89                      | 9.24         | 92.40                       | 44.54                         | 1.58                       | 0.0080                    |                           |
| 10  | 7 (0)             | 90 (+1)             | 10 (-1)                  | 77.59                               | 56.57                               | 7.85                      | 10.64        | 98.20                       | 40.80                         | 1.87                       | 0.0069                    |                           |
| 11  | 7 (0)             | 70 (-1)             | 20 (+1)                  | 74.03                               | 42.43                               | 7.52                      | 4.34         | 82.85                       | 41.90                         | 1.69                       | 0.0072                    |                           |
| 12  | 7 (0)             | 90 (+1)             | 20 (+1)                  | 77.45                               | 44.57                               | 7.87                      | 4.23         | 94.45                       | 38.93                         | 1.86                       | 0.0064                    |                           |
| 13  | 7 (0)             | 80 (0)              | 15 (0)                   | 78.01                               | 51.14                               | 7.70                      | 7.64         | 88.73                       | 61.90                         | 1.03                       | 0.0163                    |                           |
| 14  | 7 (0)             | 80 (0)              | 15 (0)                   | 78.36                               | 54.41                               | 7.76                      | 9.17         | 91.33                       | 49.92                         | 1.30                       | 0.0100                    |                           |
| 15  | 7 (0)             | 80 (0)              | 15 (0)                   | 77.08                               | 41.84                               | 8.00                      | 7.40         | 91.27                       | 36.87                         | 1.99                       | 0.0059                    |                           |
Regarding the survival rate in acidic conditions, the results obtained can be attributed to the nature of the coating agent and the porosity of the microparticles (Gomez-Mascaraque et al., 2016). The highest survival rate (79.3%) was obtained when the microorganism was encapsulated using a feed flow of 10 mL/min, an aspiration rate of 80%, and the lowest concentration of inulin (10%). Darjani et al. (2016) reported that L. casei 431 microencapsulated with a mixture of alginate and inulin in a saline solution with pH adjusted to 1.5 demonstrated a 69.8% decrease after 120 min. The authors noticed an increased survival up to 85.1% under the same conditions when a mixture of alginate/inulin/chitosan was used as coating agent.

The moisture content is an important factor that can affect the microorganisms’ viability and storage. This parameter might be influenced by several process variables, including the inlet temperature, the coating agent properties, and the feed flow rate (Khem et al., 2016). According to our experimental results, when our feed was injected at the lowest flow rate of 7 mL/min, and in the presence of the highest quantity of inulin (20%), the resulting product had the lowest moisture content (4.2%), which is an acceptable value in food products (Yonekura et al., 2014). Fernandes et al. (2016), who investigated the effect of inulin as coating agent in relation to the moisture content, obtained a moisture value from 3.3% to 3.5% using a mixture of inulin with arabic gum or modified starch as coating agents at the high temperature inlet (170 ºC).

The microencapsulation yields were mostly above 90% and were much higher than the results obtained by Anekella and Orsat (2013). In that study, the microencapsulation process of lactobacilli (Lactobacillus rhamnosus NRRL B-4495 and L. acidophilus NRRL B-442) was performed using a combination of raspberry juice with maltodextrin as wall material, and the microencapsulated yield was 48.8% at 100 ºC inlet temperature, with a coating agent ratio of 1:1, and an inlet feed rate of 40 mL/min.
The swelling capacity (SC) is another parameter to investigate the resistance of capsules before their bulk dissolution. Therefore, a higher SC is associated to the higher physical integrity of capsules before dissolution (Cheow et al., 2014). From data shown in Table 3, it can be observed that the highest SC (0.031 g/gDP) corresponded to the highest survival rate after spray drying and also to the highest survival rate under acidic condition, confirming the hypothesis of stronger integrity of particles. The lowest survival rate under acidic condition (41.8%) with the minimum SC once more confirmed the poor physical integrity of the particles resulting in the faster dissolution.

The adequacy of experimental results to fit quadratic polynomial models was analyzed using the statistical software (data not shown). The fitted models were not significant ($R^2<65\%$), and the results of ANOVA for the only significant model related to the survival rate are listed in Table 4.

| Factors | Sum of square | Degrees of freedom | Mean square | $F$-value | $p$-value | Significant |
|---------|---------------|-------------------|-------------|-----------|-----------|-------------|
| $X_1$   | 678.93        | 1                 | 678.93      | 89.80     | <0.0001   | *           |
| $X_2$   | 18.26         | 1                 | 18.26       | 2.41      | 0.1292    |             |
| $X_3$   | 196.25        | 1                 | 196.25      | 25.96     | <0.0001   | *           |
| $X_1X_2$| 14.27         | 1                 | 14.27       | 1.89      | 0.1782    |             |
| $X_1X_3$| 4.55          | 1                 | 4.55        | 0.60      | 0.4429    |             |
| $X_2X_3$| 0.11          | 1                 | 0.11        | 0.01      | 0.9038    |             |
| $X_1^2$ | 189.15        | 1                 | 189.15      | 25.02     | <0.0001   | *           |
| $X_2^2$ | 230.05        | 1                 | 230.05      | 30.43     | <0.0001   | *           |
| $X_3^2$ | 65.97         | 1                 | 65.97       | 8.73      | <0.0056   | *           |
| Error   | 264.62        | 35                | 7.56        |           |           |             |
| Total Sum of square | 1671.37 | 44                |             |           |           |             |

$R^2=0.842$  $R^2_{adj}=0.801$

Highly significant ($^*p<0.005$)
In this model ($R^2 = 0.842$), all three variables had a significant influence on the response ($p<0.001$). The F-value of the quadratic model was also significant ($p < 0.0001$). As we can observe from the quadratic model (Equation 1), the two process variables, i.e. feed flow ($x_1$) and aspiration rate ($x_2$), had a positive effect, while inulin concentration ($x_3$) had a negative effect on the survival rate after spray drying. The offset term ($\beta_0 = 73.65$), which corresponds to the predicted value of the survival rate after spray drying at the central point ($x_1 = 0; x_2 = 0; x_3 = 0$), is not significantly different from the experimental result (78.9%). Hence confirming the suitability of this model.

\[
\text{Survival rate after spray drying (\%)} = 73.65 + 10.64x_1 + 1.74x_2 - 5.72x_3 + 4.13x_1^2 + 4.56x_2^2 - 2.44x_3^2
\]

(1)

The factors which had the greatest impact were the feed flow ($\beta_1 = 10.64; \beta_1^2 = 4.13$) and the aspiration rate ($\beta_2 = 1.74; \beta_2^2 = 4.56$), while inulin concentration ($\beta_3 = -5.72; \beta_3^2 = -2.44$) was the parameter with the least influence throughout the microencapsulation process. Response surfaces of survival rate after spray drying as a function of three variables are illustrated in Figure 2.
Figure 2. Response surface plot for survival rate after spray drying as a function of aspirated rate and feed flow at inulin concentration of 10% (a), 15% (b), and 20% (c).

That result probably occurred because the high feed flow rate reduces the microencapsulation process time and the cell exposure to the high air inlet temperature. Thus, the process conditions provide the highest microbial viability using spray drying (Alves et al., 2016). Serantoni et al. (2012) also confirmed that high aspiration rate directly positively
influenced the contact time of the granulated material with the cyclone hot air in the drying chamber.

3.2. Optimization of the spray drying conditions

In order to point out the optimal operative parameters for encapsulation of \( L. \) Acidophilus La-5 using spray drying, a numerical optimization was performed. The criteria of optimization (Table 5) were chosen to maximize the survival rate after spray drying, the probiotic cell count, and the survival rate to acidic conditions. The optimum conditions predicted by the model were: inulin concentration of 10\%, aspiration rate of 82\%, and feed flow of 10 mL/min. In these conditions a high survival rate after spray drying (86.5\%), the probiotic cell count (9.0 log CFU/g), and the survival rate to acidic conditions (78.7\%) were predicted.
Table 5. Criteria for optimization of process conditions along with responses.

| Name                           | Goal          | Lower limit | Upper limit | Importance | Solution | Actual response value |
|--------------------------------|---------------|-------------|-------------|------------|----------|-----------------------|
| X₁: Feed Flow (mL/min)        | Is in range   | 4           | 10          | 3          | 10       | -                     |
| X₂: Aspiration (%)            | Is in range   | 70          | 90          | 3          | 82       | -                     |
| X₃: Inulin concentration (%)  | Is in range   | 10          | 20          | 3          | 10       | -                     |
| Survival rate after spray drying (%) | Maximize           | 63.6        | 89.1        | 3          | 86.5     | 86.5                  |
| Probiotic cell count (log CFU/g) | Maximize           | 6.3         | 9.3         | 3          | 9.0      | 9.0                   |
| Survival rate to acid conditions (%) | Maximize           | 41.8        | 79.3        | 5          | 79.3     | 78.7                  |
3.3. *In vitro* simulated gastrointestinal conditions

Free and microencapsulated probiotic cells were added during production of the mousse formulation, and their viability before and after the addition to the mousse over a 6h-assay of *in vitro* simulating gastrointestinal conditions was monitored (Figure 3).

![Graph](attachment:image.png)

**Figure 3.** Survival of *Lactobacillus acidophilus* La-5 during exposition to simulated gastrointestinal conditions. (▲) Mousse with microencapsulated cells, (■) Mousse with free cells, (Δ) Microencapsulated cells, and (□) Free cells. Different uppercase letters indicate statistically significant differences (*p*<0.05) among the four samples for the same time. Different lowercase letters indicate statistically significant differences (*p*<0.05) among different times for the same parameter.

As can be seen in Figure 3, microencapsulated probiotic cells incorporated in the mousse presented the highest survival rate throughout the *in-vitro* simulated gastrointestinal conditions. As expected, free cells were not stable in this state. The trends of samples were statistically different (*p*<0.05).

Concerning the viability before all the steps of the simulated gastrointestinal conditions, the mousse with microencapsulated cells showed counts of 6.8 log CFU/g, while
counts of the mousse with free cells, microencapsulated cells, and free cells were of, respectively, 6.6, 8.4, and 8.2 log CFU/g.

A decline in the survival rate of *L. acidophilus* La-5 in the gastric phase was observed in all the samples (*p*<0.05). The greatest reduction of cell counts occurred for the free cells (6.3 log CFU/g), followed by mousse with free cells (3.0 log CFU/g), microencapsulated cells (1.9 log CFU/g), and mousse with microencapsulated cells (1.1 log CFU/g) after 2 h of incubation.

In the enteric phase I (after 4 h of *in-vitro* incubation) the lower variations in relation to the initial population occurred for the mousse containing microencapsulated cells (1.2 log CFU/g) and microencapsulated cells (2.1 log CFU/g), respectively, while mousse with free cells (3.3 log CFU/g) and free cells (7.3 log CFU/g) presented the greatest reductions.

In the enteric phase II, after 6 h, the least variation in survival rate was observed for mousse with microencapsulated cells (1.2 log CFU/g), followed by microencapsulated cells (2.0 log CFU/g), mousse with free cells (2.9 log CFU/g), and free cells (7.4 log CFU/g). After 6 h of *in-vitro* assay, mousse containing microencapsulated cells had the highest survival rate, conferring the efficiency of inulin as protective covering agent.

The resistance of the microencapsulated *L. acidophilus* La-5 along the *in-vitro* simulated gastrointestinal conditions can be considered suitable when compared to those of other similar studies. According to results obtained by Buriti et al. (2010), a high susceptibility of *L. acidophilus* La-5 during the *in vitro* assay was observed when the strain was incorporated in a synbiotic light mousse containing sugar and a lower content of guava pulp (12.5%) and inulin (2.0%). The free probiotic cells were drastically reduced after 30 min of the *in-vitro* assay. Gomez-Mascaraque et al. (2016a) observed a viability loss for *L. plantarum* CECT using whey protein concentrate (WPC) powder as coating agent during the gastric phase. Similar results have been previously reported using *L. casei* ATCC 393
microencapsulated with reconstituted skimmed milk that increased cell viability at low pH values (Dimitrellou et al., 2016).

Similarly to what was observed in the present study for the survival of the microencapsulated probiotic strain, Schell and Beermann (2014) observed an increased survival of microencapsulated L. reuteri DSM 20016 with sweet whey and shellac during the in-vitro gastrointestinal environment. In that study, the results might have occurred due to the cell structure recovery of the injured bacteria to the less stressful conditions of the enteric phase. In this sense, Gandomi et al. (2016) observed that the microencapsulation process of L. rhamnosus GG with sodium alginate and inulin using the extrusion technique improved bacterial viability during the gastric and intestinal models. In the present study, microencapsulated L. acidophilus La-5 had a high survival rate in the in vitro gastric environment. This fact might be attributed to the resistance of inulin to the simulated gastric and intestinal fluids (Karimi et al., 2015). Besides, the low solubility of the long-chain inulin, and consequently slower rehydration of the powder, may have contributed to a delayed release of the bacterial cells in the gastrointestinal tract (Pinto et al., 2015).

Although the digestive enzymes present in the gastric and the pancreatic secretions may be harmful to the cell structure, other factors, such as peristalsis and competitive exclusion in the gut microbiota would be enough to affect the bacterial adhesion ability in the intestinal epithelium (Darilmaz et al., 2011). Moreover, Matias et al. (2016) suggested that a prolonged exposure of a microorganism to distinct environmental conditions present throughout the digestive process, such as the gastric phase and the enteric phases I and II, containing bile and pancreatin, may promote significant changes in its physiology. The authors reported that these changes might affect the surface structure integrity, the cell membrane or the cell wall, due to an adaptation process to the dynamic environment. In the present study, the coating agent was important to protect the probiotic strain throughout the
simulated gastrointestinal conditions, conferring a high survival for the microencapsulated cells, and mainly when incorporated into mousse. Thus, the use of prebiotic ingredients may be an alternative to improve their survival through the gastrointestinal tract (Hernandez-Hernandez et al., 2012).
4. CONCLUSIONS

Spray drying was employed to encapsulate *L. acidophilus* La-5. Optimization of the process parameters demonstrated that an inulin concentration of 10%, an aspiration rate of 82%, and a feed flow of 10 mL/min, ensured a high survival rate after spray drying (86.5%), a high probiotic cell count (9.0 log CFU/g), and a high survival rate to acidic conditions (78.7%). Furthermore, mousse enriched with microencapsulated cells presented the highest survival level among the samples (*p*<0.05) during the *in-vitro* simulated gastrointestinal conditions. The results of this study confirm the appropriateness of the spray drying technique to encapsulate the probiotic strain evaluated using a prebiotic compound such as inulin, especially when the microorganism was incorporated in a synbiotic mousse, leading to an excellent survival rate under *in vitro* simulated gastrointestinal conditions.
5. REFERENCES

Ahmed M., Akter M. S., Lee J. C., & Eun J. B. (2010). Encapsulation by spray drying of bioactive components, physicochemical and morphological properties from purple sweet potato. *LWT-Food Science and Technology*, 43, 1307-1312.

Alves, N. N., Messaoud, G. B., Desobry, S., Costa, J. M. C., & Rodrigues, S. (2016). Effect of drying technique and feed flow rate on bacterial survival and physicochemical properties of a non-dairy fermented probiotic juice powder. *Journal of Food Engineering*, 189, 45-54.

Amine, K. M., Champagne, C. P., Raymond, Y., St-Gelais, D., Britten, M., Fustier, P., Salmieri, S., & Lacroix, M. (2014). Survival of microencapsulated *Bifidobacterium longum* in Cheddar cheese during production and storage. *Food Control*, 37, 193-199.

Anekella, K., & Orsat, V. (2013). Optimization of microencapsulation of probiotics in raspberry juice by spray drying. *LWT - Food Science and Technology*, 50, 17-24.

Balasubramani, P., Palaniswamy, P. T., Visvanathan, R., Thirupathi, V., Subbarayan, A., & Maran, J. P. (2015). Microencapsulation of garlic oleoresin using maltodextrin as wall material by spray drying technology. *International Journal of Biological Macromolecules*, 72, 210–217.

Buriti, F. C. A., Castro, I. A., & Saad, S. M. I. (2010). Viability of *Lactobacillus acidophilus* in synbiotic guava mousses and its survival under in vitro simulated gastrointestinal conditions. *International Journal of Food Microbiology*, 137, 121–129.

Cheow, W. S., Kiew, T. Y., & Hadinoto, K. (2014). Controlled release of *Lactobacillus rhamnosus* biofilm probiotics from alginate-locust bean gum microcapsules. *Carbohydrate Polymers*, 103, 587–595.
Cook, M. T., Tzortzis, G., Charalampopoulos, D., & Khutoryanskiy, V. V. (2012). Microencapsulation of probiotics for gastrointestinal delivery. *Journal of Controlled Release*, 162, 56–67.

Corona-Hernandez, R. I., Alvarez-Parrilla, E., Lizardi-Mendoza, J., Islasrubio, A. R., Rosa, L. A., & Wall-Medrano, A. (2013). Structural stability and viability of microencapsulated probiotic bacteria: a review. *Comprehensive Reviews in Food Science and Food Safety*, 12, 614-628.

Costa, M. G. M., Ooki, G. N., Vieira, A. D. S., Bedani, R., & Saad, S. M. I. (2017). Synbiotic Amazonian palm berry (açai, Euterpe oleracea Mart.) ice cream improved *Lactobacillus rhamnosus* GG survival to simulated gastrointestinal stress. *Food & Function*, 8, 731–740.

Darilmaz, D. O., Aslim, B., Suludere, Z., & Akca, G. (2011). Influence of gastrointestinal system conditions on adhesion of exopolysaccharide-producing *Lactobacillus delbrueckii* subsp. bulgaricus strains to caco-2 cells. *Brazilian Archives of Biology and Technology*, 54, 917–926.

Darjani, P., Nezhad, M. H., Kadkhodaee, R., & Milani, E. (2016). Influence of prebiotic and coating materials on morphology and survival of a probiotic strain of *Lactobacillus casei* exposed to simulated gastrointestinal conditions. *LWT - Food Science and Technology*, 73, 162-167.

Dimitrellou, D., Kandylis, P., Petrovic, T., Dimitrijevic-Brankovic, S., Levic, S., Nedovic, V., & Kourkoutas, Y. (2016). Survival of spray dried microencapsulated *Lactobacillus casei* ATCC 393 in simulated gastrointestinal conditions and fermented milk. *LWT - Food Science and Technology*, 71, 169-174.
Encina, C., Vergara, C., Giménez, B., Oyarzún-Ampuero, F., & Robert, P. (2016). Conventional spray-drying and future trends for the microencapsulation of fish oil. *Trends in Food Science & Technology*, 56, 46-60.

Fernandes, R. V. B., Botrel, D. A., Silva, E. K., Borges, S. V., Oliveira, C. R., Yoshida, M. I., Feitosa, J. P. A., & Paula, R. C. M. (2016). Cashew gum and inulin: New alternative for ginger essential oil microencapsulation. *Carbohydrate Polymers*, 153, 133–142.

Fritzen-Freire, C. B., Prudêncio, E. S., Amboni, R. D. M. C., Pinto, S. S., Negrão-Murakami, A. N., & Murakami, F. S. (2012). Microencapsulation of bifidobacteria by spray drying in the presence of prebiotics. *Food Research International*, 45, 306–312.

Gandomi, H., Abbaszadeh, S., Misaghi, A., Bokaie, S., & Noori, N. (2016). Effect of chitosan-alginate encapsulation with inulin on survival of *Lactobacillus rhamnosus* GG during apple juice storage and under simulated gastrointestinal conditions. *LWT - Food Science and Technology*, 69, 365-371.

Gomez-Mascaraque, L. G., Morfin, R. C., Perez-Masi, R., Sanchez, G., & Lopez-Rubio, A. (2016a). Optimization of electrospraying conditions for the microencapsulation of probiotics and evaluation of their resistance during storage and in-vitro digestion. *LWT - Food Science and Technology*, 69, 438-446.

Gomez-Mascaraque, L. G., Soler, C., & Lopez-Rubio, A. (2016b). Stability and bioaccessibility of EGCG within edible micro-hydrogels. Chitosan vs. gelatin, a comparative study. *Food Hydrocolloids*, 61, 128-138.
Guo, Z., Wang, J., Yan, L., Chen, W., Liu, X., & Zhang, H. (2009). In vitro comparison of probiotic properties of *Lactobacillus casei* Zhang, a potential new probiotic, with selected probiotic strains. *LWT - Food Science and Technology*, 42, 1640-1646.

Hernandez-Hernandez, O., Muthaiyan, A., Moreno, F. J., Montilla, A., Sanz, M. L., & Ricke, S. C. (2012). Effect of prebiotic carbohydrates on the growth and tolerance of *Lactobacillus*. *Food Microbiology*, 30, 355–361.

Huang, S., Cauty, C., Dolivet, A., Loir, Y. L., Chen, X. D., Schuck, P., Jan, G., & Jeantet, R. (2016). Double use of highly concentrated sweet whey to improve the biomass production and viability of spray-dried probiotic bacteria. *Journal of Functional Foods*, 23, 453–463.

International Dairy Federation. *Fermented and non-fermented milk products. Detection and enumeration of Lactobacillus acidophilus. Culture media*. Bulletin of the IDF 306. Brussels: IDF, 1995.

Ismail, B., & Nampoothiri, K. (2010). Production, purification and structural characterization of an exopolysaccharide produced by a probiotic *Lactobacillus plantarum* MTCC 9510. *Archives of Microbiology*, 192, 1049-1057.

Karimi, R., Azizi, M. H., Ghasemlou, M., & Vaziri, M. (2015). Application of inulin in cheese as prebiotic, fat replacer and texturizer: A review. *Carbohydrate Polymers*, 119, 85–100.

Khem, S., Small, D. M., & May, B. K. (2016). The behaviour of whey protein isolate in protecting *Lactobacillus plantarum*. *Food Chemistry*, 190, 717–723.

Komatsu, T. R., Buriti, F. C. A., Silva, R. C., Lobo, A. R., Colli, C., Gioielli, L. A., & Saad, S. M. I. (2013). Nutrition claims for functional guava mousses produced with milk fat
substitution by inulin and/or whey protein concentrate based on heterogeneous food legislations. *LWT - Food Science and Technology*, 50, 755-765.

Liserre, A. M., Ré, M. I., & Franco, B. D. G. M. (2007). Microencapsulation of *Bifidobacterium animalis* subsp. *lactis* in modified alginate-chitosan beads and evaluation of survival in simulated gastrointestinal conditions. *Food Biotechnology*, 21, 1–16.

Matias, N. S., Padilha, M., Bedani, R., & Saad, S. M. I. (2016). *In vitro* gastrointestinal resistance of *Lactobacillus acidophilus* La-5 and *Bifidobacterium animalis* Bb-12 in soy and/or milk-based synbiotic apple ice creams. *International Journal of Food Microbiology*, 234, 83–93.

Paini, M., Aliakbarian, B., Casazza, A. A., Lagazzo, A., Botter, R., & Perego, P. (2015). Microencapsulation of phenolic compounds from olive pomace using spray drying: A study of operative parameters. *LWT - Food Science and Technology*, 62, 177-186.

Peighambardoust, S. H., Tafti, A. G., & Hesari, J. (2011). Application of spray drying for preservation of lactic acid starter cultures: a review. *Trends in Food Science & Technology*, 22, 215-224.

Pinto, S. S., Verruck, S., Vieira, C. R. W., Prudêncio, E. S., Amante, E. R., & Amboni, R. D. M. C. (2015). Influence of microencapsulation with sweet whey and prebiotics on the survival of *Bifidobacterium*-BB-12 under simulated gastrointestinal conditions and heat treatments. *LWT - Food Science and Technology*, 64, 1004-1009.

Rajabi, H., Ghorbani, M., Jafari, S. M., Mahoonak, A. S., & Rajabzadeh, G. (2015). Retention of saffron bioactive components by spray drying encapsulation using maltodextrin, gum Arabic and gelatin as wall materials. *Food Hydrocolloids*, 51, 327-337.
Rajam, R., & Anandhamakrishnan, C. (2015). Microencapsulation of *Lactobacillus plantarum* (MTCC 5422) with fructooligosaccharide as wall material by spray drying. *LWT - Food Science and Technology*, 60, 773-780.

Salar-Behzadi, S., Wu, S., Toegel, S., Hofrichter, M., Altenburger, I., Unger, F. M., Wirth, M., & Viernstein, H. (2013). Impact of heat treatment and spray drying on cellular properties and culturability of *Bifidobacterium bifidum* BB-12. *Food Research International*, 54, 93–101.

Schell, D., & Beermann, C. (2014). Fluidized bed microencapsulation of *Lactobacillus reuteri* with sweet whey and shellac for improved acid resistance and *in-vitro* gastro-intestinal survival. *Food Research International*, 62, 308–314.

Serantoni, M., Piancastelli, A., Costa, A. L., & Esposito, L. (2012). Improvements in the production of Yb:YAG transparent ceramic materials: Spray drying optimisation. *Optical Materials*, 34, 995–1001.

Silva, E. K., Zabot, G. L., Bargas, M. A., & Meireles, M. A. A. (2016). Microencapsulation of lipophilic bioactive compounds using prebiotic carbohydrates: Effect of the degree of inulin polymerization. *Carbohydrate Polymers*, 152, 775–783.

Tamm, F., Harter, C., Brodkorb, A., & Drusch, S. (2016). Functional and antioxidant properties of whey protein hydrolysate/pectin complexes in emulsions and spray-dried microcapsules. *LWT - Food Science and Technology*, 73, 524-527.

Venil, C. K., Khasim, A. R., Aruldass, C. A., & Ahmad, W. A. (2016). Microencapsulation of flexirubin-type pigment by spray drying: Characterization and antioxidant activity. *International Biodeterioration & Biodegradation*, 113, 350-356.

Würth, R., Hörmannsperger, G., Wilke, J., Foerst, P., Haller, D., & Kulozik, U. (2015). Protective effect of milk protein based microencapsulation on bacterial survival in
simulated gastric juice versus the murine gastrointestinal system. *Journal of Functional Foods*, 15, 116–125.

Yonekura, L., Sun, H., Soukoulis, C., & Fisk, I. (2014). Microencapsulation of *Lactobacillus acidophilus* NCIMB 701748 in matrices containing soluble fibre by spray drying: Technological characterization, storage stability and survival after *in vitro* digestion. *Journal of Functional Foods*, 6, 205–214.

Zamora-Vega, R., Montañez-Soto, J. L., Venegas-González, J., Bernardino-Nicanor, A., Cruz, L. G., & Martínez-Flores, H. E. (2013). Development and characterization of a symbiotic cheese added with *Saccharomyces boulardii* and inulin. *Journal of Microbiology Research*, 7, 2828–2834.
GENERAL CONCLUSION

Based on the results of this study, the synbiotic diet mousse (SDM) stored at -18±2 °C showed populations of the probiotic strain Lactobacillus acidophilus La-5 above 7.8 log CFU/g for 112 days of storage, ensuring the minimum recommended amount of 8.0 log CFU/daily portion for this product to be considered a probiotic food. Regarding the instrumental texture of SDM, hardness and gumminess increased and cohesiveness decreased throughout storage, while adhesiveness and springiness kept almost unvaried. Moreover, sensory acceptability was good throughout storage, with average scores from 6.67 to 7.03 for the SDM, 5.77 to 6.50 for the placebo diet mousse (PDM), and 6.83 to 7.67 for the control synbiotic mousse (CSM). The results of the clinical trials demonstrated that SDM and PDM contributed to reduce total cholesterol, HDL-cholesterol, IL-1β, IgA, and IgM in volunteers with metabolic syndrome (MetS). These findings suggest that the presence of probiotic and prebiotic ingredients in the diet mousse did not influence the risk factors related to MetS significantly. The optimization of the process conditions via spray drying for the microencapsulation of L. acidophilus La-5, using inulin as coating agent, led to an increased survival rate after spray drying (86.5%), probiotic cell count (9.0 log CFU/g), and survival rate to acidic conditions (78.7%). In this sense, the microencapsulated probiotic strain incorporated in SDM sample showed the highest in vitro gastrointestinal survival among samples evaluated (p<0.05) in the different phases of the assay (the gastric phase: 5.7 log CFU/g (83.3%), the enteric phase I: 5.6 log CFU/g (82.3%), the enteric phase II: 5.7 log CFU/g (81.4%). Thus, the incorporation of the microencapsulated L. acidophilus La-5 with inulin into SDM becomes an interesting alternative to increase the viability of the probiotic cell throughout the digestive process. However, future studies are needed to evaluate the influence of daily supplementation of microencapsulated L. acidophilus La-5 incorporated into a diet mousse on the MetS risk factors, as well as to determine whether this dessert might cause specific changes on the composition and/or activity of the intestinal microbiota of subjects with MetS.
SCIENTIFIC RESULTS CONCERNING THE PRESENT PhD THESIS

This PhD thesis also resulted in 5 abstracts presented at international scientific meetings, of which three were abroad. In ascending chronological order, they are listed as follows:

- **XAVIER-SANTOS, D.; SOLANO, J. H.; PIMENTEL, J. A.; LIMA, E. D.; SIMÃO, A. N. C.; BEDANI, R.; SAAD, S. M. I.** Potential Effect of Synbiotic Diet Dessert Containing *Lactobacillus acidophilus* La-5 on Individuals with Metabolic Syndrome: A randomized Controlled Trial. In: Probiota 2016: connecting the global business and science of pre and probiotics, Amsterdam, Holland, 2016.

- **XAVIER-SANTOS, D.; CASAZZA, A. A.; ALIAKBARIAN, B.; BEDANI, R.; SAMPAIO, F. C.; CONVERTI, A.; SAAD, S. M. I.; PEREGO, P.** Microencapsulation of *Lactobacillus acidophilus* La-5 using spray drying. In: 24th Inference ICFMH Conference, Food Micro 2016: One Health Meets Food Microbiology: Food Micro, Dublin, Irland, 2016.

- **XAVIER-SANTOS, D.; BEDANI, R.; CONVERTI, A.; PEREGO, P.; SAAD, S. M. I.** Texture profile and sensory acceptance of a synbiotic diet aerated mousse containing *Lactobacillus acidophilus* La-5, inulin, and fructooligosaccharide. In: X CIGR Section IV International Technical Symposium, Gramado, Brazil, 2016.

- **XAVIER-SANTOS, D.; SOLANO, J. H.; SIMÃO, A. N. C.; BEDANI, R.; LIMA, E. D.; SAAD, S. M. I.** Potential effect of a synbiotic diet dessert containing *Lactobacillus acidophilus* La-5 on hematological parameters in patients with metabolic syndrome. In: Probiota 2017 - Connecting the global business and science of pre and prebiotics, Berlin, Germany, 2017.
- **XAVIER-SANTOS, D.; Pires, I. S. O.; PIMENTEL, J. A.; BEDANI, R.; LIMA, E. D.; SIMÃO, A. N. C.; SAAD, S. M. I.** Impacto da sobremesa simbiótica *diet* contendo *Lactobacillus acidophilus La*-5 sobre os parâmetros inflamatórios e imunológicos em indivíduos com síndrome metabólica: um ensaio clínico randomizado. In: 19° Fórum Paulista de Pesquisa em Nutrição Clínica e Experimental, 2017, São Paulo.

The following scientific papers related to this PhD thesis were submitted for publication in peer-reviewed journals:

- **XAVIER-SANTOS, D.; LIMA, E. D.; SIMÃO, A. N. C.; BEDANI, R.; SAAD, S. M. I.** Effect of the consumption of a synbiotic diet mousse containing *Lactobacillus acidophilus La*-5 by individuals with metabolic syndrome: a randomized controlled trial. *Journal of Functional Foods*, Elsevier.

- **XAVIER-SANTOS, D.; CASAZZA, A. A.; ALIAKBARIAN, B.; BEDANI, R.; SAAD, S. M. I.; PEREGO, P.** Microencapsulation of *Lactobacillus acidophilus La*-5 using inulin as coating agent by spray drying and its survival under *in vitro* simulated gastrointestinal conditions. Prepared for submission in the next days to *International Journal of Biological Macromolecules*, Elsevier.

The following scientific articles related to this PhD thesis are being prepared for publication in indexed journals:

- **XAVIER-SANTOS, D.; B.; BEDANI, R.; CONVERTI, A.; SAAD, S. M. I.; PEREGO, P.** Texture profile and sensory acceptance of a synbiotic diet aerated mousse containing
Lactobacillus acidophilus La-5, inulin, and fructooligosaccharides. *Science Food and Agriculture*, Elsevier.

- **XAVIER-SANTOS, D.; BEDANI, R.; LIMA, E. D.; SAAD, S. M. I.** Probiotics, Prebiotics and Metabolic Syndrome. *Nutrition*, Elsevier.

**PARTICIPATION IN EVENTS, CONGRESSES, AND EXHIBITIONS**

The double PhD degree also resulted in 14 participations in scientific events and exhibitions, of which four were abroad. In ascending chronological order, they are listed as follows:

- XVIII Encontro Nacional e IV Congresso Latino Americano de Analistas de Alimentos - ENAAL 2013, São Paulo, Brazil, 2013 (Congress).
- Simpósio Renal - Ensaios de Proficiência e Materiais de Referência - Ferramentas de Garantia da Qualidade Analítica, São Paulo, Brazil, 2013 (Symposium).
- Danish-Brazilian research seminars on bioactive compounds, gut microbiota, inflammation, and metabolic disorders?, São Paulo, Brazil, 2014 (Seminars).
- Aprendizagem Baseada Em Grupos, Aplicada ao Ensino de Fisiopatologia, São Paulo, Brazil, 2014 (Seminars).
- Feira de Ciências e Tecnologia 2014: ciências e empreendedorismo, 2014. Colégio Bandeirantes, São Paulo, Brazil, 2014 (Appraiser).
- 10º Simpósio de Síndrome Metabólica do Hospital das Clínicas da FMUSP, São Paulo, Brazil, 2015 (Symposium).
- Probiota 2016: connecting the global business and science of pre and probiotics, Amsterdam, Holland, 2016 (Congress).
- UniverCity. Ingegneria alimentare e industria 4.0: dalla ricerca ai nuovi prodotti, Genoa, Italy, 2016 (Exhibition).
• 25th International ICFMH Conference – Food Micro 2016, One Health Meets Food Microbiology, Dublin, Irland, 2016 (Congress).

• XXV Congresso Brasileiro de Ciência e Tecnologia de Alimentos, Gramado, Brazil, 2016 (Congress).

• X CIGR Section IV International Technical Symposium, Gramado, Brazil, 2016 (Congress).

• 15° Evento da Série de Workshops Internacionais sobre Alimentos com Alegações de Propriedades Funcionais e/ou de Saúde: Microbioma, Probióticos e Saúde, São Paulo, Brazil, 2016 (Seminars).

• Probiota 2017 - Connecting the global business and science of pre and prebiotics, Berlin, Germany, 2017 (Congress).

• 19° Fórum Paulista de Pesquisa em Nutrição Clínica e Experimental, June 14th to 17th, São Paulo, Brazil, 2017 (Congress).

COLLABORATION IN SCIENTIFIC INITIATION PROJECT

• Collaboration as co-tutor in the scientific initiation study "Efeito do armazenamento refrigerado de musse de goiaba simbiótico diet sobre a viabilidade de Lactobacillus acidophilus La-5 e a sua sobrevivência em ensaios de sobrevivência in vitro das condições gastrintestinais”, which was conducted by the undergraduate student, Juanita Hernández Solano, in Biotechnology (Federal University of São Carlos) at the University of São Paulo, Brazil.

• Collaboration as co-tutor in the graduation thesis “Microencapsulation of Lactobacillus acidophilus La-5 using spray drying”, which is being conducted by the undergraduate student, Chiara Mucetti, in Chemistry and Pharmaceutical Technologies at the University of Genoa, Italy.
UNDERGRADUATE CLASSES TAUGHT IN HIGHER EDUCATION

- Academic support in the laboratory training activities of the Course “FBT0201 Food Technology” for undergraduate students in “Nutrition” (6 hours/week) at the University of São Paulo - Brazil.

- Academic support in the laboratory training activity of the Disciplines “FBT0530 Industrial Physics” to the students of the Graduation Program in “Pharmacy-Biochemistry” (6 hours/week) at University of São Paulo - Brazil.

- Academic support in the laboratory training activity of the Disciplines “Industrial Microbiology & Chemistry and Biotechnology of Fermentations” to the students of the Graduation Program in “Biotechnology” (8 hours) and “Industrial and Environmental Biotechnologies” to the students of the Post-graduation Program in “Chemical Engineering” (8 hours) at University of Genoa - Italy.

- Academic support in the laboratory training activity of the course of “Processi e Impianti dell'Industria Alimentare” to the students of the Graduation Program in “Chemical Engineering” (8 hours) at University of Genoa - Italy.
ANNEXES
ANNEX 1 - Approval protocol of the Research Ethics Committee of the Faculty of Pharmaceutical Sciences

PARECER CONSUBSTANTIADO DO CEP

DADOS DO PROJETO DE PESQUISA

Título da Pesquisa: Sobremesa aerada simbiótica: desenvolvimento de um produto diet e avaliação dos efeitos da ingestão sobre indivíduos com síndrome metabólica

Pesquisador: Susana Marta Isay Saad

Área Temática:

Versão: 2

CAAE: 30539214.8.0000.0067

Instituição Proponente: Faculdade de Ciências Farmacêuticas da Universidade de São Paulo

Patrocinador Principal: Financiamento Próprio

DADOS DO PARECER

Número do Parecer: 663.138

Data da Relatoria: 26/05/2014

Apresentação do Projeto:

Alguns autores enfatizam que um alimento funcional deve promover efeitos benéficos de forma satisfatória a uma ou mais funções-alvo no organismo, melhoria da saúde e prevenir o risco do desenvolvimento de doenças, além da nutrição básica. No Brasil, os alimentos com alegação de propriedade funcional ou de saúde são regulamentados pela Agência Nacional de Vigilância Sanitária através das Resoluções 16, 18 e 19 de abril de 1999, devendo ser obrigatoriamente registrados junto ao órgão competente e serem seguros para o consumo sem a supervisão médica. Atualmente, os consumidores estão se interessando cada vez mais na incorporação de compostos bioativos como ingredientes funcionais nas dietas, em virtude dos seus diversos efeitos benéficos promovidos à saúde. Dentre os alimentos funcionais, destacam-se os probióticos, prebióticos e simbióticos. A definição aceita internacionalmente é que os probióticos são micro-organismos vivos, administrados em quantidades adequadas, que conferem benefícios à saúde do hospedeiro. A influência benéfica dos probióticos sobre a microbiota intestinal humana inclui fatores como efeitos antagônicos, competição e efeitos imunológicos, resultando em um aumento da resistência contra patógenos. O grupo de pesquisa proponente tem realizado vários trabalhos no desenvolvimento de produtos lácteos simbióticos, como manjar branco e queijos. Paralelamente, foram...
desenvolvidos trabalhos relacionados com o desenvolvimento de sobremesa aerada simbiótica do tipo musee, com baixo teor de gordura, processada com a adição de uma cultura probiótica de L. acidophilus La-5, dos ingredientes prebióticos oligofrutosae e inulina. A sobremesa desenvolvida deu origem ao depósito de uma patente e foi desenvolvida uma musee de goiaba potencialmente simbiótica, suplementada com a bactéria comprovadamente probiótica L. acidophilus La-5 e com o prebiótico oligofrutose, onde o creme de leite foi parcialmente ou totalmente substituído pelo prebiótico inulina e/ou por concentrado proteico de soro. Escassos são os estudos avaliando o efeito dos micro-organismos probióticos sobre a saúde, quando incorporados em produtos alimentícios não convencionais, como sobremesas aeradas tipo musee, particularmente quando esses produtos também contêm ingredientes prebióticos. Sendo assim, a ideia de adaptar um produto simbiótico desenvolvido e bem caracterizado e com teor reduzido de gordura para um equivalente diet, sem a adição de açúcar, e testar o efeito desse produto light e diet em pacientes com parâmetros sanguíneos indicativos de síndrome metabólica torna-se um alvo de investigação bastante atraente. Desse modo, torna-se relevante à realização de uma pesquisa sobre os possíveis efeitos benéficos de uma musee aerada simbiótica diet sobre a saúde dos voluntários com síndrome metabólica, o que pode contribuir de maneira significativa ao entendimento do desempenho dos micro-organismos no organismo humano.

Objetivo da Pesquisa:
O presente projeto de pesquisa tem por objetivos: desenvolver uma sobremesa aerada simbiótica diet tipo musee, processada com a adição da cultura probiótica de Lactobacillus acidophilus La-5 e dos ingredientes prebióticos oligofrutose (FOS) e inulina, a partir da formulação com teor reduzido de gordura, mas contendo sacarose desenvolvida anteriormente; comparar o efeito do congelamento sobre as características tecnológicas, sensoriais e sobre viabilidade de Lactobacillus acidophilus La-5 no produto diet desenvolvido ao longo de seu armazenamento a -18°C e quando comparado à musee diet não simbiótica (controle) e ao similar com sacarose anteriormente desenvolvido e que será produzido para esse fim; verificar a influência da administração da musee aerada simbiótica diet sobre os parâmetros antropométricos, bioquímicos, hematólogicos, inflamatórios e relacionados com a síndrome metabólica durante o tempo 0, 4 e 8 semanas de intervenção com as sobremesas lâcteas congeladas e após 2 semanas (tempo de 10 semanas) sem administração dos produtos diet.

Avaliação dos Riscos e Benefícios:
Riscos: Os participantes podem sentir algum desconforto provocado pela picada da agulha no local.
da punção, poderão haver alguma dor decorrente da punção da pele e pessoas mais sensíveis poderão ficar com a pele arroxada (pequeno hematoma) decorrente de uma pequena perda de sangue da veia no local da punção, por até 48 horas.

Benefícios: Os participantes estarão contribuindo de forma voluntária para o desenvolvimento de uma tese de doutorado que contribuirá para o desenvolvimento de um produto diet que poderá promover efeitos benéficos aos consumidores através de ingredientes bioativos (possuem funções específicas) que irão contribuir para melhorar a qualidade de vida e bem-estar da população.

Comentários e Considerações sobre a Pesquisa:

No projeto pretende-se utilizar uma formulação classificada como funcional (musse de goiaba com probióticos e prebióticos, diet) desenvolvidas anteriormente e analisar os efeitos bioquímicos em pessoas com síndrome metabólica atendidas pelo HU/USP. Os pacientes serão indicados pela equipe médica que os atende e a participação é voluntária. O projeto é bastante importante para a área de tecnologia de alimentos e o desenvolvimento de alimentos destinados aos pacientes com síndrome metabólica.

Considerações sobre os Termos de apresentação obrigatória:

Os pesquisadores implementaram alterações no projeto e no TCLE: a correção de ‘funcionários’ para ‘postulantes a participantes da pesquisa’ e no TCLE foi incluída informação de que, mesmo havendo a constatação de benefícios com o uso do alimento, não será possível seu fornecimento após o término da pesquisa.

Recomendações:

Recomenda-se a aprovação do projeto na forma em que se encontra.

Conclusões ou Pendências e Lista de Inadequações:

Recomenda-se a aprovação do projeto na forma em que se encontra.

Situação do Parecer:

Aprovado

Necessita Apreciação da CONEP:

Não

Considerações Finais a critério do CEP:

Tendo em vista as considerações acima, este CEP entende que o adendo ao projeto pode ser aprovado.
SÃO PAULO, 27 de Maio de 2014

Assinado por:
Maurício Yonamine
(Coordenador)
ANNEX 2 - Approval protocol of the Research Ethics Committee of the University Hospital

São Paulo, 07 de julho de 2014.

Irmão(a), Sr(e)
Profa. Dra. Susana Marta Isay Saad
Departamento de Tecnologia Bioquímico-Farmacêutica
Faculdade de Ciências Farmacêuticas
UNIVERSIDADE DE SÃO PAULO

REFERENTE: Projeto de Pesquisa "Sobremesa aerada simbiótica: desenvolvimento de um produto diet e avaliação dos efeitos da ingestão sobre indivíduos com síndrome metabólica"

Pesquisador(a) responsável: Profa. Dra. Susana Marta Isay Saad
Equipe de pesquisa: Douglas Xavier dos Santos, Egidio Lima Dorea, Gelba Almeida Pinto, Maria Cecília Gusukuma, Marina Baquerizo Martínez
CAAE: 30539214.6.3002.0076
Registro CEP-HU/USP: 1358/14

Prezado(a) Senhor(a)

O Comitê de Ética em Pesquisa do Hospital Universitário da Universidade de São Paulo, em reunião ordinária realizada no dia 27 de junho de 2014, analisou o Projeto de Pesquisa acima citado, considerando-o como APROVADO, bem como o seu Termo de Consentimento Livre e Esclarecido.

Lembramos que cabe ao pesquisador elaborar e apresentar a este Comitê, relatórios parciais e final, de acordo com a Resolução nº 466/2012 do Conselho Nacional de Saúde, inciso XI.2, letra “d”.

O primeiro relatório está previsto para 27 de dezembro de 2014.

Atenciosamente,

Dr. Mauricio Seckler
Coordenador do Comitê de Ética em Pesquisa
Hospital Universitário da USP

COMITÊ DE ÉTICA EM PESQUISA DO HOSPITAL UNIVERSITÁRIO DA USP
Avenida Professor Lineu Prestes, 2565 – Cidade Universitária – 05508-090 – São Paulo – SP
Tel.: (11) 3091-4457 – E-mail: cee@hu.usp.br
ANNEX 3 - Term of Free Consent and Enlightened

TERMO DE CONSENTIMENTO LIVRE E ESCLARECIDO – TCLE

1. Informações do Sujeto da Pesquisa

| Nome: | Documento de Identidade nº: |
|------|-----------------------------|
|      |                             |

| Sexo: ( ) M ( ) F |
|------------------|

| Data de Nascimento: / / |
|-------------------------|
|                        |

| Endereço: | N° | Complemento: |
|-----------|----|--------------|
|           |    |              |

| Bairro: | Cidade: | Estado: |
|---------|---------|---------|
|         |         |         |

| CEP: | Telefones: |
|------|------------|
|      |            |

| Título do Projeto de Pesquisa: “Sobremesa aerada simbiótica: desenvolvimento do produto diet e avaliação dos efeitos da ingestão sobre indivíduos com síndrome metabólica” |

2. Duração da Pesquisa: 3 anos

3. Nome do pesquisador responsável: Dra. Susana Marta Isay Saad

Cargo/ Função: Professora

Instituição: Faculdade de Ciências Farmacêuticas/USP

Você está sendo convidado(a) a participar da pesquisa: “Sobremesa aerada simbiótica: desenvolvimento do produto diet e avaliação dos efeitos da ingestão sobre indivíduos com síndrome metabólica”. O projeto é de responsabilidade da Professora Dra. Susana Marta Isay Saad e conta com a colaboração do doutorando Douglas Xaver dos Santos, ambos pertencentes ao Departamento de Tecnologia Bioquímica-Farmacêutica da Faculdade de Ciências Farmacêuticas/USP.

A definição aceita internacionalmente é que os probióticos são micro-organismos vivos, administrados em quantidades adequadas, que conferem benefícios à saúde do hospedeiro (pessoa). Os probióticos, por sua vez, são atualmente definidos como ‘ingrediente选择mente fermentável que permitem modificações específicas na composição e/ou na atividade da microbiota gastrointestinal (micro-organismos que sobrevivem no intestino) que resultam em benefícios ao bem-estar e à saúde do hospedeiro’. O sinergismo (ação combinada) entre os micro-organismos probióticos e os prebióticos, principalmente no caso de produtos lácteos (à base de leite) está sendo cada vez mais usado na formulação de alimentos conhecidos como simbióticos (probiótico+prebiótico). A referida pesquisa tem por objetivo adaptar uma massa aerada simbiótica diet (produto sem açúcar e gordura) e avaliar os efeitos de sua ingestão (consumo) em participantes adultos com síndrome metabólica (classificação clínica de pessoas com maior possibilidade de desenvolver doenças cardiovasculares e/ou diabetes melitus tipo II). Como forma de atingir os objetivos propostos, serão realizadas análises sanguíneas.

O experimento terá a duração de 70 dias e serão selecionados 60 participantes com idades entre 18 e 65 anos (preferencialmente da comunidade USP), de ambos os sexos, que queiram participar da pesquisa e consumir a massa simbiótica diet.

______________________________
Rubrica do sujeito de pesquisa

______________________________
Rubrica Dra. Susana Marta Isay Saad
TERMO DE CONSENTIMENTO LIVRE E ESCLARECIDO – TCLE

Participante deste experimento, os pacientes com síndrome metabólica indicados pelo Dr. Egidio Lima Dornéa (CRM: 65920-SP), um dos responsáveis pelo ambulatório de doenças metabólicas do Hospital Universitário/USP, que possuam pelo menos três das cinco seguintes características: 1) Obesidade abdominal: circunferência da cintura ≥ 88cm para a mulher e ≥ 102cm para o homem; 2) hipertrigliceridemia (níveis elevados de triglicerídeos) ≥150mg/dl; 3) níveis baixos de colesterol-HDL (conhecido popularmente como colesterol "bom") ≤50mg/dl para a mulher e ≤40mg/dl para o homem; 4) Pressão arterial elevada: ≥130/85mmHg e 5) Glicose de jejun elevada ≥100mg/dl. Além disso, não serão selecionados os participantes portadores de doenças da tiroide (níveis de hormônio tiroideano alterados), renais (doenças nos rins), hepáticas (doenças no fígado), gastrointestinais (doenças nos intestinos), oncológicas (doenças cancerígenas), medicados com hipolipemiantes (reduzem os níveis de colesterol e triglicérides), hiperglicemiantes (reduzem os níveis de glicose sanguínea) e em terapia de reposição de estrogênio (reposição hormonal).

A principal motivação dos participantes da pesquisa está relacionada com a ingestão de uma sobremesa lática agradável sensorialmente (visão, paladar, olfato e toque) e que não possuiria efeitos colaterais. Os indivíduos medicados com anti-hipertensivos não serão excluídos da seleção, podendo seguir normalmente com o seu medicamento. Nenhum dos participantes seguirá uma dieta específica antes do início e durante a ingestão dos mousse diet.

Os participantes serão orientados a manter suas dietas habituais, prevendo a possível ingestão de bebidas com teor alcoólico, mantendo os níveis de atividades físicas ou outros estilos de vida durante todo o período de intervenção.

As mousse serão acondicionadas em um freezer no Departamento de Tecnologia Bioquímico-Farmacêutica (endereço na última página). Os participantes poderão passar no departamento (se preferirem) para retirarem 14 embalagens contendo 40g de produto a cada 2 semanas ou poderão receber suas amostras em locais de conveniência. Estes participantes serão orientados a estocar os produtos no freezer (temperatura de -18°C) em sua residência.

Durante a coleta da primeira amostra sanguínea (antes do período de ingestão das sobremesas lácteas), será entregue uma informativa para cada participante sobre a forma como o produto deverá ser consumido e armazenado até a entrega das próximas amostras, além de informações adicionais.

Os indivíduos farão jejum de 12 horas após a última refeição do dia. No dia seguinte, estes participantes serão submetidos à punção venosa (pica da agulha) para coleta de amostras sanguíneas nos tempos 0, 4 e 8 semanas de intervenção com as mouses diet e após 2 semanas (tomo de 10 semanas) sem administração das mouses diet. O sangue coletado será de aproximadamente 30mL, devido a necessidade de diferentes tubos de coleta com conservantes específicos para cada tipo de análises (hematológicas, inflamatórios e metabólicas). As coletas serão realizadas no Centro de Pesquisa do Hospital Universitário da USP (H/U).

Rubrica do sujeito da pesquisa
Rubrica Dra. Susana Marta Isay Saad
TERMO DE CONSENTIMENTO LIVRE E ESCLARECIDO – TCLE

Para coleta sanguínea será realizada apenas uma picada com a utilização de íntima (equipamento de coleta sanguínea) que possibilita a coleta de sangue sem a necessidade de mais de uma picada. Neste procedimento, o participante pode sentir algum desconforto provocado pela picada da agulha no local da punção, poderá haver alguma dor decorrente da punção da pele e pessoas mais sensíveis poderão ficar com a pele arrepiada (pequeno hertoma) decorrente de uma pequena perda de sangue da veia no local da punção, por até 48 horas. A coleta de sangue será realizada em local limpo e confortável, por técnicos treinados. Todo material utilizado será descartável e estéril. Posteriormente, as análises do material coletado serão realizadas nos laboratórios credenciados do Serviço de Laboratório Clínico do HU da USP, por métodos quantitativos apropriados.

Todo o procedimento será supervisionado pelo doutorando Douglas Xavier dos Santos. A coleta de sangue será realizada por equipe de profissionais treinados do HUUSP. Se houver algum benefício detectado durante o período de intervenção com as massas diet aos voluntários, não nos comprometeremos a fornecer o alimento após o término do experimento em nenhuma hipótese.

Direito dos participantes:

✓ Quaisquer danos resultantes da pesquisa serão indenizados;
✓ Você poderá recusar ou desistir do experimento a qualquer momento, sem prejudicar o acompanhamento médico realizado pela equipe do HUUSP;
✓ A qualquer momento você poderá solicitar que os seus dados sejam excluídos da pesquisa;
✓ Você receberá os resultados das análises laboratoriais (sanguíneas) individualmente e qualquer dúvida a respeito dos exames será sanada através de um profissional qualificado que possa interpretá-los;
✓ Você poderá solicitar explicações todas as vezes que achar necessário sobre o experimento que estará participando;
✓ Todas as amostras sanguíneas coletadas serão descartadas após as análises laboratoriais;
✓ Todos os participantes serão identificados por um código para evitar que o seu nome seja relacionado aos resultados obtidos e quando os resultados destes experimentos forem publicados em eventos e revistas científicas especializadas, os nomes não serão divulgados;
✓ Os participantes terão recompensa com os custos de transporte, caso eles tenham que se deslocar até o Departamento de Tecnologia Bioquímica-Farmacêutica para retirarem suas amostras de massas diet.
✓ Todos os participantes deverão permanecer no local da coleta sanguínea durante 30 minutos para recuperação após a coleta, com o direito a alimentação para a quebra do jejum.
TERMO DE CONSENTIMENTO LIVRE E ESCLARECIDO – TCLE

Benefícios:

✓ Os participantes estarão contribuindo de forma voluntária para o desenvolvimento de uma tese de doutorado que contribuirá para o desenvolvimento de um produto diet que poderá promover efeitos benéficos aos consumidores através de ingredientes bioativos (possuem funções específicas) que irá contribuir para melhorar a qualidade de vida e bem-estar da população.

Em caso de dúvidas, intercorrências clínicas ou reações adversas, o participante da pesquisa será encaminhado pela equipe do projeto de pesquisa ao HU/USP.

Endereço: Depto de Tecnologia Bioquímico-Farmacêutica da FCF/USP
Av. Prof. Lineu Prestes, 580 Bloco 16 05508-900 São Paulo - SP
Telefone: (011) 3091-2378 e-mail: susaad@usp.br.

 Ou com o Pesquisador colaborador: Me Douglas Xavier dos Santos, cel. (11) 99210-1834 e e-mail: douglas_xavier@usp.br.

Uma via deverá ser entregue a você e outra via ficará com o pesquisador responsável, pelo tempo de 5 (cinco) anos.

Consentimento Pós-Esclarecido:

Declaro que, após convenientemente esclarecido pelo pesquisador e ter entendido o que me foi explicado, canto em participar do presente Protocolo de Pesquisa.

São Paulo, de de

__________________________ __________________________
Assinatura do sujeito de pesquisa Assinatura do pesquisador responsável

Em caso de dúvida, esclarecimento ou reclamação sobre aspectos éticos dessa pesquisa, favor entrar em contato:

- Comitê de Ética em Pesquisas da Faculdade de Ciências Farmacêuticas da USP – Av. Prof. Lineu Prestes, 580 - Bloco 13A – Cidade Universitária – CEP: 05508-900 – São Paulo/SP. Fone: (11) 3091-3622, Fone-Fax: 3091-3677 – E-mail: cep@usp.br

- Comitê de Ética em Pesquisa do Hospital Universitário da USP - Av. Prof. Lineu Prestes, 2565 – Cidade Universitária – CEP: 05508-000 – São Paulo/SP - Fone: (11) 3091-9457, Fax: (11) 3091-9479. Email: cep@hu.usp.br
TERMOS DE CONSENTIMENTO LIVRE E ESCLARECIDO – TCLE

Informações do Sujeito da Pesquisa

| Nome:                          |
|-------------------------------|
| Data de Nascimento: 1/1/________ |
| Endereço: N° Complemento:       |
| Bairro: Cidade: Estado:         |
| CEP: Telefones:                |

Título do Projeto de Pesquisa: Sobremesa asesada simbiótica: desenvolvimento do produto diet e avaliação dos benefícios da ingestão sobre indivíduos com síndrome metabólica.

Duração da Pesquisa: 3 anos (análise sensorial será realizada a partir de abril de 2014).

Nome do pesquisador responsável: Prof. Dra. Susana Marta Isay Saad

Cargo/Função: Professora Associada

Instituição: Faculdade de Ciências Farmacêuticas – USP

REGISTRO DAS EXPLICAÇÕES DO PESQUISADOR AO PROVADOR SOBRE A PESQUISA

Justificativa, objetivos e procedimentos:

Vocês foram convidados para participar da análise sensorial de um musse de goiaba adicionado de micro-organismo que contribui para função intestinal (Lactobacillus acidophilus La-5) e fibra alimentar solúvel (inulina e frutooligossacarídeos). Sobremesas lácteas são alimentos que surgem com um grande potencial para uso como veículo de micro-organismos que contribuem para função intestinal, com vantagem de serem alimentos consumidos por todas as faixas etárias. A goiaba tem recebido destaque nas pesquisas voltadas para alimentos que contribuem para a saúde, devido a presença de carotenoides e a função antioxidante. Esta fruta incorporada a musse é um modo de levar ao consumidor seus benefícios de forma prazerosa. Além disso, a combinação de micro-organismos que contribuem para função intestinal e fibra alimentar solúvel agrega ainda mais valor ao alimento. O desenvolvimento deste produto é feito pelo doutorando Douglas Xavier dos Santos, sob orientação do Prof. Dr. Susana Marta Isay Saad. O produto foi elaborado e acondicionado, de acordo com as Boas Práticas de Fabricação de Alimentos, nos laboratórios do Departamento de Tecnologia Bioquímica-Farmacêutica FCF/USP. Caso você tenha interesse em participar, acomode-se junto a uma das cabines do Laboratório de Análise Sensorial (B16).

O produto a ser avaliado nesta análise pode possuir: leite desnatado, leite em pó desnatado, suco de goiaba pasteurizado, estabilizante, ácido láctico alimentício, inulina, frutooligossacarídeos e micro-organismo que contribui com a função intestinal (Lactobacillus acidophilus La-5). Todos os ingredientes da formulação são utilizados em produtos disponíveis para consumo humano, ou seja, são de grau alimentício.

Para participar desta análise, você deve ter entre 18 e 60 anos, não passar histórico de manifestação de alergia, intolerância ou outro tipo de reação (como doenças crônicas ou tratamento médico com uso de medicamentos que podiam interagir) com os ingredientes; não deve estar ganhado, restrito ou indisposto ou ter entrado em contato com materiais, alimentos ou cosméticos de cheiro forte. Atendendo a essas condições você poderá participar da análise sensorial da musse de goiaba. Caso você tenha menos de 18 anos ou mais de 60 anos, histórico de manifestação de alergia, intolerância ou outro tipo de reação com os ingredientes da musse de goiaba, esteja ganhado, restrito ou indisposto ou não tenha entrado em contato com materiais, alimentos ou cosméticos de cheiro forte, você não poderá participar desta análise.

Você receberá três amostras, uma de cada vez, cada uma com uma ficha de avaliação. A amostra contém aproximadamente 20g de musse de goiaba. Pore a amostra e registre na ficha sua opinião em relação ao produto de uma amostra.
TERMO DE CONSENTIMENTO LIVRE E ESCLARECIDO – TCLE

manner geral fazendo um ”x” em um lugar na escala de 1 a 9, onde, 1 = desgostei muito e 9 = gostei muito. Em seguida, escreva o que você mais gostou e o que menos gostou na amostra.

Sua participação é livre e você poderá comparecer no máximo uma vez a cada dia para de análise sensorial deste produto.

Os riscos de sua participação neste estudo são mínimos. Não foram encontradas evidências de risco ou desconforto relacionado à análise sensorial em estudos deste tipo, com alimentos contendo micro-organismos que contribuem para função intestinal e fibras alimentares solúveis nas proporções adicionadas a este produto. Os demais ingredientes são reconhecidamente seguros, os possíveis desconfortos são mínimos.

Não há nenhum benefício direito. Porém, você contribuirá para o desenvolvimento de alimentos com características sensoriais adequadas às expectativas de futuros consumidores.

Caso você não queira continuar participando da pesquisa, a qualquer momento você pode desistir, sem que haja qualquer prejuízo. Havendo qualquer dúvida com relação aos procedimentos, riscos e benefícios relacionados à pesquisa você deve comunicar ao grupo de pesquisa a qualquer momento. É assegurado que todas as informações pessoais serão confidenciais, o sigilo e privacidade também serão garantidos, mesmo que os resultados sejam publicados em periódicos científicos.

Serão adotadas cuidados especiais para evitar que indivíduos subordinados ou diretamente ligados ao pesquisador se sintam obrigados a participarem do estudo.

Não haverá remuneração financeira aos participantes das análises sensoriais.

Em caso de intercorrências clínicas e reações adversas durante o estudo, o voluntário deverá procurar o Hospital Universitário da Universidade de São Paulo (USP) - Av. Prof. Lineu Prestes, 2565. Cx. Universitária. (11) 3291-3000.

Os responsáveis pelo acompanhamento da pesquisa estarão à disposição para contato:

Douglas Xavier dos Santos e Susana Maria Isay Saad.
Faculdade de Ciências Farmacêuticas – Departamento de Tecnologia Bioquímico-Farmacêutica. Av. Prof. Lineu Prestes, 580 CEP 05508-000 São Paulo-SP.
Telefone: (11) 3291-2379 ou (11) 3291-3891

CONSENTIMENTO PÓS-ESCLARECIDO

Declaro que, após convenientemente esclarecido pelo pesquisador e ter entendido o que me foi explicado, consinto em participar do presente Protocolo de Pesquisa.

__________________________ de ________________

Assinatura do sujeito da pesquisa

Assinatura do pesquisador responsável

Prof. Drº. Susana Maria Isay Saad

Para qualquer questão, dúvida, esclarecimento ou reclamação sobre aspectos éticos dessa pesquisa, favor entrar em contato com o Comitê de Ética em Pesquisas da Faculdade de Ciências Farmacêuticas da Universidade de São Paulo – Av. Prof. Lineu Prestes, 580 - Bloco 13A – Butantã – São Paulo – CEP 05508-900. Fone: 3291-3622, fone-fax: 3291-3677 – e-mail: cef@usp.br
Ficha para teste de aceitação – Musse de goiaba

Nome: ______________________________________ Data: ___/___/____
Amostra: ____________

Você recebeu uma amostra de musse de goiaba. Por favor, prove a amostra e avalie de maneira geral (aparência, sabor e textura) usando a escala abaixo o seu grau de aceitação relacionado ao produto.

1 - Desgostei muito
2 - Desgostei muito
3 - Desgostei regularmente
4 - Desgostei ligeiramente
5 - Não gostei nem desgostei
6 - Gostei ligeiramente
7 - Gostei regularmente
8 - Gostei muito
9 - Gostei muito

Cite a característica que você mais gostou na amostra: ☐ ______________________________________

Cite a característica que você menos gostou na amostra: ☐ ______________________________________
# ANNEX 4 - School Records

**Janus** - Sistema Administrativo da Pós-Graduação

Universidade de São Paulo  
Faculdade de Ciências Farmacêuticas  
Documento sem validade oficial  
FICHA DO ALUNO

---

| 9133 - 8402211/1 - Douglas Xavier dos Santos |
|---------------------------------------------|
| **Email:** | douglas_xavier@usp.br |
| **Data de Nascimento:** | 28/10/1985 |
| **Cédula de Identidade:** | RG - 42.552.182-5 - SP |
| **Local de Nascimento:** | Estado de São Paulo |
| **Nacionalidade:** | Brasileira |
| **Graduação:** | Técnólogo - Centro Paula Souza - Faculdade de Tecnologia "Estudante Rafael Almeida Camariminh" - Marília - São Paulo - Brasil - 2008 |
| **Mestrado:** | Mestre em Ciência de Alimentos (1) - Universidade Estadual de Londrina - Paraná - Brasil - 2012 |

| **Curso:** | Doutorado |
| **Programa:** | Tecnologia Bioquímico-Farmacêutica |
| **Área:** | Tecnologia de Alimentos |
| **Data de Matrícula:** | 10/06/2013 |
| **Início da Contagem de Prazo:** | 10/06/2013 |
| **Data Limite para o Depósito:** | 12/06/2013 |
| **Orientador na USP:** | Prof(a). Dr(a). Susana Marta Isay Saad - 10/06/2013 até o presente. Email: susaadi@usp.br |

**Aluno USP em convênio de dupla titulação com instituição estrangeira**

**Instituição Conveniada:** Università degli Studi di Genova, Itália  
**Orientador na Instituição Conveniada:** Patrizia Pereggi  
**Proficiência em Línguas:** Inglês, Aprovado em 10/06/2013  
**Data de Aprovação no Exame de Qualificação:** Aprovado em 29/07/2015

**Data do Depósito do Trabalho:**  
**Título do Trabalho:**  
**Data Máxima para Aprovação da Banca:**  
**Data de Aprovação da Banca:**  
**Data Máxima para Defesa:**  
**Data de Defesa:**  
**Resultado da Defesa:**

**Histórico de Ocorrências:** Primeira Matrícula em 10/06/2013

---

Aluno matriculado no Regimento da Pós-Graduação USP (Resolução nº 5473 em vigor de 18/09/2008 até 19/04/2013).  
Última ocorrência: Matrícula de Acompanhamento em 06/02/2017  
Impresso em: 05/06/2017 06:54:54

**Janus** - Sistema Administrativo da Pós-Graduação
Universidade de São Paulo  
Faculdade de Ciências Farmacêuticas  
Documento sem validado oficial  
FICHA DO ALUNO

9133 - 8402211/1 - Douglas Xavier dos Santos

| Sigla       | Nome da Disciplina                                                                 | Início         | Término         | Carga Horária | Cred. Freq. Conc. Exc. | Situação      |
|-------------|-------------------------------------------------------------------------------------|----------------|----------------|---------------|------------------------|---------------|
| FBC5719/3-19 | Tratamento Gastrointestinal: Imunomodulação na Colonização e Infecção Bacteriana    | 02/08/2013     | 14/11/2013     | 90            | 6                       | 100           | A             | N             | Concluída     |
| GEN5711/4-5  | Preparação à Disciplina de Graduação (Instituto de Matemática e Estatística - Universidade de São Paulo) | 12/08/2013     | 29/11/2013     | 60            | 0                       | -             | N             | Matrícula cancelada |
| AGO5900/12/1 | Preparação Pedagógica (Instituto de Astronomia, Geofísica e Ciências Atmosféricas - Universidade de São Paulo) | 13/08/2013     | 25/11/2013     | 15            | 1                       | 75            | B             | N             | Concluída     |
| EDM5102/3/6  | Preparação Pedagógica PAE (Faculdade de Educação - Universidade de São Paulo)       | 20/08/2013     | 30/09/2013     | 60            | 0                       | -             | N             | Pre-matrícula indeferida |
| FBA5752/1/1  | Probióticos em Alimentos e Sua Implicação na Saúde Humana                           | 05/11/2013     | 16/12/2013     | 60            | 4                       | 100           | A             | N             | Concluída     |
| Atividade do Programa | Participou da etapa de estágio supervisionado em Disciplina de Apoio ao Processo de Aterramento da Disciplina FBT5011 Tecnologia de Alimentos, realizada aos alunos de graduação do curso de Farmácia e Bioquímica da Faculdade de Ciências Farmacêuticas da Universidade de São Paulo (2) | 10/02/2014 | 25/06/2014 | -             | 1                       | -             | -             | -             | -             |
| FBT5757-1/3  | Aplicação Biotecnológica de Bactérias Láticas                                       | 04/03/2014     | 07/04/2014     | 45            | 0                       | -             | N             | Matrícula cancelada |
| EDM5103/1/1  | A Formação do Professor Universitário (Faculdade de Educação - Universidade de São Paulo) | 11/03/2014     | 02/06/2014     | 120           | 0                       | -             | N             | Matrícula cancelada |
| EDM0791/6/1  | Metodologia do Ensino Superior (Faculdade de Educação - Universidade de São Paulo) | 11/03/2014     | 03/09/2014     | 120           | 8                       | 100           | A             | N             | Concluída     |
| FBT5703/3/6  | Préparo de Artigos Científicos na Área de Tecnologia Bioquímico-Farmacêutica         | 03/04/2014     | 04/06/2014     | 90            | 6                       | 100           | A             | N             | Concluída     |
| FBT5738-1/1  | Teorias Especiais em Tecnologia Bioquímico-Farmacêutica III                          | 02/03/2015     | 10/05/2015     | 30            | 2                       | 100           | A             | N             | Concluída     |

| Créditos mínimos exigidos | Créditos obtidos |
|---------------------------|-------------------|
| Disciplinas:              |                   |
| Para exame de qualificação | 0 | 28 |
| Para diploma de tese:     | 0 | 25 |

| Estágios:                  |
|----------------------------|

| Créditos Atribuídos à Tese: 167 |

Observações:

1) Curso com validade nacional, de acordo com o disposto na Portaria nº 524, de 29.04.2008, e 31.08.09 e aprovados pela Comissão de Pós-Graduação em 19/02/2014.

Conceito a partir de 02/01/1997:

A - Excelente, com direito a crédito; B - Bom, com direito a crédito; C - Regular, com direito a crédito; R - Reprovado; T - Transferência.

Última ocorrência: Matrícula de Acompanhamento em 06/02/2017
Universidade de São Paulo
Faculdade de Ciências Farmacêuticas
Documento sem validade oficial
FICHA DO ALUNO

9133 - 84022111/1 - Douglas Xavier dos Santos

| NUSP | Nome                  | Vínculo  | Função     |
|------|-----------------------|----------|------------|
| 1628231 | Susana Marta Isay Saad | FCF - USP | Presidente |

Última ocorrência: Matrícula de Acompanhamento em 06/02/2017
Impresso em: 05/06/2017 00:54:54